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1 AIM OF THE STUDY 
 
Cyclin-dependent kinase like-5 (CDKL5) disorder is a rare neurodevelopmental disease 
caused by mutations in the CDKL5 gene, located in the X-chromosome. The consequent 
unsuccessful CDKL5 protein expression in the nervous system leads to a severe phenotype 
characterized by intellectual disability, early-onset intractable epilepsy and motor impairment, 
which, together with a complex corollary symptomatology, resembles Rett syndrome.  
 
Currently, there is no cure or effective treatment for CDKL5 disorder, and the mainstay 
of care for this disorder is support for the families. Therefore, identification of specific therapies will 
represent an important achievement in the field of public health. 
 
In theory, for a monogenic disease such as the CDKL5 disorder, delivery of a wild type copy 
of the CDKL5 gene to cells lacking functional CDKL5 represents a therapeutic approach worth 
considering. There are encouraging proof-of-concept studies which demonstrate the potential 
for gene therapy, but also highlight signiﬁcant caveats for treatment of brain diseases. A new 
alternative approach to gene therapy, named “protein transduction” or “protein therapy”, has 
emerged, enabling the trans-vascular delivery of an exogenous protein to the brain following a 
simple systemic injection. It has been discovered that certain proteins and peptides exhibit the unique 
property of efficient translocation across cell membranes. This unique translocation is usually due to 
the presence of a Protein Transduction Domain (PTD) in these molecules. The HIV-1 Transactivator 
of Transcription (TAT) protein is the best characterized viral PTD containing protein. Earlier 
experiments with the TAT-PTD protein domain demonstrated successful transduction of high 
molecular weight proteins into the mouse brain [Xia, Mao, and Davidson 2001; Schwarze et al. 
1999; Nagahara et al. 1998]. Importantly, no toxic effects or immunogenicity problems of the TAT-
PTD have been reported so far.  
 
Based on these premises the overall goal of the study was to develop a protein 
replacement therapy for CDKL5 disorder aimed to compensate for the lack of function of the 
CDKL5 protein, exploiting a mouse model of the pathology. Importantly, this protein therapy has 
the advantage of a potentially rapid translation from the animal model to patients. 
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2 INTRODUCTION 
 
2.1 CDKL5 disorder: overview  
CDKL5 (cyclin-dependent kinase-like 5) disorder is a severe X-linked neurodevelopmental 
disease characterized by severe intellectual disability, generalized developmental delay and early-
onset intractable seizures. It is caused by mutations in the CDKL5 gene, leading to altered 
functionality of CDKL5 protein kinase, whose expression is high in the developing brain in 
physiological conditions. 
The CDKL5-related epileptic encephalopathy affects mostly girls and due to the numerous 
clinical features that overlap with the more characterized Rett syndrome (RTT), it has been initially 
termed as “early seizure variant” or “Hanefeld variant” of RTT. Rett syndrome etiopathogenesis 
mainly involves mutations in another X-linked gene, encoding for methyl-CpG-binding protein 2 
(MeCP2), a methylation-dependent transcriptional repressor [Lewis et al. 1992] and splicing 
regulator [Young et al. 2005]. Nonetheless a significant fraction (around 30%) of children initially 
diagnosed with RTT does not carry mutation in MeCP2 gene, and recent findings highlighted the fact 
that mutations in other genes, such as CDKL5 (on X chromosome) and FOXG1 (on human 
chromosome 14) genes, are responsible for new disorders that in many aspects overlap RTT but are 
also characterized by specific traits [Evans et al. 2005; Fehr et al. 2013; Guerrini and Parrini 2012]. 
Similarities between MeCP2-CDKL5-FOXG1 encephalopathies are related to the severe 
neurodevelopmental impairment and the consequently reduced behavioral repertoire of affected 
patients, while the characteristics of associated epilepsy are quite different [Guerrini and Parrini 
2012]. Efforts have been made to unravel the molecular bases that might underlie phenotypic 
similarities related to mutations, duplications or deletions of these genes. Notably, CDKL5 and 
MeCP2 are widely coexpressed in the brain and are similarly activated during neuronal maturation 
and synaptogenesis [Mari et al. 2005; Rusconi et al. 2008]. Furthermore, a direct interaction between 
MeCP2 and CDKL5 has been demonstrated. CDKL5 can bind and phosphorylate MeCP2 in vitro, 
and MeCP2 can in turn regulate CDKL5 gene expression, at least in certain brain areas [Bertani et al. 
2006; Carouge et al. 2010; Mari et al. 2005]. In addition, both proteins bind to different regions of 
DNA methyltransferase 1 (DNMT1), further suggesting their possible participation to common 
pathways [Kameshita et al. 2008]. 
Nevertheless, in the last few years increasing knowledge of clinical and molecular aspects of 
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MeCP2- and CDKL5- as well as FOXG1-related encephalopathies have rise the idea that they should 
be considered independent clinical entities [Fehr et al. 2013; Melani et al. 2011; Wang et al. 2012]. 
 
2.1.1 Rett syndrome 
Rett syndrome (RTT) is a childhood neurological disease characterized by features that are 
observed in many other disorders ranging from autism to Parkinson’s disease and dystonia. The 
disorder affects ~1 in 10,000 females and is most often caused by mutations in the gene encoding 
methyl-CpG-binding protein 2 (MeCP2), a transcriptional regulatory protein. Loss-of-function 
mutations in MeCP2, which is on X chromosome, account for the vast majority (~95%) of typical 
RTT cases. Most mutations arise spontaneously (de novo) in the paternal germ line; thus, individuals 
with RTT are typically females who, owing to X-chromosome inactivation, are somatic mosaics for 
normal and mutant MeCP2. Boys with mutations that cause RTT in females typically die before or 
soon after birth with a severe encephalopathy. Mutations in other genes such as cyclin-dependent 
kinase like 5 (CDKL5) and forkhead box G1 (FOXG1) can cause phenotypes overlapping with those 
seen in RTT; however, several features, such as congenital onset and infantile spasms in CDKL5-
mutant patients, and congenital onset and hypoplasia of the corpus callosum in FOXG1-mutant 
patients, distinguish these disorders from typical RTT. 
 
 
Figure 1. Staging system for classical RTT derived from Hagberg and Witt-Engerstroem. 
(Image taken from [Weaving et al. 2005]). 
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RTT is characterized by its unique time course and phenotypic complexity. Fig. 1 shows a 
proposed staging system basing on progress of symptoms. Affected individuals present with 
postnatal neurological regression, usually starting between 1.5 and 3 years of age (but sometimes as 
early as 6 months of age), with loss of acquired hand skills and spoken language and, in some cases, 
social withdrawal or extreme irritability that can resemble autism. After regression, there is a 
stabilization of skills, rather than a relentless progression, a feature that differentiates RTT from 
neurodegenerative conditions such as Batten disease or Huntington’s disease. During this pseudo-
stationary or plateau stage, characteristic features of RTT such as repetitive hand movements 
(stereotypies shown in Fig. 2), which can be present before or during regression, become more 
prominent. Later in life, many affected individuals enter a stage of motor decline in which 
ambulation can be lost, and Parkinsonian features such as rigidity and hypomimia become 
prominent. During the regression stage, some individuals with RTT develop autistic features that 
include social withdrawal, avoidance of eye contact and indifference to visual or auditory stimuli. 
After regression, some of these autistic features decrease, and most affected individuals develop 
intense eye gaze that they use for communication. Features such as stereotypies and lack of language 
skills persist throughout the life of affected individuals, although hand stereotypies can change from 
rapid movements to midline hand clasping with age. 
 
 
 
Figure 2. Stereotypic hand movements in a 4-years old girl with RTT. (Image taken from 
[Borg et al. 2005]). 
 
Additional behavioral problems include anxiety in response to novel situations, increased 
behavioral rigidity and increased pain tolerance. Individuals with RTT are considered to have severe 
intellectual disability; however, because affected individuals have severe impairments in their ability 
to communicate, it is difficult to make accurate assessments of their intellectual ability. Movement 
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abnormalities are a major issue in RTT, with the most obvious being the repetitive hand stereotypies, 
which seem to interfere with volitional hand use. Gait is almost always disrupted, with evidence of 
ataxia and apraxia. Dystonia is common, seen first in the ankles and eventually progressing to many 
joints. Axial hypotonia is present early in the disease course but, as children become young adults, 
increased tone with features of rigidity becomes more prominent. Additional movement 
abnormalities include tremor, myoclonus, chorea, facial grimacing and severe teeth grinding. Most 
individuals with RTT have scoliosis, and some require surgical intervention. Nutrition and 
gastrointestinal function are also major clinical issues in RTT, and there is marked growth failure in 
most affected individuals. It has long been recognized that head growth is impaired, resulting in 
acquired microcephaly, and height and weight are usually markedly diminished. However, a subset 
of individuals with RTT are overweight or obese, a feature that is often associated with higher 
functioning and possibly improved oromotor skills. Many individuals with RTT have various 
gastrointestinal problems, including significant chewing and swallowing difficulties, 
gastroesophageal reflux, gastrointestinal dysmotility and severe constipation, which severely 
decrease the quality of life for patients and their families. Dysregulation of breathing and autonomic 
homeostasis are very common in RTT. Respiratory abnormalities, which include periods of forceful 
breathing (hyperventilation), severe pauses in breathing (including breath holds) that can cause 
cyanosis and even loss of consciousness, and abnormal cardiorespiratory coupling, are more severe 
during wakefulness than during sleep and can be exaggerated during periods of excitement or stress. 
Autonomic abnormalities include periods of vasomotor disturbance (usually associated with cold 
hands and feet), abnormal sweating, decreased heart rate variability, evidence of sympathetic-
parasympathetic imbalance and prolongation of corrected QT interval (an indication of abnormal 
cardiac electrical activity) in a subset of individuals. One quarter of deaths in RTT are sudden and 
unexpected, and might result from complications of cardiorespiratory dysfunction. Brain electrical 
activity is not typical in individuals with RTT, as shown by the markedly disrupted pattern observed 
on electroencephalograms (EEGs) and the high probability of seizures. Seizures, ranging from 
complex partial to generalized tonic-clonic, are most commonly seen after other symptoms appear 
(usually after age two) and correlate with the severity of the phenotype. In addition to true epileptic 
events, individuals with RTT also have non-epileptic paroxysmal events, and video EEG is needed to 
differentiate between them. Despite the severity and phenotypic complexity of RTT, the brains of 
individuals with RTT do not show gross neuropathological changes, nor evidence of neuronal or 
glial atrophy, degeneration, gliosis, or demyelination, indicating that RTT is not a neurodegenerative 
disorder. Smaller total brain volume and smaller neurons (but with a higher cell density) have been 
observed in several brain regions, including the cerebral cortex, hypothalamus and the hippocampal 
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formation. The size and complexity of dendritic trees are reduced in cortical pyramidal cells, and 
levels of microtubule-associated protein-2 (MAP-2), a protein involved in microtubule stabilization, 
are lower throughout the neocortex of RTT autopsy material. In addition, the density of dendritic 
spines is lower in pyramidal neurons of the frontal cortex and in the CA1 region of the hippocampus. 
To date, no therapies are available to treat the most debilitating symptoms of RTT. However, 
the compelling need for effective treatments for RTT, coupled with the availability of good mouse 
models, is fuelling interest in translational studies aimed at identifying potential new therapeutics. 
Interestingly, it has been shown that many of the features of RTT are reversible in mice, and that 
these features are probably due to dysfunction of neurons and supporting cells, rather than neural 
degeneration. These findings provide hope that some and perhaps most symptoms can be reversed in 
affected individuals if effective therapies that can overcome the consequences of loss of function or 
dysfunction of MeCP2 will be discovered [Katz et al. 2012]. 
Even though Rett syndrome and CDKL5 disorder are almost worldwide considered different 
clinical entities, similarities between these encephalopathies are due to common molecular 
mechanisms and thus it is reasonable to think that pharmacological therapies targeted to altered 
pathways in Rett syndrome may be suitable also for CDKL5 disorder and vice versa. 
 
2.1.2 CDKL5 disorder clinical presentation and natural history 
The CDKL5 kinase was initially identified through a positional cloning study aimed at 
isolating disease genes mapping on the X-chromosome. Sequence analysis revealed homologies to 
several serine-threonine kinase genes and identified one protein signature specific for this subgroup 
of kinases, therefore, leading the authors to name the gene STK9 (Serine Threonine Kinase 9) 
[Montini et al. 1998]. 
The first described mutations in CDKL5 were reported in 2003, when Vera Kalscheuer and 
colleagues identified balanced translocations in two unrelated girls exhibiting infantile spasms and 
profound developmental delay. In both patients the CDKL5 gene was disrupted by a breakpoint on 
the X chromosome [Kalscheuer et al. 2003]. 
Due to some overlapping clinical similarities between the two reported patients and the early 
seizure variant of Rett syndrome, in the following years, other researchers studied the CDKL5 gene 
in patients who had been diagnosed with classical or variant Rett and were mutation negative to 
MeCP2 testing. These studies led to identification of intragenic CDKL5 mutations/deletions in girls 
with early onset severe seizures [Tao et al. 2004; Weaving et al. 2004]. 
In the last several years, the large number of patients reported, with detailed description of 
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epilepsy and EEG features, has permitted the delineation of a phenotypic spectrum spanning from 
milder forms – which include the possibility of autonomous walking and less severe epilepsy that is 
amenable to control – to severe forms featuring intractable seizures, more severe microcephaly and 
absence of motor milestones. In this spectrum several of the distinctive clinical features of Rett 
syndrome are lacking. For instance, girls with CDKL5 mutations do not exhibit a clear period of 
regression, neither do they present the intense eye gaze and impaired neurovegetative function 
typically seen in girls with RTT [Guerrini and Parrini 2012]. 
 
 
 
Table 1. Revised diagnostic criteria for Rett syndrome. (Table taken from [Neul et al. 2010])  
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Strikingly, only less than one-quarter of individuals with CDKL5 mutations meet the criteria 
for the early-onset seizure variant of RTT (see Table 1), as CDKL5 disorder was initially defined. 
Furthermore, besides clinical differences, recent data from characterization of CDKL5 mouse models 
support the increasing awareness that CDKL5-related encephalopathy is an independent disorder 
with an independent pathogenic mechanism. To outline the difference with respect to Rett syndrome, 
in the last few years the definition of CDKL5 gene–related epileptic encephalopathy has been 
proposed by different clinicians and researchers, and CDKL5 disorder is by this time considered an 
independent clinical entity [Amendola et al. 2014; Fehr et al. 2013; Melani et al. 2011; Wang et al. 
2012]. 
Furthermore, in the last years the screening of CDKL5 mutations has been extended to 
cohorts of both genders with undefined diagnosis of epileptic encephalopathy, infantile spasms or 
West syndrome. Interestingly, Intusoma and colleagues [Intusoma et al. 2011] suggested that 
screening among patients having intractable seizures with an onset before 6 months of age gives 
even a higher score than screening among MeCP2-negative RTT patients. 
For, the central feature of CDKL5-related phenotype is an early onset epileptic 
encephalopathy, which is associated with severe developmental delay, deceleration of head growth, 
impaired communication and, often, hand stereotypies. Several dozen girls and a few boys with 
CDKL5 gene mutations, or genomic deletions, have been reported, all having early onset intractable 
seizures. Males are at the more severe end of the phenotypic spectrum with virtually no motor 
acquisitions. Patients with CDKL5-gene abnormalities are reported to be normal in the first days of 
life to subsequently exhibit early signs of poor developmental skills, including poor sucking, and 
poor eye contact, even before seizure onset. Subsequently, absent purposeful hand use, severe 
developmental delay, and absent language skills become apparent. About only one third of patients 
will eventually be able to walk [Guerrini and Parrini 2012]. Sleep and respiratory disturbances 
represent a major issue for many patients. Isolated studies on small number of patients with CDKL5 
mutations demonstrated the presence of cardiorespiratory dysrhythmias such as tachypnoea, deep 
breathing, apnoeas and breath holding [Pini et al. 2012]. Polysomnography revealed central apnoeas 
when awake, low rapid eye movement sleep, frequent awakenings, and low sleep efficiency 
[Hagebeuk, van den Bossche, and de Weerd 2013]. Other common features of CDKL5 patients 
include autonomic features, gastroesophageal reflux, hypotonia and scoliosis. 
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Figure 3. Characteristic facial, hand and feet features in males and females with CDKL5 
disorder. (Image taken from [Fehr et al. 2013]). 
 
The described clinical symptoms are differently distributed, while early-onset epilepsy is a 
common feature of all CDKL5 patients. Epilepsy is typically manifested as an epileptic 
encephalopathy with infantile spasms starting between the first days and fourth month of life. 
Patients show a peculiar seizure pattern with generalized tonic–clonic events, gradually translating 
into repetitive distal myoclonic jerks. A generalized ictal pattern in neonates or very young infants 
has been described, but is considered to be exceptional, owing to the lack of both the functional 
cortical organization that is necessary to propagate and sustain the electrical discharge and the failure 
of interhemispheric transmission resulting from commissural immaturity. Whether this peculiar ictal 
pattern represents a unique seizure type or just an unusual expression of infantile spasms in the 
immature, and possibly malformed, brain of children with CDKL5-gene abnormalities is open to 
speculation. Follow-up studies of children older than 3 years indicate that about half of them can 
experience seizure remission, whereas the remaining continue to have intractable spasms, often 
associated with multifocal and myoclonic seizures. Early EEG findings vary from normal 
background to moderate slowing, with superimposed focal or multifocal interictal discharges and, in 
some cases a suppression burst pattern. 
There are no neuropathologic studies that have examined the brain of patients with CDKL5 
mutations. Imaging data are also scanty and nonquantitative. Bahi-Buisson et al. in 2008 reported 
‘‘cortical atrophy’’ in 13 of 20 girls, associated with areas of increased T2 signal in the white matter, 
especially in the temporal lobes in some [Guerrini and Parrini 2012]. 
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The clinical understanding of CDKL5 disorder still remains limited, with most information 
being derived from small patient groups seen at individual centers. Its genetic link to 
neurodevelopmental disorders highlights the need to characterize CDKL5 biological function, 
understand the mechanisms underlying CDKL5-related disorder, and identify effective therapies 
targeted toward slowing or reversing disease progression. 
 
2.1.3 CDKL5 mutations and genotype-phenotype relationship 
With the exception of one instance of familial occurrence, likely due to gonadal mosaicism, 
all reported cases of CDKL5 disorder are sporadic. Although the risk of gonadal mosaicism and 
consequent familial recurrence is low, genetic counseling should be offered to couples with a child 
with CDKL5-related epileptic encephalopathy [Guerrini and Parrini 2012].  
Since 2003, when Kalscheuer et al. identified the first mutations in CDKL5 in two unrelated 
girls who, in addition to mental retardation, had hypsarrhythmia and infantile spasms [Kalscheuer et 
al. 2003], patients with different phenotypic outcome of the disorder, harboring a wide range of 
pathogenic mutations, have been described in literature. About a hundred different CDKL5 patients, 
harboring a wide range of pathogenic mutations, have been described so far, including missense and 
nonsense mutations, small and large deletions, frameshifts and aberrant splicing. This mutational 
heterogeneity may in part explain the phenotypic heterogeneity. Even considering the small number 
of patients described, some “hot-spots” and genotype-phenotype correlations have been proposed. 
 
 
 
Figure 4. Schematic representation of CDKL5 protein. (Image taken from [Bienvenu and 
Chelly 2006]). 
 
The recurrent mutations identified so far affect different domains of the CDKL5 protein, the 
most important being: the ATP binding region, the Serine–Threonine protein kinase active site, and a 
large COOH-terminal extension of almost 700 amino acids, poorly characterized, that probably 
harbors several functions. Fig. 4 shows a schematic representation of CDKL5 protein important 
domains. Missense mutations almost exclusively are localized in the N-terminal domain, impairing 
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the kinase activity of CDKL5, and can therefore in most cases be considered loss-of-function 
mutations. These mutations are associated with a more severe phenotype, underlining the important 
role of CDKL5 kinase activity during brain function and development. Patients bearing missense 
mutations in the ATP binding site (such as the p.Ala40Val mutation) typically walk unaided, have 
normocephaly, better hand use ability, and less frequent refractory epilepsy when compared to girls 
with other CDKL5 mutations. On the contrary, truncating mutations can be located anywhere in the 
gene, leading to CDKL5 derivatives of various lengths. The relevance of the rather uncharacterized 
C-terminal part of CDKL5 is suggested by the fact that many pathogenic alterations involve the C-
terminus. Some reports suggest that stop-codon mutations in the C-terminus originate a milder 
clinical picture than those caused by mutations in the catalytic domain [Bahi-Buisson et al. 2012]. A 
regulatory role for the tail of CDKL5 has emerged from the characterization of few C-terminal 
truncating derivatives. In fact, it seems to act as a negative regulator of the catalytic activity of 
CDKL5 and to modulate the subcellular distribution, localizing the protein to the cytoplasm. 
Whether truncated CDKL5 mutants act as loss- or gain-of-function proteins still remains to be 
understood. Indeed, if expressed, they would be mislocalized hyperfunctional derivatives. However, 
since CDKL5 seems to exert its functions both in the nucleus and the cytoplasm, it remains possible 
that the absence of CDKL5 from the cytoplasm might also contribute to the pathogenic phenotype 
[Kilstrup-Nielsen et al. 2012]. 
Furthermore, a novel CDKL5 107 kDa isoform with an alternative C-terminus that terminates 
in intron 18 has been identified and some authors support the idea that mutations affecting this 107 
kDa isoform are likely pathogenic, while mutations only affecting the large 115 kDa protein are 
likely not involved in neurological symptoms [Bahi-Buisson et al. 2012]. 
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Figure 5. Pathogenic CDKL5 mutations. (A) Schematic representation of CDKL5115 protein 
with functional domains and signatures indicated. NLS: nuclear localization signal; NES: nuclear 
export signal. (B) Various mutations in CDKL5 reported to date are indicated corresponding to their 
location within the gene. The blue exons make up the catalytic domain, the white exons are the C-
terminal region, red and green parts show different versions of the protein. Mutations shown above 
the CDKL5 gene are deletion and frame shift mutations as well as splice variants indicated with 
cDNA nomenclature. Missense and nonsense mutations (fuchsia and black, resp.) are represented 
with amino acid nomenclature below the CDKL5 gene. (Image taken from [Kilstrup-Nielsen et al. 
2012]). 
 
Although it has been observed a relative homogeneity of the clinical phenotype in patients 
bearing the same mutation, some clinical discrepancies emerged. No clear genotype-phenotype 
correlation of CDKL5 mutations has been established so far and some authors state that the nature of 
the mutation does not correlate with the clinical heterogeneity. Accordingly, Weaving et al. reported 
of two genetically identical CDKL5-mutated twin girls with a significant discordant phenotype. 
Indeed, one proband showed a clinical phenotype overlapping RTT, whereas her twin sister showed 
autistic disorder and mild-to-moderate intellectual disability. Since both girls were characterized by 
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random X-inactivation, probably their phenotypic differences can be attributed to modifier genes that 
have been differentially influenced by environmental and/or epigenetic factors. Moreover, another 
report identified an R952X mutation with incomplete penetrance and uncertain pathogenicity. Since 
this novel mutation occurs in exon 20 that might not be highly expressed in brain, it is reasonable to 
speculate that modifier genes affecting CDKL5 splicing might be responsible for the observed 
penetrance. 
The behavior of each missense, nonsense, and frameshift mutation might be different and the 
clinical phenotype associated with each CDKL5 mutation may be the result of the nuclear or 
cytosolic accumulation of CDKL5, of its ability to bind substrates and of the residual catalytic 
activity of CDKL5. Future studies, focused on the identification of direct and indirect partners of 
CDKL5, will help defining its functions and might lead to the identification of modifier genes 
representing relevant targets for therapeutic approaches [Kilstrup-Nielsen et al. 2012]. 
 
2.2 CDKL5 gene and protein 
The cyclin-dependent kinase-like 5 gene (CDKL5), located on the X-chromosome, is 
recognized as one of the genes responsible for a form of epileptic encephalopathy classified as early 
infantile epileptic encephalopathy 2. It was identified in 1998 through an exon trapping method 
designed to screen candidate genes in Xp22 region, where several genetic disorders have been 
mapped [Montini et al. 1998]. The human CDKL5 gene occupies approximately 240 kb and is 
composed of 24 exons of which the first three exons (exon 1, 1a and 1b) are untranslated, whereas 
the coding sequence are contained within the exons 2-21. Different isoforms and splicing variants 
have been identified so far (see Fig. 6 below in the text). 
CDKL5 protein contains a conserved serine/threonine kinase domain in its N-terminal, 
sharing homology to both MAP and cell-cycle–dependent kinases known as the cyclin-dependent 
kinase-like (CDKL) kinases [Lin, Franco, and Rosner 2005]. The eukaryotic protein kinases 
represent a large superfamily of homologous proteins, related by the presence of a highly conserved 
kinase domain of 250-300 amino acids. There are two major subdivisions within the superfamily of 
eukaryotic protein kinases: the serine-threonine protein kinases and the protein tyrosine kinases. 
Sequence analysis and further characterization of the predicted CDKL5 protein revealed homologies 
to several serine-threonine kinases. Consequently Montini and colleagues first named the identified 
gene STK9 (Serine Threonine Kinase 9) [Montini et al. 1998]. Serine-threonine kinases very 
frequently have been linked to the pathogenesis of genetic disorders and a substantial number of 
human genetic disorders have been mapped to the Xp22 region. Montini et al. suggested the Nance-
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Horan syndrome (NH), a X-linked recessive disorder characterized by cataract and dental anomalies, 
as a candidate disorder for STK9 mutations. In the following five years, mutations in this gene were 
found in epileptic patients and in 2003 Kalscheuer suggested STK9 to be a chromosomal locus 
associated with X-linked infantile spasms (ISSX) [Kalscheuer et al. 2003]. The X-linked infantile 
spasm is characterized by early-onset generalized seizures, hypsarrhytmia and mental retardation and 
majority of cases are due to mutations in the aristaless-related homebox gene (ARX), which maps to 
the Xp21.3-p22.1 interval. Given the strong similarity to some cell division protein kinases, the 
STK9 gene subsequently got renamed cyclin-dependent kinase like 5, CDKL5. 
 
2.2.1 Protein structure 
The CDKL5 protein belongs to the CMGC family of serine-threonine kinases, which include 
cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAP kinases), glycogen 
synthase kinases (GSKs), and CDK-like (CDKL) kinases. It is characterized by a N-terminal 
catalytic domain (amino acids 13-297), homologous to that of other CDKL-family members, such as 
p56KKIAMRE (CDKL1), p42KKIALRE (CDKL2) and NKIAMRE (CDKL3). This N-terminal 
catalytic domain contains the ATP-binding region (amino acids 13-43), the serine-threonine kinase 
active site (amino-acids 131-143) and a Thr-Xaa-Tyr motif (TEY) at amino acids 169-171, whose 
dual phosphorylation is normally involved in activating kinases of the MAP kinase family. In 
analogy to all the other members of the family of serine-threonine kinases, 12 conserved subdomains 
can be identified in this 284-amino acid kinase domain. On the contrary, CDKL5 is unique in the 
CDKL-family as it displays an unusual long tail of more than 600 amino acids without obvious 
similarity to other protein domains but with a high degree of conservation between different CDKL5 
orthologs that differ only in the most extreme C-terminus. 
Interestingly, most of the pathogenic missense mutations identified so far involve the 
catalytic domain, suggesting that the enzymatic activity of CDKL5 is essential for normal 
neurodevelopment. However the ensemble of CKDL5 phosphorylation targets is hitherto rather 
uncharacterized. The presence of a critical arginine-residue in the kinase subdomain VIII suggests 
that CDKL5 might be a proline-directed kinase. Moreover, as some of the other CMGC protein 
kinases, CDKL5 appears capable of autophosphorylating its TEY motif [Kilstrup-Nielsen et al. 
2012]. Since the molecular characterization of CDKL5 started only in 2005, the protein still remains 
largely uncharacterized. 
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2.2.2 Protein isoforms 
In human CDKL5 the first two reported splice variants differ in the 5’UTRs and produce the 
same 115 kDa protein. They are referred to as isoform I, containing exon 1, which is transcribed in a 
wide range of tissues, and isoform II, including exon 1a and 1b, which is limited to testis and fetal 
brain [Kalscheuer et al. 2003; Williamson et al. 2012]. The resulting CDKL5 transcript generates a 
protein of 1030 amino acids with molecular weight of 115 kDa (CDKL5115) and is mainly expressed 
in the testis. More recently alternative splicing events have been identified, leading to at least three 
distinct human protein isoforms. Two of these transcripts, characterized by an altered C-terminal 
region, are likely to be very relevant for CDKL5 brain functions [Fichou et al. 2011; Williamson et 
al. 2012]. Firstly, an alternatively spliced isoform has been described in both human and mouse, 
which has an additional in-frame exon of 123 bp, exon 16b (between exons 16 and 17), producing a 
predicted protein of 120 kDa in humans and a 110 kDa protein in mice [Fichou et al. 2011; 
Rademacher et al. 2011]. Interestingly this variant is highly conserved in species through evolution, 
suggesting a potential functional role, but does not display any homology with other referenced 
sequences. Fichou et al. also demonstrated that the amount of exon 16b-containing (CDKL5115+ex.16b) 
transcript varies depending on the brain region analyzed and that this transcript is brain specific. The 
second isoform identified in the same year by Williamson and colleagues is a 107 kDa isoform with 
an alternative C-terminus that terminates in intron 18 (CDKL5107) and is the predominant isoform in 
human and mouse brains, suggesting that this isoform is likely to be of primary pathogenic 
importance in the CDKL5 disorder. For, in all human tissues CDKL5107 is the most abundant 
transcript, with tissues expressing 10- to 100-fold or more CDKL5107 than CDKL5115. In particular, 
in the whole brain there is 37-fold more of CDKL5107 than CDKL5115. Testis is the exception, with 
only 2.5-fold more CDKL5107 than CDKL5115 reflecting the relative abundance of CDKL5115 in this 
tissue. The C-terminus of CDKL5, which is different in the two isoforms, is important in modulating 
its subcellular localization, and the accumulation of truncated protein in the nucleus might be of 
pathogenic significance [Bertani et al. 2006; Rusconi et al. 2008]. Therefore the cellular distribution 
of the CDKL5107 isoform was examined, revealing subcellular localization and catalytic activity that 
overlap greatly, but not completely, with that of the previously studied human CDKL5115 protein. 
Furthermore, in vitro data indicate that proteasomal degradation of the CDKL5115 isoform is 
mediated by a signal between amino acids 904 and 1030, exclusively present in this isoform, 
whereas CDKL5107 is more stable and less prone to degradation through the proteasome pathway. As 
the C-terminus of the CDKL5107 isoform is an intronic sequence, it has not been investigated in most 
mutation screening studies to date, but after these findings Williamson and colleagues suggested that 
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screening of the intronic sequence should be included in the genetic analysis of patients with a 
suggestive clinical phenotype [Williamson et al. 2012]. 
 
 
 
Figure 6. The genomic structure of CDKL5 and its splice variants. (A) Human CDKL5 gene 
with untranslated sequences in grey and exons encoding the catalytic domain in blue. Exons 
encoding the common C-terminal region appear in white, whereas isoform-specific sequences are 
shown in red, green, and as hatched. (B) hCDKL5 protein isoforms differing in the C-terminal 
region. CDKL5115 contains the primate specific exons 19-21. In CDKL5107, intron 18 is retained. The 
inclusion of exon 16b would generate CDKL5115+ex.16b and/or CDKL5107+ex.16b. hCDKL5-ex19 is a 
hypothetical splice variant in which exon 19 is excluded generating alternative C-terminus (light 
blue). (C) Murine CDKL5 isoforms. mCDKL5105 harbors a distinct C-terminal region encoded by a 
mouse specific exon 19 (orange). As in humans, the retention of intron 18 generates the common 
CDKL5107 isoform. (Image taken from [Kilstrup-Nielsen et al. 2012]). 
 
Although the CDKL5107 isoform is the most important CDKL5 splice variant, there are other 
species-specific CDKL5 splice variants. A previously unidentified CDKL5 splice variant has been 
described in rat neurons and glial cells [Chen et al. 2010]. It produces a protein product with a 
variant C-terminus, ending in rat exon 19, and has a specific tissue distribution. Further investigation 
of CDKL5 in the mouse or rat as a model for human disease must consider these species-specific 
variants. 
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2.2.3 Modulation of CDKL5 abundance and localization 
Expression studies in human and mouse tissues have shown that CDKL5 mRNA is present 
mainly in the brain, where the transcripts levels are the highest, but also in a wide range of tissues. 
Indeed, it can easily be detected in tissues such as testis, lung, spleen, prostate, uterus, and placenta, 
while it is barely present, or under detection levels, in heart, kidney, liver, and skeletal muscle. 
Interestingly, CDKL5 expression in the brain correlates with neuronal maturation. For 
CDKL5 levels reach the highest in conjunction with the development and differentiation of this 
organ: CDKL5 is only weakly present during embryogenesis and get strongly induced in the early 
postnatal stages until P14 in mice, where after it declines. A detailed analysis of CDKL5 expression 
in adult mouse brain shows that its mRNA levels are particularly high in the forebrain. Higher 
expression levels are detected in the most superficial cortical layers, particularly involved in the 
connection of the two hemispheres through the corpus callosum. A slightly higher abundance of 
mRNA in the frontal cortical areas might suggest a role for CDKL5 in the physiology of such brain 
districts. Notably, fairly strong staining is detected in the motor cortex and the cingulate cortex, an 
area of high interest for the origin of a wide plethora of mental diseases. Furthermore, high levels of 
expression are detected in the pyriform cortex and, possibly, in the entorhinal cortex. Concerning the 
hippocampus, a brain area that partly shares the same developmental origin as the cortex, very high 
levels of CDKL5 mRNA have been found in all the CA fields but in the dentate gyrus, possibly in 
accordance with the establishment of CDKL5 transcription in fully mature neuronal phenotypes, 
given that the DG neuronal population undergoes adulthood neurogenesis. Considering the fair 
expression levels of CDKL5 in the striatum, it might be assumed that the glutamatergic and the 
gabaergic neurons are by far the two cellular types expressing most of the brain CDKL5. 
Accordingly, very low expression was detected in dopaminergic areas such as the substantia nigra or 
the ventral tegmental area or in noradrenergic areas such as the locus coeruleus. Interestingly, 
however, very high levels of CDKL5 transcripts are detected in several thalamic nuclei, including the 
geniculate nuclei. In the cerebellum, CDKL5 mRNA is expressed in all the lobules and, possibly, in 
the Purkinje cells; its levels, however, appear significantly lower when compared to the other brain 
areas [Kilstrup-Nielsen et al. 2012]. 
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Figure 7. CDKL5 expression is highly induced at early postnatal stages of brain 
development. (A-G) Immunohistochemistry experiments showing CDKL5 expression in the cortex 
(A-D) and hippocampus (E-G) of mouse brains at different embryonic or postnatal stages (H) 
Western blot showing CDKL5 and MeCP2 levels in the total brain at different embryonic and 
postnatal stages (I) Western blot showing CDKL5 and MeCP2 levels in different brain area of adult 
mice (P120). (Image taken from [Rusconi et al. 2008]).  
 
Recently, studies on the characterization of CDKL5 transcriptional regulation have been 
started. In 2010, Carouge and colleagues found in the rat gene a CpG-rich sequence of 0.8 kb, well 
conserved in the mouse and human counterparts [Carouge et al. 2010]. Interestingly, authors 
demonstrated that DNA methylation involving this area inhibits CDKL5 expression and the kinase 
gene is a target of repression mediated by MeCP2. These data apparently contrast earlier reports 
where CDKL5 mRNA levels were found unaltered in RTT patient lymphocytes or brains of MeCP2-
null mice [Mari et al. 2005; Weaving et al. 2004]. However, these contradictory results might stem 
from the capability of MeCP2 to act on different genes according to the specific cellular type. 
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CDKL5 transcription appears to be regulated by different stimuli and depending on the specific brain 
district. For instance, treatment with cocaine, which enhances local serotonin levels, significantly 
reduces CDKL5 transcription in the striatum of rats, but not in the frontal cortex [Carouge et al. 
2010]. 
Concerning the protein expression, available data suggest that the levels of kinase more or less 
coincide with those of mRNA in the adult brain. At the cellular level, CDKL5 is easily detectable in 
neurons while it is expressed at very low levels in the glia. The presence of different CDKL5 splice 
variants with different relative abundance depending on the localization, indicates that alternative 
splicing is involved in regulating CDKL5 functions. At the functional level, it still needs to be 
established whether the different CDKL5 isoforms have distinct functions, whereas the subcellular 
localization is grossly identical. CDKL5 functions seem to be regulated both through its subcellular 
localization and through its synthesis and degradation. In brain, CDKL5 is initially predominantly 
cytoplasmic and progressively accumulates in the nucleus, starting from roughly P14 when 
approximately 40% of total CDKL5 can be detected in this compartment. However, CDKL5 
significantly translocates to the nucleus in certain brain areas: in the cerebellum, for example, more 
than 80% of CDKL5 remains cytoplasmic while in the cortex it is almost equally distributed between 
cytoplasm and nucleus. Exogenous CDKL5 shuttles constitutively between the two main 
compartments in cultured non-neuronal cells through an active nuclear export-dependent mechanism 
involving the C-terminus of the protein and the CRM1 nuclear export receptor. Interestingly, 
however, in resting rat hippocampal neurons the protein is not dynamically shuttling and its nuclear 
exit appears to be regulated by specific stimuli: glutamate treatment induces an active export of 
CDKL5 leading to its accumulation in the cytoplasm. In the future, it will be interesting to 
understand whether post-translational modifications or interactions with other proteins are involved 
in regulating the nuclear export/import of CDKL5, and which other stimuli influence localization and 
activity of CDKL5 [Kilstrup-Nielsen et al. 2012]. 
To date, a limited knowledge of the stimuli affecting CDKL5 expression and activities is 
available. In particular, it has been demonstrated that BDNF, an activity-regulated gene encoding a 
neurotrophin already involved in several neurological and psychiatric disorders including RTT, 
induces a transient phosphorylation of CDKL5. For its part the kinase is required for the capability of 
BDNF to activate Rac1 [Chen et al. 2010]. Rac1 belongs to the Rho GTPase family of proteins and 
represents a critical regulator of actin remodeling and neuronal morphogenesis, suggesting an 
involvement of CDKL5 in such processes. Furthermore, it was demonstrated that CDKL5 is 
transported outside the nucleus into the cytoplasm in response to activation of extrasynaptic NMDA 
receptors (NMDA-R). Recent publications suggest that extrasynaptic NMDA-Rs have a role in LTD 
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and dephosphorylation of the transcription factor CREB; alterations in the cross-talk between 
synaptic and extrasynaptic receptor activities might play an important role in seizures. Of interest, 
CDKL5 is degraded by the proteasome in response to extended glutamate bath stimulation or other 
death stimuli. These results, linking CDKL5 to programmed cell death pathways, appear particularly 
intriguing considering that (i) local cell death and pruning enable proper brain development and (ii) 
proteolysis by the ubiquitin-proteasome pathway is emerging as a new mechanism controlling 
synaptic plasticity [Kilstrup-Nielsen et al. 2012]. 
Concerning this, recent findings show that, at all stages of development, neuronal 
depolarization induces a rapid increase in CDKL5 levels, mostly mediated by extrasomatic synthesis. 
In young neurons, this induction is prolonged, whereas in more mature neurons, NMDA-R 
stimulation induces a protein phosphatase 1-dependent dephosphorylation of CDKL5 that is 
mandatory for its proteasome-dependent degradation. As a corollary, neuronal activity leads to a 
prolonged induction of CDKL5 levels in immature neurons but to a short lasting increase of the 
kinase in mature neurons. Recent results demonstrate that many genes associated with autism 
spectrum disorders are crucial components of the activity-dependent signaling networks regulating 
the composition, shape, and strength of the synapse. Thus, it is reasonable to speculate that CDKL5 
deficiency disrupts activity-dependent signaling and the consequent synapse development, 
maturation, and refinement [La Montanara et al. 2015]. 
 
2.2.4 CDKL5 kinase targets and critical determinants of substrate recognition 
CDKL5 protein is a kinase whose function seems to be very relevant in particular in the 
central nervous system, by regulating different molecular pathways. However its phosphorylation 
targets are poorly known. 
First MeCP2 protein was identified as a target of CDKL5, at least in vitro [Bertani et al. 
2006; Mari et al. 2005]. Given the similarities between CDKL5 disorder and Rett syndrome and 
considering that the cause of RTT has been attributed to mutations in the MeCP2 gene, it is tempting 
to speculate about the relationship between RTT and CDKL5 disorder on the basis of 
phosphorylation of MeCP2 by CDKL5. However, due to the fact that phosphorylation of MeCP2 by 
CDKL5 is relatively weak [Kameshita et al. 2008], it is not reasonable to assume that MeCP2 is a 
direct substrate of CDKL5. Afterwards, DNA methyltransferase 1 (DNMT1) and netrin-G1 ligand 
(NGL-1) have been reported to be phosphorylated by CDKL5 [Kameshita et al. 2008; Ricciardi et al. 
2012]. DNMT1 is an enzyme that recognizes and methylates hemimethylated CpG after DNA 
replication to maintain methylation patterns, interacting among other proteins with MeCP2. 
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Interestingly, NGL-1 plays a crucial role in early synapse formation and subsequent maturation. 
Furthermore, its phosphorylation by CDKL5 strengthens the NGL1-PSD95 interaction, 
demonstrating a role for CDKL5 in spine development and synapse morphogenesis [Ricciardi et al. 
2012]. In addition, more recently it was identified amphiphysin 1 (AMPH1) as a direct, strongly 
phosphorylated, CDKL5 substrate in the mouse brain [Sekiguchi et al. 2013]. AMPH1 is a brain 
specific protein that plays important roles in neuronal transmission and neuronal development, thus 
suggesting a potential role of CDKL5 in fine control of endocytotic processes in neuronal cells by 
which neuronal development may be stringently regulated. Furthermore, a lack of AMPH1 is known 
to cause seizures and striking learning deficits, pointing at AMPH1 as a putative critical molecular 
component of the pathogenesis underlying CDKL5 neurodevelopmental disorder. 
In order to clarify the physiological substrates of CDKL5, it is important to elucidate the 
detailed molecular mechanisms of substrate recognition by CDKL5. Therefore, the molecular basis 
of substrate recognition by CDKL5 were recently analyzed by Katayama and colleagues. By using 
catalytically active CDKL5(1−352) and AMPH1/AMPH2 as model substrates, authors identified the 
consensus phosphorylation sequence to be RPXSX. Moreover, they reported that CDKL5 recognizes 
not only the sequence RPXSX around the phosphorylation site (i.e. Ser
293
) of AMPH1, but also the 
different region (CLAP domain) as a docking site. These results suggest that CDKL5 shows 
substrate specificity more restricted than that of other CMGC family protein kinases such as ERK2 
and Dyrk1A [Katayama, Sueyoshi, and Kameshita 2015]. Considering that AMPH1 is the most 
efficient and specific in vitro substrate for CDKL5 identified so far and considering its functions in 
the developing central nervous system, the molecular mechanisms underlying the 
neurodevelopmental control through phosphorylation of AMPH1 by CDKL5 surely represent an 
issue to be elucidated. 
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Figure 8. Critical determinants of substrate recognition and phosphorylation site of 
AMPH1 by CDKL5, as compared to AMPH2 isoform. Both the phosphorylation site sequence 
(RPXSX) and the CLAP domain structure in AMPH1 play crucial roles in recognition and 
phosphorylation by CDKL5. (Image taken from [Katayama, Sueyoshi, and Kameshita 2015]). 
 
2.3 Molecular mechanisms involved in CDKL5 function 
CDKL5 is a ubiquitous protein but is expressed mainly in brain (cerebral cortex, hippocampus, 
striatum, cerebellum, brainstem), thymus and testes [Lin, Franco, and Rosner 2005]. In the 
developing mouse brain, CDKL5 expression is strongly induced in early postnatal stages, and in the 
adult brain CDKL5 is present in mature neurons, but not in astroglia. CDKL5 levels are low in the 
embryonic cortex and are strongly induced at perinatal and postnatal stages in maturing neurons in 
the cerebral cortex and hippocampus. This expression profile first suggested a role of CDKL5 
protein in neuronal maturation [Rusconi et al. 2008]. CDKL5 shuttles between the cytoplasm and the 
nucleus, which might reflect a function in both cellular compartments (see e.g. Fig. 9). 
 
 
 
Figure 9. A model depicting some of the CDKL5 functions in cytoplasmic and nuclear 
compartments. (A) In the cytoplasm CDKL5 is involved in the regulation of actin cytoskeleton and 
dendritic arborization. This function is mediated by the interaction of CDKL5 with Rac1. (B) In the 
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cytoplasmic compartment, the levels of CDKL5 are regulated by degradation. (C) In the nucleus, 
CDKL5 has been proposed capable of interacting and phosphorylating MeCP2 and DNMT1, thereby 
influencing gene expression and DNA methylation. (Image taken from [Kilstrup-Nielsen et al. 
2012]). 
 
 Its presence in the cell nucleus varies at the regional level of the adult brain and is 
developmentally regulated [Rusconi et al. 2008]. CDKL5 is a kinase, though its phosphorylation 
targets are poorly known. It is reported that in vitro CDKL5 phosphorylates MeCP2, suggesting a 
common signaling pathway between these two proteins [Mari et al. 2005]. A series of experiments 
by Chen et al. first provided evidence that CDKL5 plays a critical role in neuronal morphogenesis, 
and that migratory defects may cause early seizures in patients with CDKL5 mutations. These 
authors observed that downregulating CDKL5 by RNA interference (RNAi) in cultured cortical 
neurons inhibits neurite growth and dendritic arborization, whereas overexpressing CDKL5 has 
opposite effects [Chen et al. 2010]. Knocking down CDKL5 in the rat brain by in utero 
electroporation resulted in delayed neuronal migration and severely impaired dendritic arborization 
[Chen et al. 2010]. Recently the first two mouse models for CDKL5-gene–related epileptic 
encephalopathy have been developed, further shading light on molecular mechanisms regulated by 
CDKL5. It has been demonstrated that loss of CDKL5 impairs brain development and cognitive 
behavior in knockout mice. Furthermore, at the molecular level it has been shown that CDKL5 plays 
a critical role in coordinating multiple signaling cascades, by regulating, among others, the 
AKT/mTOR/rpS6 and AKT/GSK-3β pathways, important for brain development [Amendola et al. 
2014; Wang et al. 2012]. A detailed characterization of CDKL5 mouse models is reported below in a 
separate section. 
 
2.3.1 CDKL5 regulates the function of epigenetic factors and transcriptional regulators 
The first demonstrating the phosphorylation activity of CDKL5 were Mari et al. in 2005. 
Considering the similar phenotypes caused by mutations in MECP2 and CDKL5, they investigated 
the expression patterns of both proteins in embryonic and postnatal mouse brains. CDKL5 and the 
transcriptional repressor MeCP2 show a spatial and temporal overlapping expression during neuronal 
maturation and synaptogenesis in the brain, in favor of a possible involvement of the two proteins in 
the same development pathway [Mari et al. 2005]. A schematic representation of MeCP2 mechanism 
of action as transcriptional regulator is depicted below in Fig. 10. 
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Figure 10. Vignettes of MeCP2 functions as a transcriptional regulator. MeCP2 binds to 
methylated CpG regions upstream of the transcriptional start site of target genes and recruits co-
factors for repression (A) or activation (B) of transcription. (Image taken from [Samaco and Neul 
2011]). 
 
Authors also investigated whether MeCP2 and CDKL5 directly interact in vitro and in vivo. 
By classical pull-down assays Mari and colleagues demonstrated that MeCP2 and CDKL5 are 
directly interacting in vitro and that a portion on MeCP2, containing the last residues of the TRD and 
the C-terminal region, is responsible for this association. An analog interaction was demonstrated 
also in vivo by co-immunoprecipitation experiments. Given the interaction between MeCP2 and 
CDKL5 and the overlapped expression in different brain regions, it was further investigated whether 
CDKL5 is able to autophosphorylate and to phosphorylate MeCP2. The results demonstrated that 
CDKL5 is able to phosphorylate itself and to mediate MeCP2 phosphorylation, suggesting that these 
proteins belong to the same molecular pathway. Nevertheless, there are some controversial results 
from another research group, which was able to demonstrate the autophosphorylation ability of 
CDKL5, but not to confirm that CDKL5 directly phosphorylate MeCP2 [Lin, Franco, and Rosner 
2005]. 
Furthermore, a recent report suggested a new link between CDKL5 and MeCP2. Indeed, both 
proteins have been shown to bind to DNA methyl-transferase 1 (DNMT1), an enzyme that 
recognizes and methylates hemimethylated CpG dinucleotides after DNA replication in order to 
maintain a correct methylation pattern [Kameshita et al. 2008]. More recently Carouge and 
colleagues addressed the question of the transcriptional control of CDKL5 by MeCP2 as a potential 
link between the two genes, taking advantage of in vivo MeCP2 induction by cocaine in rat brain 
structures [Carouge et al. 2010]. Their data revealed that over-expression of MeCP2 in transfected 
cells results in the repression of CDKL5 expression and that in vivo MeCP2 directly interacts with 
32 
 
CDKL5 gene in a methylation-dependent manner. Taken together these results are consistent with 
the hypothesis of CDKL5 being a MeCP2-repressed target gene and provide new insights into the 
mechanism by which mutations in the two genes result in overlapping neurological symptoms 
[Carouge et al. 2010]. 
An interesting feature of CDKL5 that distinguishes it from MeCP2 is its subcellular 
localization. While MeCP2 is only a nuclear protein, CDKL5 shuttles between the nucleus and the 
cytoplasm. The subcellular localization of CDKL5 within the cell seems to be important for its 
function. In the nucleus CDKL5 co-localizes and is associated with a number of splicing factors that 
are stored in specific nuclear foci called nuclear speckles, in both cell lines and tissues. In these 
structures CDKL5 seems to manage the nuclear trafficking of splicing factors and thus influencing 
the complex splicing machinery [Ricciardi et al. 2012]. It is already known that phosphorylation of 
the RS domain of Serine-rich (SR) splicing factors is necessary to release these factors from speckles 
and to direct them to sites where pre-mRNA processing takes place. Considering that several protein 
kinases have been described to be able to phosphorylate the RS domain of SR proteins, Ricciardi and 
colleagues have hypothesized that CDKL5 as well could have a role in nuclear speckles 
organization. Interestingly, it has been demonstrated that CDKL5 acts on nuclear speckle 
disassembly determining a redistribution of at least some speckle proteins [Ricciardi et al. 2009]. 
These results suggest that CDKL5 may play a role in controlling gene expression through 
phosphorylation of DNMT1 and alteration of CpG methylation, which may affect the transcription of 
numerous genes. In addition, altering the distribution of the splicing factor machinery within the 
nucleus may result in alternative splicing of different RNAs leading to a subset of proteins with 
subtly altered functions. 
MeCP2 and DNMT1 are well-known DNA-binding proteins that may function in the nucleus 
and they both were shown to be phosphorylated by CDKL5 in vitro. Nevertheless it is still unclear 
whether or not these proteins are direct target of CDKL5 in neurons, since the phosphorylation of 
these proteins is rather weak as the endogenous substrates. Furthermore it is important to mind that 
CDKL5 is known to be localized not only in the nucleus but also in the cytoplasm. Cellular 
localization of CDKL5 was reported to change during the process of development: it is mainly 
expressed in the cytoplasm in the early stages and gradually increased in the nucleus thereafter. 
Therefore, it is important to increase the knowledge about the endogenous substrates for CDKL5 in 
the early developing brain in relation to neurodevelopmental disorders resulted from mutations in the 
CDKL5 gene [Sekiguchi et al. 2013]. 
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2.3.2 CDKL5 affects proliferation and differentiation of cultured neuronal cells 
An elegant study carried out by Valli and colleagues in 2012, before the creation of CDKL5 
knockout (KO) mouse models, took advantage of neuroblastoma cell cultures (SH-SY5Y and 
SKNBE cell lines) to study CDKL5 functions in vitro. Neuroblastoma cells share several features 
with normal neurons and thus are considered a good in vitro model to study the biochemical and 
functional properties of neuronal cells, particularly when they are induced to differentiate upon 
treatment with agents such as retinoic acid. Authors described a correlation between CDKL5 
expression and SH-SY5Y differentiation: differentiating SH-SY5Y neuroblastoma cells exhibited 
strong up-regulation of CDKL5 expression. Conversely, over-expression of CDKL5 protein in SH-
SY5Y cells was shown to promote neuronal differentiation (Fig. 11). 
 
 
 
Figure 11. CDKL5 induces differentiation in the SH-SY5Y neuroblastoma cell line. 
Contrast phase images show that over-expression of CDKL5 through adenoviral infection induces 
differentiation in presence or not of retinoic acid (RA). (Image taken from [Valli et al. 2012]). 
 
Consistently with these data, it was observed that CDKL5 negatively regulates cell 
proliferation in the SH-SY5Y neuroblastoma cell line, by arresting the cell cycle in the G0/G1 
phases. Neuronal proliferation and differentiation represent two closely related processes, primarily 
important during brain development. Interestingly, CDKL5 expression was shown to be inhibited by 
MYCN, a transcription factor that promotes cell proliferation during brain development and plays a 
relevant role in neuroblastoma biology. Indeed, authors showed that MYCN acts as a direct repressor 
of the CDKL5 promoter [Valli et al. 2012]. These findings not only proposed a cellular mechanism 
that may explain molecular aspects of the disease phenotype, but also provided a good in vitro model 
to test the activity of a synthetic CDKL5 protein. 
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Another recent study carried out by University of Siena, Italy, correlates CDKL5 to neuronal 
differentiation. By using induced pluripotent stem (iPS) cells derived from fibroblasts of MECP2-
mutated and CDKL5-mutated patients, authors showed that neurons with CDKL5 mutation and 
neurons with MECP2 mutation have a common altered gene, GRID1, encoding for glutamate D1 
receptor (GluD1). GluD1 is a member of the delta family of ionotropic glutamate receptors which is 
involved in neuronal maturation. It does not form AMPA or NMDA glutamate receptors, yet it acts 
like an adhesion molecule by linking the postsynaptic and presynaptic compartments, preferentially 
inducing the inhibitory presynaptic differentiation of cortical neurons. Results demonstrated that 
GRID1 expression is down-regulated in both MECP2 and CDKL5-mutated iPS cells and up-
regulated in neuronal precursors and mature neurons. Although available data point to a role for 
GRID1 in neuronal maturation, no data are presently available on which could be the function of 
GluD1 in neuronal precursor cells. However, both Glutamate and GABA ionotropic receptor 
subunits and functional receptor channels are expressed very early during brain development in 
proliferating neuroepitelial cells and are considered important for events such as precursors 
proliferation, migration, differentiation and survival. It is thus possible that an alteration of GluD1 
levels in precursor cells might influence one of these processes and result in alteration of subsequent 
brain development. Importantly, these data suggest another functional link between MECP2 and 
CDKL5 genes and provide novel insights into disease pathophysiology, identifying possible new 
common therapeutic targets for treatment of RTT and CDKL5 disorder [Livide et al. 2015]. 
 
2.3.3 CDKL5 affects neuronal development and morphogenesis 
As already discussed, CDKL5 expression correlates both in vitro and in vivo with neuronal 
maturation, reaching the highest levels of expression when neurons acquire a mature phenotype, thus 
suggesting an involvement of the kinase in neuronal differentiation and arborization. One of the first 
in vivo studies on the effects of CDKL5 loss-of-function demonstrated that CDKL5 affects neuronal 
morphogenesis and dendritic arborization in cortical rat neurons subject to RNAi-mediated 
knockdown of CDKL5 [Chen et al. 2010]. It was proposed a cytoplasmic mechanism as it was found 
out that in fibroblasts and neurons CDKL5 co-localizes with F-actin in the growth cone and forms a 
protein complex with Rac1, a critical regulator of actin remodeling and neuronal morphogenesis. In 
particular, as already mentioned, it was hypothesized that loss of CDKL5 influences neuronal 
morphogenesis by deregulating the BDNF-Rac1 signaling pathway [Chen et al. 2010]. 
Recent studies on a CDKL5 KO mouse model confirmed the importance of CDKL5 in 
neuronal maturation: highly immature pattern and reduced dendritic arborization in cortical and 
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hippocampal neurons were observed in CDKL5 KO mice [Amendola et al. 2014; Fuchs et al. 2014]. 
Details are thoroughly discussed below in the text. 
Furthermore, one of the very few targets of CDKL5 identified so far is amphiphysin 1 
(AMPH1), a brain specific protein involved in neuronal transmission and synaptic vesicle recycling 
through clathrin-mediated endocytosis [Sekiguchi et al. 2013]. As previously briefly described, in 
2013 Sekiguchi and colleagues explored the endogenous substrates of CDKL5 in mouse brains 
extracts and found AMPH1 as specific cytoplasmic substrate of CDKL5. They demonstrated that 
CDKL5 phosphorylates AMPH1 exclusively at Ser
293
 and that this phosphorylation is disrupted 
when mutations in the catalytic domain of CDKL5 occur. It still remains unclear what effect 
phosphorylation of AMPH1 by CDKL5 has on its function in neuronal development, but 
interestingly AMPH1 deficient mouse shows major learning difficulties and irreversible seizures, 
suggesting that AMPH1 is a critical molecular component of the pathogenic pathway of the CDKL5 
disorder [Sekiguchi et al. 2013]. 
 
2.3.4 CDKL5 contributes to correct dendritic spine structure and synapse activity 
Further investigating the role of CDKL5 in neuronal morphogenesis, it was demonstrated that 
CDKL5 contributes also to correct spine structure and synapse activity. It was shown that CDKL5 
localizes almost exclusively at the post synaptic density of excitatory synapses, both in vivo and in 
vitro. CDKL5 silencing in rat hippocampal neurons leads to severe deficits in spine density and 
morphology and similar alterations have been found in neurons established from patient fibroblast-
derived pluripotent stem cells (iPSCs), indicating that CDKL5 is required for ensuring a correct 
number of well-shaped spines. In line with the compromised development of spines, CDKL5-
downregulated neurons exhibit a significant decrease in spontaneous miniature excitatory 
postsynaptic currents (mEPSCs), while there was no significant effect on inhibitory synapse density 
or any significant changes in miniature inhibitory postsynaptic currents [Ricciardi et al. 2012]. These 
data suggest that CDKL5 is a key-limiting factor in regulating glutamatergic synapse formation and 
that changes in excitatory synaptic strength might be responsible, at least in part, for the 
neurodevelopmental symptoms associated with this disorder.  
As previously outlined, at the molecular level CDKL5 interacts and phosphorylates the 
netrin-G1 ligand (NGL-1), a synaptic cell adhesion molecule (CAMs) that plays a crucial role in 
synapse homeostasis. NGLs have a conserved C-terminal PDZ-binding domain, which specifically 
binds to the multidomain protein postsynaptic density (PSD) 95, a protein that plays a significant role 
in learning and memory. PSD-95 is a major scaffold in the postsynaptic density and has an essential 
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role in synapse development and maturation. NGL-1 spine-inducing capability is promoted by 
targeting PSD-95 to new forming dendritic protrusions. CDKL5 phosphorylates NGL-1 on a unique 
serine (Ser
631
), which is very close to the PZD-binding domain and this phosphorylation event 
ensures a stable association between NGL-1 and PSD-95 [Ricciardi et al. 2012]. These data indicate 
that CDKL5 is critical for the maintenance of synaptic contacts, mainly by regulating the NGL-1 
phosphorylated state and thereby its ability to bind PSD-95 and by stabilizing this association.  
More recently the critical role of CDKL5 in regulating spine development and synapse 
activity was further demonstrated by the fact that CDKL5 was shown to directly bind to PSD-95, in a 
palmitoylation-dependent way. The PSD-95 N-terminal domain is post-translationally modified by 
palmitoylation, a reversible attachment of 16-carbon palmitate to a cysteine residue. Such palmitate 
cycling on PSD-95 controls its polarized targeting to synapses, which is essential for its synaptic 
function. CDKL5 binds to palmitoylated PSD-95 and this binding promotes the targeting of CDKL5 
to excitatory synapses. There were proposed two possible ways by which palmitoylated PSD-95 
regulates synaptic targeting of CDKL5. First, CDKL5 may bind to palmitoylated PSD-95 at the 
Golgi apparatus and then the complex moves to the postsynaptic side. Second and more likely 
important in neurons, free CDKL5 is captured by newly palmitoylated PSD-95 at the dendrites and 
then trafficked to synapses, to become enriched at the subsynaptic site. Taken together these results 
demonstrate a critical role of the palmitoylation-dependent CDKL5-PSD95 interaction in localizing 
CDKL5 to synapses for normal spine development [Zhu et al. 2013].  
In particular, PSD-95 is a central element of the postsynaptic architecture of glutamatergic 
synapses, mediating postsynaptic localization of AMPA and NMDA receptors. PSD-95 is released 
from postsynaptic membranes in response to Ca
2+ 
influx via NMDA receptors and it has been 
recently shown that Ca
2+
/calmodulin (CaM) binds at the N-terminus of PSD-95. This N-terminal 
capping blocks palmitoylation, which is required for postsynaptic PSD-95 targeting and the binding 
of CDKL5, in turn promoting Ca
2+
-induced dissociation of PSD-95 from the postsynaptic membrane 
[Zhang et al. 2014]. Very recently, a further confirmation of the close relationship between CDKL5 
and PSD-95 came from a study on a newly generated CDKL5 KO mouse model, which reported that 
adult mutant mice show a significant reduction in spine density associated with a reduction in PSD-
95-positive synaptic puncta [Della Sala et al. 2015]. 
These data imply that two pathways are important in mediating the cytoplasmic function of 
CDKL5: first of all CDKL5 is required for BDNF-induced activation of Rac1, which participates in 
stabilizing the actin cytoskeleton; on the other hand CDKL5, PSD-95 and NGL-1, form a protein 
complex that functions coordinately to regulate synapse development. These data show that different 
CDKL5-signaling cascades are involved in synaptic plasticity and learning, acting on spines, 
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dendritic branching and actin cytoskeleton and elucidate, in part, how the lack of CDKL5 may 
contribute to the typical neuronal phenotype of the CDKL5 disorder. 
 
2.3.5 Loss of CDKL5 alters lipid serum profile in patients 
Very recently, an Italian group lead by Dr. Hayek and Dr. Valacchi demonstrated a 
cholesterol homeostasis perturbation in CDKL5 patients, similarly to what previously described by 
the same group for RTT patients [Pecorelli et al. 2011; Sticozzi et al. 2013]. Such alteration was 
associated with oxidative-mediated loss of the high-density lipoprotein receptor SRB1 (scavenger 
receptor class B, type 1) and impaired activation of the defensive system Nrf2 (nuclear factor 
erythroid 2-related factor 2). In addition, CDKL5 fibroblasts showed an increase in 4-hydroxy-2-
nonenal– and nitrotyrosine–SRB1 adducts that lead to its ubiquitination and probable degradation. 
In particular, authors found a significant increase in HDL and LDL levels in CDKL5 patients. 
Indeed, SRB1 is involved in the binding of HDL and LDL, thereby promoting selective tissue uptake 
of cholesterol. Furthermore, SRB1 is also implicated in several other cellular processes, such as 
recognition of pathogens and apoptotic cells as well as uptake of lipid-soluble antioxidants. 
The presence of systemic redox imbalance has been described for both RTT and CDKL5 
disorders although the molecular mechanism responsible for increased oxidative stress was not 
elucidated [Leoncini et al. 2015; Pecorelli et al. 2011]. One of the main mechanisms involved in the 
cellular antioxidant defense is the activation of the Nrf2 system, a major transcription factor for 
antioxidant and cytoprotective responses. Upon oxidative stress, Nrf2 translocates into the nucleus 
and binds to electrophile response elements (EpRE’s, also known as antioxidant response elements), 
increasing transcription of genes related to cellular defense. Impaired Nrf2 activation has been 
suggested for several pathologies. CDKL5 patients show an increase in both oxidative and 
nitrosative stress markers and a Nrf2 aberrant activation, all factors that can contribute to cell 
damage, thus demonstrating a novel mechanism in CDKL5 pathology. 
Because of the strictly controlled diet of patients, the reported increase in serum cholesterol 
levels should be the consequence of an altered lipid metabolism linked to the disease. In addition, 
cholesterol has multiple roles in the nervous system, from membrane trafficking to myelin formation, 
along with synapses formation. Therefore, the understanding of cholesterol metabolism has become 
an emerging area in several neurological diseases. These findings highlights a possible common 
denominator between RTT syndrome and CDKL5 disorder and a possible common future 
therapeutic target [Pecorelli et al. 2011]. 
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Figure 12. Several mechanisms can play a role in CDKL5 disorder, such as redox 
imbalance and altered cholesterol pathway. Owing to a possible Nrf2 aberrant activation with a 
defective expression of Nrf2 target genes, in CDKL5-defective cells the redox imbalance can 
contribute to the loss of SRB1 as a consequence of increased oxidative modifications and ubiquitin 
adduct formation in SRB1 protein. In addition, the decrease in SRB1 levels is associated with the 
reduction in intracellular lipid uptake and the increase in serum lipoproteins found in CDKL5 
patients. Finally, a possible positive feedback loop can be the cause of the SRB1 mRNA 
overexpression. ARE, antioxidant-response element. (Image taken from [Pecorelli et al. 2011]). 
 
2.3.6 Oxidative stress and inflammatory status are dysregulated in CDKL5 patients 
A complex cytokine dysregulation was recently evidenced in RTT and CDKL5 patients. In 
CDKL5 disorder in particular, both T helper type 1- (Th1-) related cytokines (IL-1 , TNF- , IFN- , 
and IL-12p70) and T helper type 2- (Th2-) related cytokines (IL-4, IL-5, IL-6, IL-10, IL-13, and IL-
33), except for IL-4, were found to be upregulated. Moreover, increased levels were observed also 
regarding proinflammatory IL- 22 and regulatory T (T-reg) cytokine TGF- 1. Chemokines were 
found unchanged. Interestingly, the observed cytokine dysregulation was proportional to clinical 
severity, inflammatory status, and redox imbalance. Furthermore, 12-month supplementation with  -
3 polyunsaturated fatty acids (PUFAs), in the form of fish oil before food intake, partially 
counterbalanced cytokine changes, as well as aberrant redox homeostasis and the inflammatory 
status. 
The overall cytokine pattern changes in CDKL5 patients appear to reflect a likely 
macrophage dysregulation/dysfunction. In particular a strongly increased production of TNF-  and a 
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strongly increased release of IL-10 and IL-12p70 were evidenced. TNF-  is a proinflammatory 
cytokine, produced in response to inflammatory stimuli. Elevated levels of TNF-  have been 
reported in rheumatoid arthritis, ankylosing spondylitis, irritable bowel disease, and psoriasis. 
Actually, none of the clinical features observed in these associated pathologies are usually present in 
CDKL5 disorder. Upregulation of both Th1- and Th2-related cytokines in CDKL5 disorder does not 
translate into increased inflammatory marker levels, likely due to a bulk increase in the anti-
inflammatory IL-10 (about 21-fold), a key regulator cytokine of immune response. The clinical 
translation for the observed changes remains to be elucidated. Nevertheless, cytokine dysregulation 
in RTT appears to be associated with a proinflammatory status, as evidenced by raised erythrocyte 
sedimentation rate (ESR) values, as nonspecificmarker of inflammation, and an acute phase protein 
response. On the other hand, the final result in CDKL5 remains unclear, given that ESR was found to 
be slightly higher than control values, although not statistically different. To date, no information 
concerning immunological response, inflammatory status, or defense against infections is available 
for this condition. Overall, the observed cytokine dysregulation does not appear to translate into a 
primary immunodeficiency, nor in a classical autoimmune disease. Although the reasons behind to 
date observed cytokine dysregulation are unknown, possible explanations may include either a 
defective genetic/epigenetic control on target genes or an aberrant redox imbalance. 
Oxidation of polyunsaturated fatty acids, with consequent enhanced formation of isoprostanes 
and neuroprostanes (markers of brain grey matter oxidative injury), is one of major features of 
oxidative stress. Analysis of the redox status in both RTT and CDKL5 disorder evidenced oxidative 
imbalance, mirrored by a strong decrease in reduced/oxidized glutathione (GSH/GSSG) ratio in both 
conditions. 
Therefore, a complex interplay exists between cytokines, redox homeostasis, and 
inflammatory status in RTT and CDKL5 disorder. Statistically, cytokine levels were found to explain 
a very consistent fraction of the observed variance for subclinical inflammation and redox 
abnormality, thus indicating that the aberrant immune response, as regulated by cytokine signalling, 
is intimately related to redox imbalance and both are likely responsible for modulating phenotype 
severity. 
A beneficial effect of  -3 PUFAs, in the form of fish oil containing mainly eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA), partially counterbalance cytokine changes, aberrant 
redox homeostasis and proinflammatory status. In particular, a consistent number of the investigated 
cytokines appear to be rescued following a 12-month high dosage supplementation. Target cytokines 
for  -3 PUFAs include TNF- , IL-4, IL-5, IL-13, IL-17A, IL-8, IP-10, and I-TAC in CDKL5 
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patients. These data appear to further support and extend prior reports on the immunomodulatory 
effects of DHA and EPA in biological systems. 
These findings indicate that RTT and CDKL5 disorders are associated with a subclinical 
immune dysregulation, as a likely consequence of a defective inflammation regulatory signaling 
system. This abnormal regulation of the inflammatory response appears to be an unrecognized 
hallmark feature of such diseases, intimately related to oxidative stress imbalance and likely 
contributing to disease expression [Leoncini et al. 2015]. 
 
2.3.7 CDKL5 is overexpressed in Adult T-cell Leukemia (ATL) cells 
Another involvement of CDKL5 in peripheral processes was found by chance in Adult T-cell 
Leukemia (ATL) biology. In 2007 Kawahara and colleagues attempted a comprehensive analysis of 
human leukocyte antigen (HLA) class I-bound peptides presented on ATL cells. They took 
advantage of the latest technology of mass spectrometry combined with reversed phase liquid 
chromatography (LC/MS) to identify novel tumor-associated antigens. The sequenced peptides for 
those compatible with the motives of the respective HLA class I alleles were screened and then the 
candidate peptides were narrowed down according to the differential expression of their source 
proteins between ATL cells and normal CD4+ T cells. Interestingly, among these candidates, authors 
found CDKL5 protein to be highly expressed in several ATL cell lines and some ATL clinical 
samples, but not in normal CD4+ T cells. Therefore, they focused on CDKL5 as a putative novel 
target of immunotherapy for ATL. They furthermore induced cytotoxic T-lymphocytes from a donor 
that specifically killed CDKL5+ ATL cells [Kawahara et al. 2007]. The identification of CDKL5 as 
tumor-associated antigen indicates for the first time in vivo an involvement of CDKL5 in tumor 
biology. While in neuroblastoma cells over-expression of CDKL5 inhibits proliferation and induces 
differentiation, indicating a sort of anti-tumor effect of CDKL5, no tumor development has been 
reported so far in CDKL5-deficient patients, but it should be kept in mind that reported patients are 
all young. Interestingly, on the contrary of what happens in neuroblastoma cells, the kinase was 
found to be over-expressed in ATL. Kawahara and colleagues did not investigate the specific role of 
CDKL5 in ATL pathogenesis, but its function in blood cells represents an interesting cue to study. 
 
2.4 CDKL5 KO mouse models 
CDKL5 is an X-linked gene associated with early infantile epileptic encephalopathy 2 
(EIEE2), atypical Rett syndrome (RTT), and autism spectrum disorders (ASDs). Patients with 
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CDKL5 mutations display a heterogenous array of clinical phenotypes, the most prominent of which 
include early-onset seizures and intellectual disability with autistic features. CDKL5 is a 
serine/threonine (S/T) kinase that is highly expressed in the brain [Kilstrup-Nielsen et al. 2012] and 
in vitro studies demonstrated that it may mediate the phosphorylation of MeCP2 [Mari et al. 2005], 
DNMT1 [Kameshita et al. 2008], NGL-1 [Ricciardi et al. 2012] and AMPH1 [Sekiguchi et al. 2013]. 
RNAi-mediated knockdown studies showed that CDKL5 can regulate neuronal outgrowth and 
synapse stability [Chen et al. 2010; Ricciardi et al. 2012]. Despite these proposed functions, the exact 
role of CDKL5 in the brain functions remains unclear, and thus requires further investigation. The 
limited understanding of CDKL5 mechanisms of action and its associated signal transduction 
pathways has hindered the development of therapeutics for CDKL5-related disorders. For this 
reason, in order to investigate the functions of CDKL5 in a disease model and identify potential 
avenues of therapeutic intervention, two different CDKL5 KO mouse models have been recently 
developed. 
 
2.4.1 The Wang model: deletion of exon 6 
In 2012 Wang and colleagues from the University of Pennsylvania, with Dr. Zhou 
coordinating the research group, generated the first CDKL5 KO mouse. It models a splice site 
mutation found in a CDKL5 patient. This mutation results in the skipping of human CDKL5 exon 7, 
generating a premature termination codon and causing an early truncation of CDKL5 in its N-
terminal kinase domain, thereby disrupting kinase activity. To mimic the effects of this splice site 
mutation, it was deleted mouse CDKL5 exon 6 through homologous-mediated recombination in 
embryonic stem cells. Deletion of CDKL5 exon 6 leads to a similar shift in the reading frame and 
premature truncation within the N-terminal kinase domain, likely representing a loss-of-function 
mutation (Fig. 13). Experimental mice have been backcrossed onto the C57BL/6 background for at 
least six generations and knockout mice resulted viable, fertile, and with normal appearance, growth, 
and overall brain morphology. Since CDKL5 is localized on X chromosome, the genotypes deriving 
from deletion of CDKL5 gene are: homozygous females (-/-), heterozygous female (+/-) and 
hemizygous males (-/Y). 
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Figure 13. Generation of CDKL5 KO mice in the Wang model. (A) Targeting strategy. 
Three loxP sites and a neomycin positive selection cassette (Neo) were inserted surrounding the 
genomic locus of CDKL5 exon 6 via homologous recombination. Upon Cre-directed recombination, 
both the Neo cassette and exon 6 were excised. (B) Schematic of CDKL5 protein in WT and KO. The 
excision of exon 6 causes a reading frame shift, resulting in a TAA stop codon in the 5' end of exon 7, 
leading to truncation of CDKL5 in its kinase domain (red). (Image taken from [Wang et al. 2012]). 
 
Core characteristics of CDKL5-related disorders include early-onset seizures, severe 
intellectual disability, and autistic-like features. In the behavioral analysis, the Wang model mirrors 
the latter features, but not early-onset seizures. Despite the large degree of homology between the 
murine and human CDKL5 protein, the absence of spontaneous seizures observed in the CDKL5 KO 
mice may reflect a distinct function or modification of CDKL5 in humans that is absent in lower 
organisms. Moreover, the C57BL/6 genetic background is known to confer increased seizure 
resistance, thus potentially occluding spontaneous seizures in the CDKL5 KO mice. CDKL5 KO 
mice display hyperactivity, motor defects, reduced anxiety, decreased sociability, and impaired 
learning and memory. These phenotypes have been described in other ASD and RTT mouse models 
and may mimic the absence of hand skills, intellectual disability, hyperactivity, and poor response to 
social interactions that have been described in CDKL5 patients. 
Sensory information processing measured as an event-related potential (ERP) has recently 
been proposed as a biomarker to monitor neural circuit function in ASD and RTT animal model. In 
the Wang model ERP analysis showed attenuated and delayed ERP polarity peaks in the KO 
compared to WT mice, suggestive of impaired neuronal connectivity, which is consistent with 
43 
 
findings in ASD and RTT patients and animal models. 
Given the highly conserved S/T kinase domain in CDKL5, the CDKL5 loss-of-function 
disrupts phosphorylation profile of CDKL5 kinase substrates and related signaling pathways, thereby 
mediating deficits in neuronal network communication and autistic-like behaviors. Therefore, to 
investigate the signaling networks affected by the absence of CDKL5 in vivo, Wang and colleagues 
surveyed the S/T kinome profile in CDKL5 KO mice, assessing the consequence of CDKL5 loss-of-
function on overall S/T phosphorylation events. Interestingly, the S/T kinome study revealed that 
many signal transduction pathways are disrupted in CDKL5 KO mice. Of these, many pathway 
components, including the AKT–mTOR pathway, have been implicated in the etiology of ASDs. 
Given that mTOR is a known regulator of cell growth, proliferation, motility, and neural plasticity, 
one consequence of reduced AKT–mTOR activity in the absence of CDKL5 is the disruption of 
neuronal development. Accordingly, RNAi-mediated knockdown of CDKL5 results in impaired 
dendritic outgrowth, neuronal migration, and spine maturation. Together, these data suggest a 
mechanism by which CDKL5 regulates AKT–mTOR-mediated cellular development, thus 
implicating the AKT–mTOR pathway as a potential therapeutic target for treatment of patients with 
CDKL5-related disorders. 
In addition to the AKT–mTOR pathway, authors found that the phosphorylation profiles of 
kinases involved in synaptic plasticity, including PKA, PKC and PKD, as well as kinases involved in 
cellular metabolism, including AMPK, ATM/ATR, and casein kinase (CK) were also decreased in 
CDKL5 KO mice. Notably, links between these signaling pathways have been previously described, 
as CK regulates glutamatergic synaptic transmission, ATM mediates AKT S
473
 phosphorylation, and 
mutations in ATM cause the neurodegenerative movement disorder ataxia telangiectasia. Although 
many of these signaling changes may be indirect effects of CDKL5 loss-of-function, these data 
suggest that CDKL5 plays a critical role in coordinating multiple signaling cascades. It is possible, 
therefore, that CDKL5 may serve to mediate cross-talk between these signaling pathways [Wang et 
al. 2012]. 
 
2.4.2 The Amendola model: deletion of exon 4 
At the same time, in parallel to the previously described model, another CDKL5 KO mouse 
model was created by the EMBL in Monterotondo (Italy), by the group lead by Dr. Gross. A 
constitutive knockout allele of CDKL5 was produced by germline deletion of exon 4 of a CDKL5 
conditional knockout allele produced by standard gene targeting in embryonic stem cells. Stem cell 
clones were injected into C57BL/6N host embryos. A loxP site was inserted upstream of the exon 4 
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and positive offspring were further crossed to C57BL/6J congenic Cre-deleter mice to generate the 
CDKL5 null allele. Similarly to the Wang model, knockout mice have no differences in viability, 
body weight and brain weight compared to wild type littermates. Furthermore, in order to better 
define the role of CDKL5 in neurons, authors also used a conditional knockout approach to map the 
behavioral features identified to distinct populations of forebrain neurons [Amendola et al. 2014]. 
 
 
 
Figure 14. Generation of CDKL5 conditional KO mice in the Amendola model. Figure 
shows genomic organization of the CDKL5 locus showing critical exon 4 (ENSMUSE00000346596), 
the targeting construct, successfully targeted CDKL5 locus (genotyping primers indicated by 
arrows), FRT-deleted conditional CDKL5 KO allele, and Cre-deleted constitutive CDKL5 KO allele. 
(Image taken from [Amendola et al. 2014]). 
 
Behavioral features 
Behavioral characterization on constitutive CDKL5 KO mice revealed abnormal clasping of 
hind-limbs in a significant fraction of heterozygous and homozygous female as well as hemizygous 
male mice while no, or very low levels of clasping were seen in wild type littermates (Fig. 19). 
Home cage activity showed a significant decrease in locomotion, not seen when mice were placed in 
a novel open arena, suggesting that the deficit did not reflect a reduced capacity for locomotion (Fig. 
19, graph). Furthermore, loss of CDKL5 impairs hippocampus-dependent learning and memory, 
assessed with Y-maze, Morris Water Maze and Passive Avoidance tasks. This finding is consistent 
with neuroanatomical defects seen in the hippocampus of knockout mice, reported below [Fuchs et 
al. 2015; Fuchs et al. 2014]. 
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Figure 15. Behavioral impairments in the CDKL5 KO mice. Image shows clasping behavior 
(on the left) and locomotor activity (on the right). Image taken from [Amendola et al. 2014]. 
 
Neurophysiological features 
Several physiological substrates were examined, including spontaneous and convulsant-
induced electroencephalograph (EEG) activity and visual evoked potentials (VEPs). The visual drum 
test showed that CDKL5 KO mice have a significant decrease in the number of head tracks responses 
to a continuously moving visual stimulus compared to wild type littermates and VEP analysis 
indicated deficient visual processing in the mutant mice. Although early onset seizures are a 
prominent feature of CDKL5 disorder, no evidence for spontaneous seizures emerged during 
videotaped observations. By backcrossing consitutive CDKL5 KO mice onto the DBA/2J 
background, Amendola and colleagues demonstrated that the C57BL/6 genetic background, known 
to have high seizure resistance, was not masking an epileptic phenotype as no evidence of 
spontaneous seizures in knockout mice emerged on the DBA/2J genetic background. While CDKL5 
KO mice do not exhibit spontaneous seizures or increased seizure susceptibility, they do show 
abnormal EEG response to pro-convulsant (kainic acid) treatment [Amendola et al. 2014]. 
 
Neuroanatomical features 
Anatomical analysis was carried out in order to identify aberrant morphological features of 
neurons, including cortical neuron dendritic arborization reported following the developmental 
knockdown of CDKL5 in rat [Chen et al. 2010]. Reduced dendritic arborization in CDKL5 KO mice 
was observed in layer V cortical and CA1 hippocampal pyramidal neurons: total length of apical 
dendritic arbors was significantly reduced in homozygous (-/-) female and hemizygous (-/y) male 
CDKL5 KO mice compared to wild type littermates, while dendritic arbor length of cortical neurons 
in heterozygous (-/+) female CDKL5 KO mice showed an intermediate mean distribution. Reduced 
dendritic arborization was associated with a significant reduction in cortical thickness and in the 
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thickness of hippocampal layers, including CA1, stratum oriens and the molecular layer of both the 
upper and lower blades of the dentate gyrus [Amendola et al. 2014]. 
A further characterization of hippocampus features in the Amendola CDKL5 KO mouse 
model was carried out by our laboratory. In the early postnatal period, CDKL5 brain expression 
exhibits a peak [Ricciardi et al. 2012; Zhu et al. 2013], suggesting its potential importance in brain 
maturation and function. We mainly focused our study on the hippocampal dentate gyrus as it is a 
region that largely develops postnatally, thus representing an ideal model to study neurogenesis and 
brain development. 
 
 
Figure 16. An overview of hippocampal neurogenesis. (Image taken from [Masiulis, Yun, 
and Eisch 2011]). 
 
We found a higher proliferation rate of neural precursors in CDKL5 KO mice in comparison 
with wild type mice. However, there was an increase in apoptotic cell death of postmitotic granule 
neuron precursors, resulting in a reduction in total number of granule cells. Looking at dendritic 
development, we found that in CDKL5 KO mice the newly-generated granule cells exhibited a 
dendritic tree with a highly immature pattern, evidenced by little branching and elongation (See Fig. 
17). These data suggest that CDKL5 plays a fundamental role on postnatal hippocampal 
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neurogenesis, by affecting neural precursor survival and maturation of newborn neurons [Fuchs et al. 
2014]. 
 
 
 
Figure 17. Post-mitotic neurons in the dentate gyrus of CDKL5 KO mice. (A) Schematic 
representation of adult hippocampal neurogenesis. The subgranular zone (SGZ) of the dentate gyrus 
(DG) is inhabited by a heterogonous population of cells which go through a series of stages 
associated with proliferative activity: from stem cell (type 1 cells, expressing Nestin and SOX2) over 
intermediate progenitor stages (type 2a/b and type 3) to postmitotic maturation. Doublecortin (DCX) 
is widely expressed by the actively dividing type 2b and type 3 intermediate progenitor cells and also 
by immature granule neurons and these two cell types can be distinguished based on their 
morphology: while type 2b/3 cells are orientated parallel to the SGZ (red asterisks), immature 
granule neurons have a vertical orientation and extend long apical processes into the granule cell 
layer (GR). (B) Examples of sections processed for DCX immunostaining from the DG of wild-type 
(+/Y) and hemizygous male (-/Y) CDKL5 KO mice. The high magnification photomicrograph show 
immature DCX-positive neurons (vertical orientation with apical processes; black arrows) in the 
innermost portion of the GR and type 2b/3 DCX-positive granule cells (orientated parallel to the 
GR; red asterisks) in the SGZ. (Image taken from [Fuchs et al. 2014]). 
 
Besides the dendritic arborization, dendritic spines of knockout mice were analyzed. It has 
been recently shown that rodent neurons silenced for CDKL5 and iPSC-derived neurons from 
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patients with CDKL5 mutations exhibit aberrant dendritic spines. Furthermore, CDKL5 was shown 
to interact with synaptic proteins in vitro [Chen et al. 2010; Ricciardi et al. 2012]. A first in vivo 
dendritic spine analysis in the CDKL5 KO mouse model demonstrated that CDKL5 plays a crucial 
role in the organization and maintenance of synaptic structure. Physiologically adult dendritic spines 
maintain a significant degree of plasticity undergoing different processes such as formation, 
elongation, stabilization, and retraction. Thus, to understand the role of CDKL5 in these processes, 
the dynamical changes of dendritic spines in CDKL5 KO mice were analyzed, both during postnatal 
development and adulthood. Taking advantage of in vivo two photon imaging, evidence showed that 
CDKL5 absence results in a specific deficit of dendritic spines stabilization that is prominent in 
juvenile mice and that persists in the adult. Consistently, the density of dendritic spines is greatly 
reduced. Moreover, spine deficits are accompanied by molecular and functional synaptic alterations, 
consisting in a reduction of synaptic PSD-95, impaired LTP maintenance, and reduced spontaneous 
EPSC frequency [Della Sala et al. 2015]. 
 
  Molecular features 
Molecular analyses of CDKL5 KO mice brains were carried out on several signaling 
pathways identified to be altered in MeCP2 knockout mice and thought to be relevant to Rett 
syndrome. A first screening revealed that no change in MeCP2 protein levels and BDNF 
immunoreactivity, reported to be reduced in MeCP2 knockout brain, occurred in CDKL5 KO mice. 
Looking at the molecular mechanisms whereby loss of CDKL5 may alter brain development, 
it was identified a central role of activated protein kinase B (PKB/AKT), a critical component of 
neurotrophin signaling and up-stream modulator of different signaling pathways. Decreased levels of 
phosphorylated AKT were observed in extracts of hippocampus from CDKL5 KOs when compared 
to wild type littermates. Moreover, as reported in MeCP2 mutant mice, levels of Ser
240/244
-
phosphorylated ribosomal protein S6 (rpS6), a ribosomal regulatory subunit and modulator of protein 
translation, were significantly reduced in somatosensory cortex of CDKL5 KO mice. 
Phosphorylation of Ser
240-244
 residues of S6 ribosomal protein is specifically induced by the action of 
the mTOR/PI3K pathway. These findings suggest that down-regulation of the rpS6 pathway may be 
a common signaling deficit in CDKL5 disorder and Rett Syndrome and point to defective 
translational regulation as a potential core mechanisms for common pathological features of these 
disorders [Amendola et al. 2014]. 
Besides disruption of AKT/mTOR/rpS6 signaling cascade, it was observed also disruption of 
the AKT/GSK3β signaling pathway in neural precursor cells of CDKL5 KO mice, leading to reduced 
phosphorylation at Ser
9
 of GSK-3β. Glycogen synthase kinase 3 (GSK-3β) is a ubiquitously active 
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serine/threonine kinase which is inhibited upon phosphorylation at Ser
9
 by AKT. AKT/GSK-3β 
signaling is known to regulate diverse developmental events in the brain, including neurogenesis, 
neuron survival and differentiation. Further evaluation of phosphorylation levels of proteins involved 
in the AKT/GSK-3β pathway showed lower phosphorylation levels of: i) PDK1 (PDK1 stands 
upstream by phosphorylating AKT), ii) AKT, at its two critical residues Thr
308
 and Ser
473
, iii) GSK-
3β at Ser9, and iv) CREB at Ser133 in CDKL5 KO in comparison with wild type mice. While CREB 
phosphorylation and consequent DNA binding is inhibited by activated (Ser
9
-dephosphorylated) 
GSK-3β, collapsin response mediator protein-2 (CRMP2) is phosphorylated and consequently 
inactivated by GSK-3β. In contrast, GSK-3β controls the amount of β-catenin by negatively 
regulating β-catenin protein stability. In line with an increased activity of GSK-3β, there were found 
higher phosphorylation levels of CRMP2 and lower levels of β-catenin. No differences were found 
between CDKL5 KO and wild type mice in the phosphorylation levels of ERK, suggesting a specific 
alteration of the AKT/GSK-3β pathway in the absence of CDKL5. These findings strongly suggest a 
putative mechanism by which loss of CDKL5 impairs neuron survival and maturation by disrupting 
the AKT/GSK-3β signaling pathway [Fuchs et al. 2014]. 
 
 
 
Figure 18. Diagram of AKT/GSK-3β signaling cascade. Proteins emphasized in red showed 
significantly altered phosphorylation or expression whereas proteins emphasized in blue did not 
show significantly alteration in CDKL5 KO mice in comparison to wild-type littermates. Lithium, an 
inhibitor of GSK-3β, is green colored. Image taken from [Fuchs et al. 2014]. 
 
In conclusion, these data indicate a central role of the AKT/mTOR/rpS6 and AKT/GSK-3β 
signaling pathways in the pathogenesis of CDKL5 disorder and point toward such pathways as 
potential therapeutic targets for the treatment of neurological symptoms of the disease. A first 
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investigation of treatments targeted to these molecular pathways is reported below in the text. 
 
Ex vivo neuronal culture analysis 
An ex vivo analysis of neuronal precursor cells (NPCs) derived from CDKL5 KO mice was 
carried out by our laboratory. Cultures of NPCs from the subventricular zone (SVZ) of CDKL5 KO 
mice were observed to exhibit the same defects observed in vivo in granule cell precursors. Namely, 
in cultures of neuronal precursor cells derived from wild type mice there were more neurons (β-
tubulin III positive cells) than in cultures of neuronal precursor cells derived from CDKL5 KO mice. 
This suggests that the loss of CDKL5 decreases the survival of postmitotic neurons. Assessment of 
neurite outgrowth in β-tubulin III positive cells demonstrated that neurons generated from CDKL5 
KO NPCs were less differentiated compared to wild type neurons. These results indicate that 
postmitotic NPCs from CDKL5 KO mice have an intrinsic defect, not only in cell survival, but also 
in neuronal maturation. Furthermore, disruption of the AKT/GSK3β signaling pathway in neural 
precursor cells of CDKL5 KO mice, leading to reduced phosphorylation at Ser
9
 of GSK-3β, was 
observed. As shown in Fig. 19, pharmacological normalization of GSK-3β phosphorylation levels 
restored neuron survival and maturation, suggesting a potential therapeutic strategy to test in vivo 
[Fuchs et al. 2014]. 
 
 
 
Figure 19. AKT/GSK3-β pathway immunoreactivity in NPCs from CDKL5 KO mice. 
Representative double-fluorescence images of NPCs after 6 days of differentiation. Cells with 
neuronal phenotype are immunopositive for β-tubulin III (red) and cells with astrocytic phenotype 
are immunopositive for GFAP (green). Cell nuclei were stained using Hoechst dye (blue). NPC 
cultures from KO mice treated with Litium, a GSK-3β inhibitor, exhibit restored maturation. (Image 
taken from [Fuchs et al. 2014]). 
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Conditional CDKL5 KO models 
To help identify the cell-types in which CDKL5 deletion drives pathological phenotypes, 
Amendola and colleagues examined mice carrying a Cre-conditional knockout (cKO) allele of 
CDKL5. The CDKL5 conditional knockout allele was crossed with the Dlx5/6::Cre transgene or  
with the Emx1::Cre transgene respectively for deletion in forebrain GABAergic neurons (e.g. 
cortical interneurons, striatal medium spiny neurons) or in cortical glutamatergic neurons (e.g. 
cortical and hippocampal pyramidal neurons). 
Both Dlx5/6 and Emx1 cKO mice appeared outwardly normal at birth and showed normal 
body weight and viability when compared to littermate controls. A general behavioral screen 
revealed abnormal clasping of hind-limbs in a significant fraction of Emx1-conditional, but not in 
Dlx5/6-conditional CDKL5 KO mice. Continuous monitoring of home cage activity revealed a 
significant decrease in locomotion in hemizygous male Dlx5/6-conditional, but not Emx1-
conditional CDKL5 KOs. Finally, measurement of head tracking responses to a continuously moving 
visual stimulus in the visual drum test showed that Emx1 cKO mice showed a trend for decreased 
head tracking, while Dlx5/6 cKO did not show deficits. 
Taken together these data argue that the behavioral phenotypes seen in CDKL5 KOs can be 
mapped to diverse forebrain neuronal populations, with defects in limb clasping and head tracking 
associated with glutamatergic neurons and hypolocomotion associated with GABAergic neurons. 
These findings reveal a double dissociation of behavioral phenotypes and have several implications. 
First, they suggest that behavioral deficits in CDKL5 disorder derive from the localized absence of 
the kinase in forebrain neurons. Second, they suggest that the limb control and eye tracking 
phenotypes depend on cortical motor and visual circuit deficits that are separable from those 
underlying hypotonia. Whether the later phenotype depends on deficits in cortical interneuron 
function or deficits in subcortical circuits cannot be determined at this point, although the double 
dissociation observed in Emx1- and Dlx5/6-conditional mice suggests that non-cortical regions 
control the hypolocomotion phenotype. Basing on these findings, it is reasonable to hypothesize that 
therapies aimed at re-expression of CDKL5 in cortical pyramidal neurons may have success in 
reversing the most debilitating behavioral phenotypes of the disorder [Amendola et al. 2014]. 
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2.5 Current perspectives of treatment for CDKL5 disorder 
2.5.1 Pharmacological therapies 
CDKL5 disorder is a chronic debilitating condition associated with severe intellectual 
disability. The neurodevelopmental delay associated with mutations in the CDKL5 gene leads to 
gross motor impairment, autistic-like features and intractable epileptic seizures from the very first 
months of life. No cure is currently available for CDKL5 patients given the complexity of this 
disease, thus having a strong impact on patients’ families and on health-care system. Current 
treatments focus only on managing symptoms and reducing seizure frequency, but have limited 
effectiveness [Bahi-Buisson and Bienvenu 2012]. 
The analysis of genetic models of CDKL5 deletion enabled the identification of signaling 
pathways involved in the brain action of CDKL5. There were reported deficits in the activation of 
several kinases, suggesting them as potential targets for symptomatic therapies. Below there are 
reported the few treatments that have been attempted so far to modulate specific aspects of the 
neurological phenotype of CDKL5 KO mice. 
 
GSK-3β inhibitor SB216763  
Exploiting one of the newly generated CDKL5 KO mouse models, our laboratory recently 
described important defects in the hippocampus of knock-out mice. As CDKL5 expression is higher 
in the developing brain and seems to be very important in neurogenesis processes, we focused a great 
part of our work on the hippocampus, a region characterized by ongoing postnatal neurogenesis, that 
plays a key role in learning and memory. We found that loss of CDKL5 impairs postnatal 
hippocampal development with a reduction in neuronal precursor survival and maturation. At the 
molecular level, these defects are accompanied by increased activity of the kinase GSK-3β, a crucial 
inhibitory regulator of many neurodevelopmental processes [Fuchs et al. 2014]. As a consequence, 
the following step of our study was to establish whether pharmacological inhibition of GSK-3β could 
correct hippocampal developmental defects due to CDKL5 loss. We found that treatment with the 
GSK-3β inhibitor SB216763 fully rescues hippocampal development and behavioral deficits in a 
mouse model of CDKL5 disorder. In particular, treatment in developing mice (P20-P45) with 
SB216763 restored neuronal precursor survival, dendritic maturation and connectivity in term of 
synapse maturation. Parallel to these structural effects, pharmacological inhibition of GSK-3β 
restored hippocampus-dependent learning and memory in the CDKL5 KO mouse. Importantly, all 
these structural and functional effects were retained one month after treatment cessation (P75). 
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At present, there are no therapeutic strategies to improve the neurological defects of subjects 
with CDKL5 disorder. Current results point at GSK-3β inhibitors as potential therapeutic tools for 
the improvement of abnormal brain development in CDKL5 disorder [Fuchs et al. 2015]. 
 
 
AKT/mTOR/rpS6 pathway activator IGF-1 
Very little is known about the function of CDKL5 in brain cells. In mice, CDKL5 is 
expressed at low levels at embryonic stages and its expression is markedly up-regulated during 
postnatal brain development. Expression analysis suggested that CDKL5 can be localized in 
postsynaptic structures where RNA interference and mutation analysis showed that it can regulate 
dendritic spine density and morphology and modulate excitatory synaptic function. The synaptic 
localization of CDKL5 seems to be regulated by its direct interaction with the palmitoylated form of 
PSD-95, or by the formation of a complex involving PSD-95 and its interacting protein NGL-1, a 
target of CDKL5 kinase activity. Considering the strong impairment in dendritic spine stability 
observed in juvenile CDKL5 KO mice, this phenotype was used by Della Sala and colleagues to 
evaluate the effects of a treatment aimed at ameliorating CDKL5 KO mice condition. 
Furthermore, among the other kinases whose activation was found altered in the CDKL5 KO 
mouse model, phosphorylation of Ser
240-244
 of S6, a specific target of the AKT-mTOR pathway, is 
downregulated in CDKL5 mutants. The AKT-mTOR pathway is an important molecular cascade 
involved in several neurodevelopmental disorders and it is hypofunctional also in RTT models 
carrying MeCP2 deletion. Insulin-like growth factor 1 (IGF-1) is an activator of the AKT-mTOR 
pathway and treatment with IGF-1 was found to ameliorate spine dynamics and behavioral 
phenotype in murine models of RTT. For, a clinical trial on the use of IGF-1 in MeCP2 patients is 
currently ongoing and the results of the phase 1 study have been recently published [Khwaja et al. 
2014]. 
Basing on these considerations, Della Sala and colleagues treated young (P24-P27) and adult 
(P120-P124) CDKL5 KO mice, showing that IGF-1 is able to rescue S6 phosphorylation, spine 
deficits and defective PSD-95 expression also in this mouse model. In particular, authors found that 
systemic IGF-1 treatment restored spine density and spine elimination rate. Interestingly, the 
increased spine density induced by IGF-1 was still present 20 days after the end of IGF-1 treatment, 
suggesting that the spines induced by IGF-1 are long-lasting and thus candidating IGF-1 as a 
treatment for synaptic deficits in CDKL5 disorder [Della Sala et al. 2015]. 
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2.5.2 Gene therapy 
Gene therapy - the replacement of a mutated gene that causes disease with a healthy and 
functioning copy of the gene - has becoming a realistic treatment option for genetic based neurologic 
disorders over the past year. A decade ago, strategies for gene delivery to the brain were limited 
mostly to stereotaxic injection of viral vectors to the brain and any measure of widespread gene 
delivery was achieved by the use of multiple injections to create pockets of transgene expression 
throughout the brain. Recently, advancements in viral vector design and the exploration of 
alternative routes of administration have made global Central Nervous System (CNS) gene delivery a 
possibility. The most prominent CNS gene delivery vector is currently adeno-asscociated virus 
(AAV). Several features make AAV vector an ideal gene delivery vehicle to the CNS. Although 
AAV naturally infects humans, it is nonpathogenic and is classified as a dependovirus, because 
infection by AAV occurs only in the presence of a helper virus, either adenovirus or herpesvirus. In 
addition to its safety, AAV can infect both dividing and non-dividing cells and has the ability to 
confer long-term stable gene expression without causing associated inflammation or toxicity. 
Additionally, rapidly evolving vector production and purification methods facilitate both basic 
research applications as well as the ability to produce the large quantities needed for some clinical 
trials. Using AAV, advancements in global CNS gene delivery have accelerated to the point that 
treatments for neurodevelopmental disorders, such as Fragile X Syndrome, Rett Syndrome and 
CDKL5 disorder, seem within the reach. 
The expectation for gene therapy in the treatment of genetic brain disease is high, because 
much has been promised with this technology and scientific community interest on gene therapy is 
increasing. However, gene delivery efficacy and genome transduction safety problems have not been 
completely overcome to enable easy translation from animal models to patients. Anyway no 
treatments are currently available to improve the neurological phenotype of patients with CDKL5 
disorder, thus investigating the possibility of developing a gene therapy to compensate for the lack of 
CDKL5 in the CDKL5 KO mouse model, in parallel to basic research studies on other therapeutic 
interventions, surely represents an interesting option to consider. 
 
2.5.3 Protein replacement therapy 
Recently, a new alternative approach to gene therapy, named “protein transduction” or 
“protein therapy” has emerged that enables the trans-vascular delivery of an exogenous protein to the 
brain following a simple systemic injection. Lately, it has been discovered that certain proteins and 
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peptides exhibit the unique property of efficient translocation across cell membranes. This unique 
translocation is usually due to the presence of a Protein Transduction Domain (PTD) in these 
molecules. PTDs are small peptides that are able to ferry even large molecules into cells 
independently of classical endocytosis. This property makes PTDs ideal tools to transfer proteins and 
other molecules into living cells for therapeutic purposes. The mechanism by which this 
internalization takes place is poorly understood. Although the exact mechanism of transduction is 
unknown, internalization of these proteins is not receptor- or transporter-mediated. It is therefore 
likely that all cell types are transducible by these PTDs. PTDs are valuable research tools, as they 
can be used to deliver molecules into living cells under physiological conditions. 
The first proteins to be described to have transduction properties were of viral origin. These 
proteins are still the most commonly accepted models for PTD action. The HIV-1 Transactivator of 
Transcription (TAT) protein is the best characterized viral PTD containing protein. The minimal 
PTD of TAT has been identified as a 9 amino acid protein sequence [Wender et al. 2000]. Earlier 
experiments with the TAT-PTD protein domain demonstrated successful transduction of fusion 
proteins up to 120 kDa into murine cells [Nagahara et al. 1998; Schwarze et al. 1999; Xia, Mao, and 
Davidson 2001]. Schwarze et al. reported that a recombinant TAT-β-galactosidase protein, injected 
intraperitoneally into mice, was distributed to all tissues including the brain and retained its 
biological activity [Schwarze et al. 1999]. Importantly, no toxic effect and immunogenicity problems 
of the TAT-PTD have been reported so far [Verdurmen and Brock 2011]. 
 
 
 
Figure 20. Schematic representation of TAT protein transduction domain ability to carry 
cargo molecules through cell membranes. 
 
TAT-MECP2 fusion protein  
Recently Prof. Franco Laccone (a genetist presently at the Institute of Medical Genetics, 
University of Vienna) has developed a synthetic MeCP2 sequence for a protein substitution therapy 
(Patent WO/2007/115578; University of Göttingen, Germany). The invention relates to codon-
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optimized nucleic acid sequences for the expression of the MeCP2 protein in heterologous 
expression systems (i.e. human protein in Escherichia coli) fused to the TAT-PTD domain. Prof. 
Laccone demonstrated that the purified TAT-MeCP2 fusion protein retains its biological activity and 
is efficiently delivered into the brain. He demonstrated that daily injections of the purified TAT-
MeCP2 improved motor learning and extended lifespan of a mouse model of Rett syndrome (see 
website: WIPO, Search International and National Patent Collections). This is the first demonstration 
of a possible therapeutic use of a TAT-fusion protein in the nervous system to ameliorate the course 
of a genetic disease. 
 
Synthetic TATκ-PTD 
The trans-acting activator of transcription (TAT) protein transduction domain (PTD) 
mediates the transduction of peptides and proteins into target cells. The TAT-PTD has an important 
potential as a tool for the delivery of therapeutic agents. The production of TAT fusion proteins in 
bacteria, however, is often problematic because of protein insolubility and the absence of eukaryotic 
post-translational modifications. An attractive alternative, both for in vitro protein production and for 
in vivo applications, is the use of higher eukaryotic cells for secretion of TAT fusion proteins. 
However, the ubiquitous expression of furin endoprotease (also called PACE or SPC1) in the 
Golgi/endoplasmic reticulum of cells, and the presence of furin recognition sequences within TAT-
PTD, results in the cleavage and loss of the TAT-PTD domain during its secretory transition through 
the endoplasmic reticulum and Golgi, via the costitutive pathway. Detailed analysis of TAT 
sequence revealed the presence of two furin cleavage sites, characterized by the amino acid 
sequences RXRR or RXKR (where X can be any amino acid). To overcome this problem, in 2008 
Flinterman and colleagues successfully developed a synthetic TATκ-PTD in which mutation of the 
furin recognition sequences, but retention of protein transduction activity, allows secretion of 
recombinant proteins, followed by successful uptake of the modified protein by the target cells. In 
particular, authors introduced mutations into the HIV-TAT within amino acid 47–57 sequence 
YGRKKRRQRRR (furin sites: RKKR and RQRR in bold) to generate a synthetic modified TAT, 
which lacked the furin sites but retained the protein transduction ability. The resulting sequence is 
YARKAARQARA and this novel TAT was named TATκ [Flinterman et al. 2009]. This novel 
strategy for sure has important potential for the efficient delivery of therapeutic proteins. Given its 
advantages, the TATκ sequence has been used in the present study, where we fused this modified 
transduction domain to CDKL5, obtaining a TATκ-CDKL5 fusion protein. 
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3 MATERIALS AND METHODS 
 
3.1 Constructs 
3.1.1 TAT-CDKL5 fusion protein for bacterial expression 
E. coli codon-optimized TAT-CDKL5115 open reading frame was cloned into the pET-28a 
expression vector. The pET-28a-TAT-CDKL5 plasmid was transformed into E. Coli BL21(DE3) 
cells and recombinant clones were grown in TYP medium at 37°C until OD600 around 0.4–0.8. 
Expression was induced with 1.0 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) for 3 hours at 
37°C. Cells were harvested and protein extracts were obtained by sonication. Expression was 
checked either by Coomassie stained protein gel or western blot in both the total cell extract (soluble 
+ insoluble) and the soluble fraction only. 
 
3.1.2 TAT-CDKL5 fusion protein for expression in mammalian cells 
TAT-CDKL5115 fusion gene was cloned into the expression plasmid pTriEx-1.1 with two 
purification tags, Strep-tag and 6xHis-tag, added at the C-terminal region. HEK 293T cells were 
transfected with pTriEx-1.1-TAT-CDKL5 plasmid. Cells were grown for 24 hours and TAT-CDKL5 
protein was recovered from the cell lysate with a lysis buffer containing 50 mM Tris/HCl pH=8, 500 
mM NaCl, 20mM imidazole and EDTA-free protease inhibitors. Extraction was obtained by 
sonication and 0.25% Nonidet-P40 was then added. After an additional hour of incubation with lysis 
buffer on ice, supernatant was filtered and added to NiNTA agarose beads (buffer exchanged with 
lysis buffer) in order to purify TAT-CDKL5 from the total proteins extract. Binding was performed 
in a rotating wheel at room temperature for 30 minutes. Beads were washed twice (washing buffer 
contained 50 mM Tris/HCl pH=8, 500 mM NaCl, 50 mM imidazole) and TAT-CDKL5 was eluted 
for 30 minutes (elution buffer contained 50 mM Tris/HCl pH=8, 500 mM NaCl, 500 mM imidazole). 
Imidazole was removed with overnight dialysis with PBS at 4°C and TAT-CDKL5 purification was 
checked with western blot analysis. 
 
3.1.3 Secretable TATκ-CDKL5 fusion proteins 
CDKL5115, CDKL5107 and CDKL5115-3xFLAG-2xSTOP cDNAs were cloned into the XhoI 
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site of the secretable vector pPTK-GFP kindly provided by Dr. Tavassoli. As described by authors 
[Flinterman et al. 2009], this plasmid carries a modification of TAT linked to GFP (TATκ-GFP), 
cloned in frame with a signal peptide (Igκ-chain leader sequence) present in a modified mammalian 
pSecTag2 eukaryotic expression vector (Invitrogen) in which the zeocin selectable marker had been 
replaced by puromycin. The murine Ig κ-chain V-J2-C signal peptide directs the product to the 
constitutive secretion pathway. The vector contained also two successive tags (myc-tag and 6xHis-
tag) and the resulting constructs were TATκ-GFP-myc-6xHis (original plasmid), TATκ-GFP-
CDKL5115-myc-6xHis, TATκ-GFP-CDKL5107-myc-6xHis and TATκ-CDKL5115-3xFLAG (which 
was cloned AgeI/XhoI to eliminate the GFP sequence). For each construct, insert was PCR-amplified 
and purified with gel-extraction. The following primers were used: 
CCGCTCGAGCGAAGATTCCTAACATTGG (forward for TATκ-GFP-CDKL5, both isoforms), 
CCGCTCGAGCGGACTTGCCCGTCAGTGCC (reverse for TATκ-GFP-CDKL5115), 
CCGCTCGAGCGGACAAGGCTGTCTCTTTTAAATC (reverse for TATκ-GFP-CDKL5107), 
GCACCGGTGAAGATTCCTAACATTGG (forward for TATκ-CDKL5115-3xFLAG), 
CCGCTCGAGCGGATCACTACTTGTCATCGTCATCC (reverse for TATκ-CDKL5115-3xFLAG). 
All primers were purchased by Sigma-Aldrich. 
 
3.2 Production and Purification of the TATκ-CDKL5 Protein 
3.2.1 Transient transfection 
Human embryo kidney 293T cells were seeded to be 70-90% confluent at transfection. The 
following day cells were transfected with Metafectene EASY+ (Biontex) or Lipofectamine 3000 
(Invitrogen) according to the supplier's instructions. The culture medium was changed immediately 
before and after 4 hours from transfection with DMEM high glucose culture medium without serum. 
 
3.2.2 Stable clones selection 
5’000’000 293T cells were seeded in 10-cm culture dishes and transfected the following day 
with 20 µg of TATκ-GFP, TATκ-GFP-CDKL5 and TATκ-CDKL5-3xFLAG constructs using 
Metafectene EASY+ (Biontex) or Lipofectamine 3000 (Invitrogen) according to instructions. After 3 
days cells were put under selection with 5 µg/ml puromycin. Selection medium was changed every 
3–4 days and clones were picked after 3 weeks.  
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3.2.3 Concentration/Purification of supernatant 
At 48 hours after transfection or stable clones seeding, serum-free culture medium was 
collected, centrifuged to pellet cell debris and filtered through 0,2 µm syringe filters in order to avoid 
subsequent clogging of centrifugal filters. The culture medium was then transferred to Amicon Ultra 
Centrifugal Filters (Millipore) with 50 kDa molecular weight cut-off and was centrifuged at 4 °C 
resulting in a 20 or 480-fold concentration (for in vitro and in vivo studies respectively). For in vivo 
treatments the preparation underwent buffer exchange with 80 volumes of saline (NaCl 0.9% sterile 
solution). 
 
3.3 Cell cultures 
3.3.1 HEK 293T cell line 
Human embryo kidney 293T cell line was cultured in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM of glutamine 
and antibiotics (penicillin, 100 U/ml; streptomycin, 100 μg/ml), in a humidified atmosphere of 5% of 
CO2 in air at 37 °C. 
For evaluation of protein transduction activity, 75’000 293T cells per well were seeded onto 
poly-D-lysine coated slides in 24 well plates. 24 hours after plating, medium was replaced with 100 
µL of fresh DMEM with 20% FBS and 100 µL of 40x serum-free concentrated medium containing 
either vehicle (i.e. 48 hours serum-free culture medium from 293T cells) or TATκ-GFP-CDKL5 
protein. After different times (30 min – 1 hour – 2 hours) cells were gently washed with PBS and 
fixed with a 4% paraformaldehyde solution for 20 minutes at room temperature, and 
immunocytochemistry anti-GFP was performed. 
 
3.3.2 Neuroblastoma SH-SY5Y cell line 
Human neuroblastoma cell line SH-SY5Y, obtained from ATCC (Manassas, VA, USA) were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-
inactivated FBS, 2 mM of glutamine and antibiotics (penicillin, 100 U/ml; streptomycin, 100 μg/ml), 
in a humidified atmosphere of 5% of CO2 in air at 37 °C. Cell medium was replaced every 3 days 
and the cells were sub-cultured once they reached 90% confluence. 
Neuroblastoma SH-SY5Y cells were treated with TATκ-CDKL5 fusion proteins. The day 
before treatment SH-SY5Y were plated onto poly-D-lysine coated slides in 24 well plates at density 
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of 150’000, 60’000 or 10’000 cells/well for protein transduction assay, proliferation assay and 
differentiation assay respectively. The following day cells medium was replaced with 100 µL of 
fresh DMEM with 20% FBS and 100 µL of 40x serum-free concentrated medium containing vehicle 
(i.e. 48 hours serum-free culture medium from 293T cells), TATκ-GFP, TATκ-GFP-CDKL5115, 
TATκ-GFP-CDKL5107 or TATκ-CDKL5115-FLAG. The treatment was left for either 1 hour or 
overnight respectively for protein transduction assay and proliferation assay, while it was left 
overnight and replaced every day for three days for differentiation assay. At the end of each 
treatment cells were gently washed with PBS and fixed with a 4% paraformaldehyde 4% glucose 
solution for 20 minutes at room temperature, and the relative analysis were performed. 
 
3.3.3 Neuronal Precursor Cells 
Cells were isolated from the subventricular zone (SVZ) of newborn (P1–P2) CDKL5 KO +/Y 
and CDKL5 KO −/Y male mice. To obtain neurospheres, cells were cultured in suspension in 
DMEM/F12 (1:1) containing B27 supplements (2%), FGF-2 (20 ng/ml), EGF (20 ng/ml), heparin (5 
μg/ml), penicillin (100 units/ml), and antibiotics. Primary neurospheres were dissociated at days 7–8 
using Accutase (PAA, Pasching, Austria) to derive secondary neurospheres. The subculturing 
protocol consisted of neurosphere passaging every 7 days with whole culture media change (with 
freshly added FGF-2 and EGF). All experiments were done using neurospheres obtained after one to 
three passages from the initially prepared cultures. Cell cultures were kept in a humidified 
atmosphere of 5% CO2 at 37 °C. 
For differentiation analysis, neurospheres obtained after three passages in vitro were 
dissociated and plated on cover slips coated with 15 μg/ml poly-l-ornithyine (Sigma) at density 
20’000 cells/well. Cells were grown for 2 days and then transferred to a differentiating medium 
(EGF and FGF free plus 1% foetal bovine serum) from day 3 for 7 days. TATκ-CDKL5 fusion 
proteins were daily administered at a final 10x concentration after buffer exchange with DMEM-F12, 
avoiding complete change of culture medium. Every 3 days, half of the medium was replenished 
with fresh differentiating medium. Differentiated cells were fixed with a 4% paraformaldehyde 4% 
glucose solution at room temperature for 30 minutes and incubated with anti-glial fibrillary acidic 
protein (1:400; GFAP mouse monoclonal, Sigma) and anti-β-tubulin III (1:100; rabbit polyclonal, 
Sigma), as primary antibodies, and with anti-mouse FITC-conjugated (1:100; Sigma) and anti-rabbit 
Cy3-conjugated (1:100; Jackson Laboratories), as secondary antibodies. Samples were 
counterstained with Hoechst-33258. 
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3.4 Biochemical Assays 
3.4.1 Kinase Assay 
Protein kinase activity results in the incorporation of radiolabeled phosphate from [γ32P]-ATP 
into a peptide or protein substrate. As a substrate we used TATκ-GFP-CDKL5 itself, exploiting the 
autophosphorylation activity of CDKL5. TATκ-GFP-CDKL5 and TATκ-GFP concentrated media 
underwent buffer exchange with a 50 mM Tris/HCl (pH=8) - 500 mM NaCl solution and were 
subject to purification with Ni-NTA resin exploiting the 6xHis-tag at the C-terminus. The buffer 
used contained a high saline concentration in order to minimize protein precipitation and, PMSF 
protease-inhibitor added, it was used also to wash Ni-NTA beads before and after the protein 
binding. After the overnight binding, Ni-NTA slurry beads were buffer exchanged with a proper 
buffer (aqueous solution containing: Hepes-NaOH 20 mM (pH=7.4), NaCl 10 mM, MgCl2 1 mM) 
and were subject to a kinase assay with 2mM cold ATP and 10 µCi radioactivity from [γ32P]-ATP 
for 1 hour at 32°C. The reaction was stopped by adding SDS-PAGE loading buffer and boiling for 5 
minutes at 100°C. The mix was then immediately loaded onto a polyacrylamide gel and transferred 
to a nitrocellulose membrane. The radioactivity incorporated into TATκ-GFP-CDKL5 as a 
consequence of autophosphorylation was assessed by exposing an autoradiographic film to the 
western blot membrane for 4 days. Radioactive signal on the film was then confirmed by western 
blot anti-CDKL5 (1:1000; Sigma). 
 
3.4.2 Immunocytochemistry 
For immunofluorescence studies the following antibodies were used. Primary antibodies: 
anti-GFP rabbit polyclonal (1:500, Invitrogen) and anti-FLAG M2 mouse monoclonal (1:1000; 
Sigma) were used in order to detect the fusion protein inside target cells; anti-β-tubulin III rabbit 
polyclonal (1:500, Sigma) and anti-glial fibrillary acidic protein (1:400; GFAP mouse monoclonal, 
Sigma) were used in order to discriminate neurons (β-tubulin III positive) from glia in NPC cultures. 
Secondary antibodies: Cy3-conjugated anti-rabbit antibody (1:200, Jackson Immuno Research 
Laboratories), Cy3-conjugated anti-mouse antibody (1:200, Jackson Immuno Research 
Laboratories), FITC-conjugated anti-rabbit antibody (1:200, Jackson Immuno Research 
Laboratories). Cells were counterstained with Hoechst-33258, which allowed the identification of 
mitotic and apoptotic nuclei. Fluorescence images were taken on an Eclipse TE 2000-S microscope 
(Nikon, Tokyo, Japan) equipped with a digital camera Sight DS-2MBW (Nikon). 
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3.4.3 Confocal analysis 
Confocal microscopy was used to confirm TATκ-GFP-CDKL5 localization inside target 
cells, after immunofluorescence and western blot analysis. Images immunoprocessed for rabbit anti-
GFP antibody (1:500, Invitrogen) were acquired on a Nikon Ti-E fluorescence microscope coupled 
with an A1R confocal system (Nikon, Tokyo, Japan). Pictures were taken as Z-stack with slices of 
0.4 μm. 
 
3.4.4 Analysis of neurite outgrowth 
Phase contrast photographs of neuroblastoma cell cultures for differentiation analyses were 
taken at various time intervals with an Eclipse TE 2000-S microscope (Nikon, Tokyo, Japan) 
equipped with an AxioCam MRm (Zeiss, Oberkochen, Germany) digital camera. Different areas 
were randomly selected and neurite outgrowth was measured using the image analysis system Image 
Pro Plus (Media Cybernetics, Silver Spring, MD 20910, USA). Only cells with neurites longer than 
one cell body diameter were considered as neurite-bearing cells. The total length of neurites was 
divided for the total number of cells counted in the areas. 
 
3.4.5 Western blot assay 
For the preparation of total cell extracts, cells were lysed in RIPA lysis buffer (Tris–HCl 50 
mM, NaCl 150 mM, Triton X-100 1%, sodium deoxycholate 0.5%, SDS 0.1%, protease and 
phosphatase inhibitors cocktails 1%; Sigma). Protein concentration was estimated by the Lowry 
method and 30 μg of total proteins were subjected to electrophoresis on a 4–12% NuPAGE Bis-Tris 
Precast Gel (Novex, Life Technologies, Ltd, Paisley, UK) and transferred to a Hybond ECL 
nitrocellulose membrane (Amersham Life Science). The following primary antibodies were used to 
reveal the presence of TATκ-CDKL5 fusion proteins in transfected or treated cells: anti-CDKL5 
(1:1000; Sigma), anti-GFP (1:1000, Invitrogen), anti-FLAG M2 (1:1000; Sigma). 
 
3.5 Animal handling 
3.5.1 Animal housing and Genotyping 
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Mice for testing were produced by crossing CDKL5 KO +/− females with CDKL5 KO Y/− 
males and CDKL5 KO +/− females with Y/+ males. Littermate controls were used for all 
experiments. Animals were karyotyped by PCR on genomic DNA using the following primers: 108 
F: 5′-ACGATAGAAATAGAGGATCAACCC-3′, 109R: 5′-CCCAAGTATACCCCTT TCCA-3′; 
125R: 5′-CTGTGACTAGGGGCTAGAGA-3′ [Amendola et al. 2014]. The day of birth was 
designed as postnatal day (P) zero and animals with 24 hours of age were considered as 1-day-old 
animals (P1). After weaning, mice were housed three to five per cage on a 12-hours light/dark cycle 
in a temperature-controlled environment with food and water provided ad libitum. Experiments were 
performed in accordance with the Italian and European Community law for the use of experimental 
animals and were approved by Bologna University Bioethical Committee. In this study all efforts 
were made to minimize animal suffering and to keep the number of animals used to a minimum. 
 
3.5.2 Intracerebroventricular cannula implantation and microinjections 
Adult mice (3 to 6 months old) were anesthetized with ketamine (100-125 mg/kg) and 
xylazine (10-12.5 mg/kg). Intracerebroventricular (ICV) guide cannula (diameter 22 G, C313G, 
Plastics One, USA) was implanted in mice basing on the following stereotaxic coordinates: 0,6 mm 
posterior and 1,2 mm lateral to bregma, 2 mm depth from the bone surface. Seven days after 
implantation mice were infused by using a Hamilton syringe connected to a motorized nanoinjector 
(at a rate of 0.5 l/min). An internal cannula (diameter 26 G, C312I, Plastics One, USA) was used for 
ICV injections. TATκ-GFP-CDKL5 or TATκ-GFP in saline were injected with the mouse 
anesthetized at light on. Each mouse received 5 or 10 daily injections with protein in 10 µL bolus 
volume. Infusion rate was always set at 1 µL/min. The correct cannula position was verified by 
histology after ink injection (2 µL) at sacrifice. 
 
3.5.3 Intravenous injections 
Adult mice (3 to 4 months old) were anesthetized with ketamine (100-125 mg/kg) and 
xylazine (10-12.5 mg/kg) and dilation of the tail veins was stimulated by placing the tail in a warmer 
environment (40 ºC water bath) for several minutes. Body temperature was maintained by means of a 
heated stage. A small-volume sterile insulin syringe with a permanently attached needle (27 gauge) 
was used in order to have the lower dead volume possible. Being careful not to introduce any air into 
the syringe, 200 µL of protein preparation were withdrawn. The needle was then inserted 5 mm into 
the tail vein and verification of the needle to be in vein was ensured by pullback. Being careful not to 
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perforate the vein, preparation was slowly injected. The needle was then removed and ehanol swab 
was applied directly to the injection site for 5-10 seconds to stop any bleeding. Each mouse received 
5 daily injections. 
 
3.5.4 Subcutaneous injections 
Mouse pups (P7) were injected with up to 1 mL vehicle (i.e. 48 hours serum-free culture 
medium from 293T cells), TATκ-GFP or TATκ-GFP-CDKL5 concentrated media administered 
subcutaneously. Animals were sacrificed 4 hours after the injection, brains were fixed with a 4% 
paraformaldehyde solution and immunohistochemistry anti-GFP, followed by a tyramide-based 
signal amplification, was performed to detect the protein in the brain. 
 
3.6 Behavioral testing 
3.6.1 Morris Water Maze Test 
Mice were trained in the Morris Water Maze task to locate a hidden escape platform in a 
circular pool. The apparatus consisted of a large circular water tank (1 m diameter, 50 cm height) 
with a transparent round escape platform (10 cm
2
). The pool was virtually divided into four equal 
quadrants identified as north-east, north-west, south-east, and south-west. The tank was filled with 
tap water at a temperature of 22 °C up to 0.5 cm above the top of the platform and the water was 
made opaque with milk. The platform was placed in the tank in a fixed position (in the middle of the 
north-west quadrant). The pool was placed in a large room with a number of intra- (squares, 
triangles, circles and stars) and extra-maze visual cues. After training, each mouse was tested for two 
sessions of 4 trials each per day, for 5 consecutive days with an inter-session interval of 40 min 
(acquisition phase). A video camera was placed above the center of the pool and connected to a 
video-tracking system (Ethovision 3.1; Noldus Information Technology B.V., Wageningen, 
Netherlands). Mice were released facing the wall of the pool from one of the following starting 
points: North, East, South, or West and allowed to search for up to 60 s for the platform. If a mouse 
did not find the platform, it was gently guided to it and allowed to remain there for 15 s. During the 
inter-trail time (15 s) mice were placed in an empty cage. The latency to find the hidden platform 
was used as a measure of learning. Retention was assessed with one trial without platform (probe 
trial), on the sixth day, 24 h after the last acquisition trial, using the same starting point for all mice. 
Mice were allowed to search for up to 60 s for the platform. For the probe trial, the percentage of 
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time spent and the frequency of entrances into the quadrant in which the platform had been located 
during training, the percentage of time spent in the other quadrants and the latency of the first 
entrance in the former platform quadrant were employed as measures of retention of acquired spatial 
preference. 
 
3.6.2 Y-Maze Test 
Y-Maze Spontaneous Alternation task was used to measure the willingness of mice to explore 
new environments and hippocampus dependent spatial reference memory. Each mouse was placed at 
the distal part of one arm facing the center of the maze. Each of the three arms was 34 cm × 5 cm × 
10 cm height, angled 120° from the others and made of gray opaque plastic. After introduction into 
the maze, the animal is allowed to freely explore the three arms for 8 min. Over the course of 
multiple entries into the arm, the subject should show a tendency to enter a less recently-visited arm. 
Arm entries were defined by the presence of all four paws in an arm. The 8-min trial was recorded 
and scored via the ANY-maze video tracking software (Stoelting). The maze was cleaned with 50% 
ethanol after each trial. The percentage of spontaneous alternations is defined as: (total 
alternations/total arm entries − 2) × 100. One alternation is defined as consecutive entries into three 
different arms. 
 
3.6.3 Passive Avoidance Test 
For the Passive Avoidance test we used a tilting-floor box (47 × 18 × 26 cm) divided into two 
compartments by a sliding door and a control unit incorporating a shocker (Ugo Basile, Italy). This 
classic instrument for Pavlovian conditioning exploits the tendency in mice to escape from an 
illuminated area into a dark one (step-through method). On the first day mice were individually 
placed into the illuminated compartment. After 60 s of habituation period, the connecting door 
between the chambers opened. In general, mice step quickly through the gate and enter the dark 
compartment due to their innate tendency to prefer dark areas and avoid bright ones. Upon entering 
the dark compartment, mice received a brief foot shock (2 mA for 3 s) and were removed from the 
chamber after 15 s of latency. If the mouse remained in the light compartment for the duration of the 
trial (358 s), the door closed and the mouse was removed from the light compartment. The chambers 
were cleaned with 70% ethanol between testing of individual mice. After a 24 hour retention period, 
mice were placed back into the light compartment and the time it took them to re-enter the dark 
compartment (latency) was measured up to 358 s. 
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3.6.4 Clasping behavior 
Mice were suspended by their tail 1 m above the ground for 2 min. Hind-limb clasping was 
assessed from video recordings and the total time spent in the clasping position was measured. A 
clasping event is defined by the retraction of limbs into the body and toward the midline. Data are 
presented as percentage of time spent in the clasping position in the 2 minutes.  
Clasping is a typical behavior of CDKL5 KO mice [Amendola et al. 2014]. Nevertheless a 
small variability between CDKL5 KO mice leads a small percentage of knockouts not to show 
clasping behavior. Therefore each animal was tested both before and after the treatment to reduce 
intra-strain variability and animals not exhibiting clasping behavior before the treatment were 
excluded by the analysis. 
 
3.7 Histological Procedures 
3.7.1 Tissue fixation 
Some animals were deeply anesthetized and transcardially perfused with phosphate buffered 
saline (PBS), followed by a 4% solution of paraformaldehyde in 100 mM PBS, pH 7.4. Brains were 
stored in the fixative for 24 h, cut along the midline and kept in 20% sucrose in phosphate buffer for 
an additional 24 h. Hemispheres were frozen and stored a −80°C. The right hemisphere was cut with 
a freezing microtome into 30-μm-thick coronal sections that were serially collected in antifreeze 
solution containing sodium azide. 
Some animals were deeply anesthetized and the brain was removed and cut along the midline. 
One hemisphere was Golgi-stained using the FD Rapid Golgi Stain™ Kit (FD NeuroTechnologies, 
Inc., Columbia, MD, USA) according to instructions and subsequently cut into 80-μm-thick coronal 
sections. Hippocampus and cortex from the other hemisphere and the cerebellum were rapidly frozen 
with dry ice and stored a −80°C for subsequent total protein extraction. 
 
3.7.2 Immunohistochemistry 
One out of 12 serial brain sections from the region of interest were used for 
immunohistochemistry with the following antibodies: anti-GFP rabbit polyclonal (1:500, Invitrogen), 
anti-doublecortin (goat polyclonal, 1:100, sc-8066, Santa Cruz Biotechnology), anti-cleaved caspase-
67 
 
3 (rabbit polyclonal, 1:200, 9661, Cell Signaling Technology), anti-synaptophysin (SY38 mouse 
monoclonal Ab, 1:1000, MAB 5258, Merck Millipore), anti-AIF1 (rabbit polyclonal, 1:1000, 
Thermo Scientific). For anti-GFP and anti-cleaved caspase-3 immunohistochemistry procedures the 
signal was amplified through TSA cyanine-3 plus evaluation kit (Perkin Elmer), according to 
instructions. 
 
3.7.3 Number of DCX-positive cells 
DCX-positive type 2b/3 cells (parallel-oriented to the subgranular zone), and DCX-positive 
immature granule neurons (vertically-oriented cells with long apical processes), were separately 
counted in one out of 12 hippocampal sections. The count was done within an area that included the 
subgranular zone and the deepest two rows of cells in the granular layer. DCX-positive cells were 
expressed as number of cells/mm
2
. 
 
3.7.4 Measurement of the dendritic tree 
Dendritic trees of DCX-positive granule cells sampled in the inner part of the granule cell 
layer close to the subgranular zone, and Golgi-stained granule cells and CA1 pyramidal neurons 
were traced with a dedicated software, custom-designed for dendritic reconstruction (Immagini 
Computer, Milan, Italy), interfaced with Image Pro Plus. The dendritic tree was traced live, at a final 
magnification of 500×, by focusing into the depth of the section. The operator starts with branches 
emerging from the cell soma and after having drawn the first parent branch (order 1, primary 
dendrite) goes on with all daughter branches of the next order in a centrifugal. At the end of tracing, 
the program reconstructs the number and length of individual branches of each order, the mean 
length of branches of each order, total number of branches and total dendritic length. 
 
3.7.5 Spine density/morphology 
In Golgi-stained sections, spines of granule cells were counted using a 100× oil immersion 
objective lens. Dendritic spine density was measured by manually counting the number of dendritic 
spines on dendritic segments in the inner and outer half of the molecular layer and expressed as the 
number of dendritic spines per 20 μm dendritic length. The dendritic spine length was measured by 
manually drawing a vertical line from the tip of the protrusion to the point where it met the dendritic 
shaft. The number of spine clusters was counted manually on dendritic segments in the inner and 
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outer half of the molecular layer and expressed as number of spine clusters per 50 μm dendritic 
length. 
 
3.7.6 Synaptophysin densitometry 
One out of 12 free-floating coronal sections from the DG of animals were processed for 
immunohistochemistry as previously described [Guidi et al. 2013]. Intensity of SYN 
immunoreactivity was determined by optical densitometry of immunohistochemically stained 
sections. Fluorescence images were captured using a Nikon Eclipse E600 microscope equipped with 
a Nikon Digital Camera DXM1200 (ATI system). Densitometric analysis in the molecular layer and 
cortex was carried out using the Image Analysis System Image Pro Plus (Media Cybernetics, Silver 
Spring, Md. 20910, USA). A box of 4000 µm
2
 was placed in the cortical layers II, III and IV-VI and 
a box of 400 µm
2
 was placed in stratum radiatum of CA1 and stratum moleculare of the dentate 
gyrus. Measurements were taken in each region of interest, normalized to background. In particular, 
for each image the intensity threshold was estimated by analyzing the distribution of pixel intensities 
in the areas that did not contain immunoreactivity and this value was subtracted to calculate the 
optical density of each sampled area. 
 
3.7.7 Number of apoptotic cells 
Apoptotic cells (cleaved caspase 3-positive cells) were counted in one out of 12 sections. The 
count was done in the hippocampal granular layer. The total number of apoptotic cells in the granular 
layer was estimated by multiplying the number of cells counted in the series of sampled sections by 
the inverse of the section sampling fraction (ssf = 1 / 12). 
 
3.8 Statistical analysis 
Data from single animals were the unity of analysis. Results are presented as mean ± standard 
error of the mean (±SE). The software SPSS was used for statistical analysis. Statistical testing was 
performed using a two-way analysis of variance (ANOVA) with genotype (CDKL5 +/Y; CDKL5 
−/Y) and treatment (vehicle, TATκ-CDKL5 protein) as fixed factors and mouse as random factor, or 
using a one-way ANOVA followed by Fisher LSD post hoc test or Duncan's test. A p-value < 0.05 
was considered to be statistically significant. 
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4 RESULTS 
4.1 TAT-CDKL5 can be efficiently produced as secretable fusion protein in 
mammalian cells 
4.1.1 TAT-CDKL5 recombinant protein cannot be produced in bacteria 
To develop a protein therapy for CDKL5 disorder the first step was to produce and purify a 
TAT-CDKL5 fusion protein. The low cost and simplicity of cultivating bacteria make the bacterial 
expression system a preferable choice for the production of therapeutic proteins, both on a lab scale 
and in industry. The most commonly used bacterium for recombinant protein production is 
Escherichia coli, an enteric bacterium that has a long pedigree of safe use in laboratories and 
industry. E. coli is a particularly suitable host because it is well characterized physiologically and 
metabolically; it was among the first organisms to have its entire genome sequenced and many 
molecular biology tools are available for engineering its DNA sequences to generate novel 
functionality [Overton 2014]. Bacteria have not developed sophisticated mechanisms for performing 
posttranslational modifications, such as glycosylation, which are present in higher organisms. As a 
consequence, an increasing number of protein therapeutics is expressed in mammalian cells. 
However, for proteins that are not required to be synthesized in a glycosylated or extensively post-
translationally modified form, bacteria are an excellent expression system because of their relative 
simplicity. 
Given these premises, the first attempt to produce a recombinant TAT-CDKL5 fusion protein 
was carried out using a common bacterial expression system. An E. coli codon-optimized TAT-
CDKL5 open reading frame was cloned into the pET-28a vector. pET-28a-TAT-CDKL5 plasmid 
was transferred into E. Coli BL21 cells and recombinant clones were grown in TYP medium at 37°C. 
Following a 3-hr expression induced with 1.0 mM IPTG, cells were harvested, sonicated and protein 
extracts were obtained. No TAT-CDKL5 protein expression was detected in E. Coli protein extracts 
(Fig. 21), suggesting the absence, or very low levels, of TAT-CDKL5 expression. 
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Figure 21. TAT-CDKL5 full-length recombinant production in E. coli BL21. Image shows 
result of Coomassie blue staining of a gel loaded with E.coli lysate prior to IPTG induction (lane 1) 
and after 3 hours of IPTG induction (lane 2). 
 
Indeed, the difficulty in obtaining a constitutively active full-length CDKL5 through E. coli 
expression systems has been reported by various authors in the past few years [Katayama, Sueyoshi, 
and Kameshita 2015]. 
Furthermore, it has recently been demonstrated that CDKL5 is almost completely degraded in 
E. coli bacterial cells (unpublished observation by Dr. Tutino). In particular, E. coli insoluble 
fraction (i.e. bacterial pellet) contains TAT-CDKL5 products whose size is compatible with either 
aggregated (higher molecular weight) or proteolytically cleaved (lower molecular weight) forms. On 
the other hand, the soluble fraction, namely the only fraction from which the protein can be 
recovered, does not contain full-length TAT-CDKL5 protein. 
Taken together, such observations hinder the production of TAT-CDKL5 fusion protein 
through the classical bacterial expression systems. 
 
4.1.2 Inefficient TAT-CDKL5 protein purification from mammalian cells 
Due to the impossibility of producing the recombinant TAT-CDKL5 protein in bacteria, we 
set up expression of the recombinant protein in mammalian cells. This method is less efficient, but 
has the great advantage of ensuring exactly the same post-translational modifications carried by the 
endogenous protein. For this reason about half of all recombinant therapeutic proteins currently on 
the market are produced in mammalian cells. 
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Hence, the TAT-CDKL5 fusion gene was cloned into the expression plasmid pTriEx-1.1. 
This plasmid is designed to allow expression of genes in multiple expression systems and high 
expression levels of target proteins. In order to purify the TAT-CDKL5 protein, we added two 
successive tags, Strep-tag and 6xHis-tag, at the C-terminal region of the TAT-CDKL5 gene. HEK 
293T cells were transfected with TAT-CDKL5 plasmid. Cells were grown for 24 hours and TAT-
CDKL5 protein was recovered from the cell lysate and purified using an immobilized-metal affinity 
chromatography that is based on the proven 6xHis-tag-Ni-NTA interaction. We found that the 
starting quantity of soluble recombinant TAT-CDKL5 protein obtained from HEK 293T cell extract 
was very low (Fig. 22-A). It should be noted that purification of a large protein like CDKL5 (115 
kDa) may be inefficient due to insolubility of the protein. After trying various buffer conditions, we 
found that the best condition to enhance TAT-CDKL5 protein solubility and stability requires a lysis 
buffer with high ionic strength (500 mM NaCl) (data not shown). However very little purified 
protein  was eluted from the column (Fig. 22-A), and the dialysis or diafiltration process to remove 
the imidazole led to an even lower quantity of protein (Fig. 22-B). 
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Figure 22. TAT-CDKL5 fusion protein expression and purification in HEK 293T 
mammalian cells. (A) Taking advantage of a 6xHis-tag, TAT-CDKL5 protein was purified from cell 
extract using Ni-NTA beads. We found that the starting quantity of protein produced in 293T cells is 
low (Total cell extract) and a consistent fraction of protein is lost at every purification step, so that 
very few purified (Eluate) protein is obtained. (B) After purification the eluate underwent dialysis or 
diafiltration to remove mobile phase containing imidazole, leading to a very small amount of 
purified protein. 
 
4.1.3 Efficient expression pattern and purification of secretable TATκ-CDKL5 fusion 
proteins 
In order to overcome purification problems and enhance protein recovery, we took advantage 
of a novel system for the secretion of TAT recombinant proteins from mammalian cells. The success 
of this system is due to the identification and modification of the two furin sites present in the TAT 
peptide. Furin is the best-characterized mammalian enzyme from the subtilisin-like convertases and 
is an endoprotease that recognizes and cleaves the amino acid sequences RXRR or RXKR, where X 
can be any amino acid. Furin is mainly localized in the trans-Golgi network but can translocate 
between the trans-Golgi network and the cell surface (Denault JB 1996). Therefore, the presence of 
these furin sites in the TAT moiety results in the TAT peptide being cleaved from fusion proteins 
that are secreted via the constitutive pathway. Recently, Flinterman and colleagues introduced 
mutations to destroy the two furin cleavage sites without affecting TAT protein transduction ability. 
The modified TAT was named TATκ [Flinterman et al. 2009]. 
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A TATκ-CDKL5 fusion gene containing a human CDKL5 was cloned into the expression 
plasmid pSecTag2 (Life Technologies). This plasmid is designed to allow expression of genes in 
mammalian hosts and high expression levels of target proteins. Proteins expressed from pSecTag2 
are fused at the N-terminus to the murine Igκ chain leader sequence for protein secretion in culture 
medium. Due to the absence of a suitable anti-CDKL5 antibody, the TATκ-CDKL5 fusion protein 
was tagged with a GFP protein to monitor the expression levels and localization of the TATκ-
CDKL5 fusion protein. Furthermore, to facilitate protein purification, the TATκ-CDKL5 fusion 
protein was configured to include a myc-tag and 6xHis tag at the C-terminal region of the TATκ-
GFP-CDKL5 gene.  
HEK 293T cells were transfected with the TATκ-GFP-CDKL5 expression plasmid and 
grown in serum-free medium (High glucose Dulbecco's Modified Eagle Medium, DMEM). After 48 
hours the medium was collected, diafiltered and concentrated with 50 kDa cut-off Amicon ultra 
centrifugal filters (Fig. 23-A exemplifies the procedure). This method allows high recovery of the 
secreted TATκ-GFP-CDKL5 protein. 
Fig. 23-B demonstrates western blot analysis results from TATκ-GFP-CDKL5 protein 
expression in transfected HEK 293T cells. Western blot image on the left demonstrates TATκ-GFP-
CDKL5 fusion protein expression in cell homogenates from transfected HEK 293T cells, while 
western blot image on the right demonstrates TATκ-GFP-CDKL5 fusion protein accumulation in 
concentrated (20×) cell culture medium from transfected HEK 293T cells. 
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Figure 23. TATκ-CDKL5 Production method. (A) Scheme of the production and 
purification of the fusion protein TATκ-GFP-CDKL5. TATκ-CDKL5 protein was GFP tagged in 
order to identify CDKL5. (B) Western blot analysis with anti-CDKL5 antibody confirmed TATκ-
CDKL5 protein expression in transfected 293T cells (left panel) and accumulation in the 
concentrated culture medium (right panel). 
 
The main advantages of using this production method instead of recovering the protein from 
cell lysate consist in higher recovery of protein together with the advantage of avoiding the use of 
strong chemicals for lysis and purification. Indeed, physiological buffers are used during the whole 
process. 
 
4.2 Target cells are efficiently transduced by TATκ-CDKL5 
To evaluate the efficiency of transduction of TATκ-GFP-CDKL5 protein, HEK 293T cells 
were incubated with the purified/concentrated fusion protein. After different incubation times, cells 
were lysed and total protein extracts were transferred to a nitrocellulose membrane for 
immunoblotting for TATκ-GFP-CDKL5 protein quantification. As shown in Fig. 24-C, TATκ-GFP-
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CDKL5 is internalized by cells after only about 30 minutes of incubation. Other cultures were treated 
in parallel and were fixed and immunostained with an anti-GFP specific antibody to visualize the 
transduced TATκ-GFP-CDKL5 protein. As demonstrated in Fig. 24-A, TATκ-GFP-CDKL5 protein 
was efficiently translocated into the cells. 
The internalization in target cells was confirmed by confocal microscopy (Fig. 24-B). SH-
SY5Y neuroblastoma cells were incubated for 30 minutes with the supernatant collected from 293T 
cells expressing TATκ-GFP-CDKL5. Fig. 24-B shows serial confocal images (1-12) of TATκ-GFP-
CDKL5 transduced SH-SY5Y cells, demonstrating that TATκ-GFP-CDKL5 protein is internalized 
by target cells and localized both in the nucleus and cytoplasm of SH-SY5Y cells (Fig. 24-B), 
consistently with CDKL5 cellular distribution [Rusconi et al. 2008]. 
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Figure 24. Internalization of TATκ-CDKL5 by target cells. (A) 293T target cells treated 
with concentrated culture medium with or without TATκ-GFP-CDKL5. Cells were stained for GFP 
expression using a primary antibody to GFP and a secondary antibody labeled with Cy3 (red). All 
cells were CDKL5 positive to a variable degree. (B) Confocal microscopy showing TATκ-GFP-
CDKL5 expression in target cells. SH-SY5Y cells were treated with TATκ-GFP-CDKL5 for 30 
minutes and examined by confocal microscopy (Z stack size 0.4 µm). (C) Western blot analysis of 
homogenates of 293T cells treated for different times with concentrated medium containing TATκ-
GFP-CDKL5. Note that TATκ-GFP-CDKL5 protein is internalized by target cells. 
 
4.3 TATκ-CDKL5 retains wild type activity 
4.3.1 TATκ-CDKL5 retains kinase activity 
TATκ-GFP-CDKL5 fusion protein was purified from culture medium on a Ni-NTA resin, 
exploiting the 6xHis purification tag at the C-terminus. It has been shown that the CDKL5 kinase has 
a high autophosphorylation activity [Lin, Franco, and Rosner 2005; Mari et al. 2005]. As shown in 
Fig. 25, which show the results from an in vitro kinase activity assay with radioactive [γ32P]-ATP, 
purified TATκ-GFP-CDKL5 protein preserves its autophosphorylation activity. This demonstrates 
that the purified fusion protein retains its kinase activity. 
 
 
 
Figure 25. Kinase activity assay. Panel on the left shows results from the kinase assay 
demonstrating that TATκ-GFP-CDKL5 fusion protein retains CDKL5 autophosphorylation activity. 
Band corresponding to CDKL5 was confirmed by western blot analysis using an anti-CDKL5 
antibody, shown in the right panel. 
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4.3.2 TATκ-CDKL5 inhibits proliferation and induces differentiation of SH-SY5Y 
neuroblastoma cells 
As previously described, the CDKL5 gene affects both the proliferation and differentiation of 
neural cells [Valli et al. 2012]. Therefore, neuroblastoma cells were employed to study the TATκ-
CDKL5 function in vitro. SH-SY5Y cells were treated with purified TATκ-GFP-CDKL5 or TATκ-
GFP (as a control) the day after seeding. In particular, cells were incubated with the concentrated 
media containing the concentrated/purified protein for about 24 hours. Cell proliferation was 
evaluated as a mitotic index (the ratio between the number of cells in a population undergoing 
mitosis to the number of cells) using Hoechst nuclear staining. Differentiation was evaluated by 
examining neurite growth, which is a sign of neuronal differentiation. For this analysis, cells were 
grown for an additional 2 days and neurite outgrowth was measured using an image analysis system.  
The increase of CDKL5 protein levels within neuroblastoma cells (through TATκ-GFP-
CDKL5 protein treatment) caused a strong inhibition of cell proliferation (Fig. 26) with no increase 
in apoptotic cell death (data not shown) compared to controls. Furthermore, as shown in Fig. 27, 
TATκ-GFP-CDKL5 promotes neuroblastoma cell differentiation as indicated by neurite outgrowth in 
SH-SY5Y cells. These results demonstrate that synthetic TATκ-CDKL5 is functional in an in vitro 
neuronal model. 
 
 
 
Figure 26. Effect of TATκ-GFP-CDKL5 on neuroblastoma cell proliferation. (A) Images of 
Hoechst stained nuclei of SH-SY5Y cells treated with TATκ-GFP-CDKL5 or TATκ-GFP for 24 
hours. Examples of mitotic (i.e. proliferating) cells are indicated by an arrow. (B) Quantification of 
the mitotic index evaluated as number of mitotic cells on total cell number. Note the large reduction 
in the number of proliferating cells. Values represent percentage of mean  SEM. *** p < 0.001 as 
compared to TATκ-GFP treated cells (T-test). 
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Figure 27. Effect of TATκ-GFP-CDKL5 on neuroblastoma cell differentiation. (A) 
Representative phase-contrast images of SH-SY5Y cells treated with TATκ-GFP or TATκ-GFP-
CDKL5 and cultured for 72 hours. Note that cells treated with TATκ-GFP-CDKL5 have longer 
processes. (B) Quantification of neurite outgrowth of SH-SY5Y cells treated with TATκ-GFP or 
TATκ-GFP-CDKL5. Values represent mean  SE. * p < 0.05 (T-test). 
 
4.3.3 Expression and activity comparison between secretable TATκ-CDKL5 constructs 
In order to simplify biochemical analysis of TATκ-CDKL5, we added a GFP-tag sequence in 
frame with CDKL5, given that no good anti-CDKL5 antibodies are available to date. Therefore we 
created TATκ-GFP-CDKL5115 and TATκ-GFP-CDKL5107 constructs, and a TATκ-GFP construct to 
be used as negative control. Considering that a GFP-tagged protein might have different activity 
compared to the native protein [Stevens et al. 2010], we tested the in vitro activity of TATκ-GFP-
CDKL5115 in parallel to a TATκ-CDKL5115 with only a small 3xFLAG-tag at the C-terminus. As 
shown in Fig. 28, we demonstrated that both the proteins have the same effect on SH-SY5Y 
neuroblastoma cells in term of inhibition of proliferation, indicating that the GFP-tag does not alter 
CDKL5 activity. 
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Figure 28. Comparison between the effect of TATκ-GFP-CDKL5 and TATκ-CDKL5-
FLAG on neuroblastoma cell proliferation. SH-SY5Y cells were treated with TATκ-GFP, TATκ-
GFP-CDKL5 or TATκ-CDKL5-FLAG for 24 hours and the mitotic index was evaluated as number of 
mitotic cells on total cell number. Note that the two fusion proteins show a similar activity of 
inhibition of SH-SY5Y mitosis compared to TATκ-GFP treated control cells. Values represent mean 
 SEM.  *** p < 0.001 as compared to TATκ-GFP treated cells (T-test). 
 
4.3.4 TATκ-CDKL5 restores neurite development of Neuronal Precursor Cells derived from 
CDKL5 KO Mice 
In order to further confirm the functionality of the recombinant protein before starting in vivo 
experiments, an ex vivo treatment was performed on Neuronal Precursor Cells (NPCs) derived from 
mouse brains. NPC cultures from CDKL5 KO (−/Y) mice and wild type (+/Y) mice were treated 
with TATκ-GFP-CDKL5 or TATκ-GFP. Neuronal maturation was evaluated by measuring the total 
neuritic length of differentiated neurons (positive for β-tubulin III). An evaluation of neurite length 
was performed using the image analysis system Image Pro Plus (Media Cybernetics, Silver Spring, 
Md. 20910, USA). The average neurite length per cell was calculated by dividing the total neurite 
length by the number of cells counted in the areas. As shown in Fig. 29, the absence of CDKL5 in 
KO NPCs causes a reduction in the maturation of new neurons, but treatment with TATκ-CDKL5 
restores neurite development. 
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Figure 29. Effect of TATκ-GFP-CDKL5 on NPCs cultures. (A) Images of β-tubulin III 
stained neuronal precursor cells from the CDKL5 KO (-/Y) and wild type (+/Y) mouse. Cultures 
were treated with TATκ-GFP-CDKL5 or TATκ-GFP during differentiation. (B) Neuronal maturation 
was evaluated by measuring the total neuritic length of differentiated neurons (positive for β-tubulin 
III). Values represent mean  SE. ** p < 0.01 as compared to +/Y; # p < 0.05 as compared to the -/Y 
samples (Bonferroni's test after ANOVA). 
 
4.4 TATκ-CDKL5 production optimization for in vivo treatments 
4.4.1 Creation of mammalian stable clones expressing different TATκ-CDKL5 isoforms 
Based on the promising results obtained in vitro, we started planning in vivo studies, in order 
to set up a reproducible TATκ-CDKL5 protein production. The generation of stably-transfected cell 
lines is essential for a wide range of applications, such as gene function studies, drug discovery 
assays, or the production of recombinant proteins [Wurm 2004]. In contrast to transient expression, 
stable expression allows long term, as well as defined and reproducible, expression of the gene of 
interest. Therefore we created 293T cell lines that stably express the recombinant TATκ-GFP-
CDKL5 protein as well as TATκ-GFP protein as a negative control.  
Alternative splice isoforms for the CDKL5 gene have been described (Kilstrup-Nielsen, 
2012). The original CDKL5 transcript generates a protein of 1030 amino acids (CDKL5115; 115 
kDa). While CDKL5115 is the first characterized CDKL5 isoform, a recently identified transcript, 
characterized by an altered C-terminal region, is likely to be relevant for CDKL5 brain functions 
(CDKL5107; 107 kDa) [Williamson et al. 2012]. To compare the levels of production and activity of 
the two CDKL5 isoforms, we created different 293T cell lines that express either TATκ-GFP-
CDKL5115 or TATκ-GFP-CDKL5107 isoform. Consistently with the reported higher stability of the 
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107 kDa isoform to proteasomal degradation [Williamson et al. 2012], we found that the recovery of 
TATκ-GFP-CDKL5107 fusion protein from culture medium was higher than that of TATκ-GFP-
CDKL5115 (Fig. 30). 
Importantly, at a functional level, we found that the two isoforms have a comparable 
inhibition effect on neuroblastoma cell proliferation (FIG R12), indicating a similar enzymatic 
activity. 
 
 
 
Figure 30. Comparison of the expression and secretion pattern of TATκ-GFP-CDKL5115 
and TATκ-GFP-CDKL5107 . Images show western blots of 20-fold concentrated culture medium of 
transfected 293T cells (panel on the left) or in stable clones (panel on the right) expressing TATκ-
GFP-CDKL5. 
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Figure 31. Effect of TATκ-GFP-CDKL5115 and TATκ-GFP-CDKL5107 isoforms on SH-
SY5Y neuroblastoma cells proliferation. SH-SY5Y cells were treated with TATκ-GFP, TATκ-GFP-
CDKL5115 or TATκ-GFP-CDKL5107 for 24 hours and the mitotic index was evaluated as number of 
mitotic cells on total cell number. Note that the two CDKL5 isoforms show a similar activity of 
inhibition of SH-SY5Y mitosis compared to TATκ-GFP treated control cells. Values represent mean 
 SEM. * p < 0.05 and ** p < 0.01 as compared to TATκ-GFP treated cells (T-test). 
 
4.4.2 TATκ-CDKL5 fusion protein in culture medium can be concentrated up to 480× 
In order to formulate a more suitable preparation for in vivo treatments, TATκ-GFP-CDKL5 
proteins were purified from serum-free culture medium at increasing concentrations (40- 60-120-
240- 480- fold). Starting from the 20-fold medium concentration used for in vitro studies, we reached 
a maximum of 480-fold concentration without protein precipitation (Fig. 32). Once the highest 
concentration that did not cause protein precipitate had been found, the concentrated medium was 
subjected to buffer exchange with sterile saline. 
 
 
 
Figure 32. Increasing concentration of culture medium containing TATκ-CDKL5. Image 
shows an anti-CDKL5 western blot analysis of conditioned media from 293T cells expressing TATκ-
GFP-CDKL5. Note that the protein does not precipitate at 480-fold concentration. 
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4.4.3 Quantification of the purified TATκ-CDKL5 protein 
The established formulation for in vivo treatments takes into account different variables 
among which the most important is protein concentration. Therefore, we quantified the purified 
TATκ-CDKL5 protein. Using a purified GFP protein at a known concentration as reference standard, 
we quantified TAT-GFP-CDKL5115 and TAT-GFP-CDKL5107 proteins through western blot analysis 
using an anti-GFP antibody. We calculated that in 480-fold purified medium the 115-kDa isoform is 
about 0.5 ng/µL concentrated while the 107-kDa isoform can be more efficiently produced with a 
final concentration of 8-10 ng/µL. 
 
The first in vivo treatments were performed with intracerebroventricular injections. Such a 
technique limits the volume of bolus to 10-15 µL per injection. We started experiments with the 
lower concentration, treating adult animals with 10 µL of TAT-GFP-CDKL5115 preparation, 
corresponding to 5 ng/day of protein. As described in detail in the text below, treatment did not cause 
evident side effects and, as a matter of fact, improved various aspects of brain functionality. 
Therefore, we performed the following treatments with a higher protein concentration using the 
TAT-GFP-CDKL5107 preparation, maintaining the same bolus volume of 10 µL, and thus injecting 
about 80 ng of protein per day. Even though a more precise quantification is required, results 
demonstrated a dose-dependent improvement of the analyzed neurophysiological aspects. 
 
4.4.4 Temperature and time of storage do not affect TATκ-CDKL5 protein stability 
Purified proteins often need to be stored for an extended period of time, still retaining their 
original activity. Stability is an inherent property of the protein(s) of interest. Not all proteins behave 
similarly under the same storage conditions. We evaluated the stability of the purified TATκ-GFP-
CDKL5 protein after a long period at -80°C and a freezing-thawing cycle. We treated SH-SY5Y 
neuroblastoma cells with a freshly-produced protein, in parallel with a protein stored at -80°C for 
one month. We performed a proliferation assay evaluating the mitotic index as previously described 
and observed that the stored protein maintained the same anti-proliferative activity of the freshly-
produced protein (Fig. 33), indicating that storage in freezing conditions did not alter CDKL5 
activity.  
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Figure 33. Histogram showing the activity of purified TATκ-GFP-CDKL5115 and TATκ-
CDKL5115-FLAG tested immediately after production or after a freeze-thaw cycle. Protein activity 
was evaluated as ability to inhibit SH-SY5Y neuroblastoma cells proliferation. SH-SY5Y cells were 
treated with TATκ-GFP, TATκ-GFP-CDKL5115 or TATκ-CDKL5115-FLAG freshly produced or 
freezed-thawed proteins for 24 hours and the mitotic index was evaluated as number of mitotic cells 
on total cell number. Values represent mean  SEM. 
 
Furthermore, we evaluated the stability of TATκ-CDKL5-FLAG (data not shown) and 
TATκ-GFP-CDKL5 at 37°C, in order to assess the protein stability at a physiological temperature. 
Thus we kept aliquots of purified proteins at 37°C for different periods, starting from 24 hrs to one 
week. Through western blot analysis we demonstrated that a substantial amount of both proteins 
remains in the preparation after 3 days of storage at 37°C (Fig. 34) and it is still detectable after one 
week (data not shown). Such information enables the use of reservoir-based therapeutic systems in 
future preclinical studies and drug development, in view of clinical trials which need patient 
compliance and controlled release. 
 
 
 
Figure 34. Western blot analysis showing degradation on time of TATκ-GFP-CDKL5 at 
physiological temperature. Aliquots of protein were kept in the incubator at 37°C for different times. 
After three days of incubation a consistent amount of the full-length protein is revealed with an anti-
CDKL5 antibody in the western blot membrane. 
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4.5 Intracerebroventricular treatment with TATκ-CDKL5 restores neuronal 
maturation and survival 
4.5.1 TATκ-CDKL5 restores dendritic arborization 
The first in vivo study was scheduled with TATκ-GFP-CDKL5115 or vehicle injected directly 
to the third cerebral ventricle of adult mice (4-6 months of age) for 5 consecutive days (experimental 
schedule in Fig. 35). 
 
 
 
Figure 35. ICV short-treatment schedule. Male CDKL5 WT (CDKL5
+/Y
) and CDKL5 KO 
(CDKL5
-/Y
) mice received treatment with vehicle (n=6) or TATκ-GFP-CDKL5115 (n=6) as indicated 
above. Treatment period consisted of a single daily intraventricular injection for 5 consecutive days. 
Animals were sacrificed 1 hour after the last injection or after 3 days. Some animals from each 
experimental group were behaviorally tested as indicated. 
 
In this study we initially used the CDKL5115 isoform since from in vitro studies CDKL5 
isoform is the best known from a functional point of view. Twenty-four hours after the last injection 
animals were sacrificed, and the dendritic morphology of newborn hippocampal granule cells was 
analyzed with immunohistochemistry for doublecortin (DCX), a microtubule-associated protein 
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expressed by neuronal precursor cells and immature neurons. As previously described [Amendola et 
al. 2014; Fuchs et al. 2014], the hippocampal region shows major structural and functional defects in 
CDKL5 KO mice, representing a brain structure that is well suited for the study of the effects of 
therapies on CDKL5 KO mice. Indeed Fig. 36-A demonstrates that DCX positive neurons of CDKL5 
KO mice exhibit shorter processes than those of their wild type counterparts. Importantly, TATκ-
GFP-CDKL5115 fusion protein administered intraventricularly was observed to increase neurite 
length and branch number in CDKL5 KO mice to levels similar to wild type (Fig. 36-A,B). Fig. 36-C 
shows examples of the reconstructed dendritic tree of newborn granule cells of wild type (+/Y), 
hemizygous CDKL5 KO (−/Y) mice, and their relative counterparts treated with TATκ-GFP-
CDKL5115 fusion protein. Quantification of the dendritic size of DCX positive cells demonstrated 
that, while untreated CDKL5 KO (−/Y) mice had a shorter dendritic length and a reduced number of 
segments than wild type mice, TATκ-GFP-CDKL5115 treated knockout (−/Y) mice showed an 
increase in both parameters that became even larger in comparison with +/Y mice (Histograms in 
Fig. 36-B). 
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Figure 36. Effects of 5-days treatment with TATκ-GFP-CDKL5115 on immature neurons. 
(A) Images of hippocampus (dentate gyrus) sections immunostained for DCX of WT male mice (+/Y) 
and CDKL5 KO male mice (-/Y). Note the reduced neurite length and number of newborn granule 
cells in CDKL5 KO (-/Y) as compared to WT mice (+/Y). TATκ-GFP-CDKL5 administered once 
daily by intraventricular injection for five consecutive days was observed to increase neurite length 
and number of newborn granule cells in CDKL5 KO mice to levels similar to wild-type. Scale bar = 
60 mm. (B) Quantification of the mean total dendritic length (upper panel), and mean number of 
dendritic segments (lower panel) of newborn granule cells (DCX-positive cells) of the hippocampus 
(dentate gyrus). Values represent mean  SE. ** p < 0.01; *** p < 0.001 as compared to +/Y; # p < 
0.05 as compared to the -/Y samples (Bonferroni’s test after ANOVA). (C) Examples of the 
reconstructed dendritic tree of newborn granule cells. 
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The effects of TATκ-GFP-CDKL5115 treatment on the dendritic architecture were further 
examined by evaluating each dendritic order separately. A striking feature of CDKL5 KO mice is the 
absence of branches of higher orders (Fig. 37; red arrows). While wild type (+/Y) mice have up to 10 
orders of branches, CDKL5 KO (−/Y) mice lack branches of orders 8-10. In addition, CDKL5 KO 
(−/Y) mice show a reduced branch length of orders 5-8 (Fig. 37-A) and a reduced number of 
branches of orders 6-8 (Fig. 37-B). These data indicate that in CDKL5 KO mice the dendritic tree of 
the newborn granule cells is hypotrophic and that this defect is due to a reduction in the number and 
length of branches of intermediate orders and a lack of branches of higher orders. It was observed 
that all these defects were completely rescued by TATκ-GFP-CDKL5115 treatment (FIGS. 37-A,B), 
indicating that protein therapy has a positive impact on the dendritic development of newborn 
neurons. 
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Figure 37. Effects of 5-days treatment with TATκ-GFP-CDKL5115 on dendritic 
arborization. Quantification of the mean length (A) and mean number (B) of branches of the 
different orders of newborn granule cells of the dentate gyrus of WT male mice (+/Y) and CDKL5 
KO male mice (-/Y) treated for 5 consecutive days with vehicle or TATκ-GFP-CDKL5. Arrows 
indicate the absence of branches in CDKL5 KO male mice (-/Y) treated with vehicle. Values 
represent mean  SE. * p < 0.05; ** p < 0.01 as compared to +/Y; # p < 0.05 as compared to the -/Y 
samples (Bonferroni’s test after ANOVA).  
 
Furthermore, we analyzed the effects of treatment on the dendritic architecture of mature 
neurons. To this end we examined Golgi-stained granule neurons located in the middle portion of the 
granule cell layer. While CDKL5 KO (−/Y) mice show a shorter length of dendritic branches 
compared to wild-type (+/Y) mice, these defects were completely rescued by treatment with TATκ-
GFP-CDKL5 (Fig. 38-A). In both treated −/Y and +/Y mice total dendritic length became even 
larger in comparison with untreated +/Y mice. These results show that the impaired dendritic 
architecture of mature granule neurons observed in CDKL5 −/Y mice was restored by treatment with 
TATκ-GFP-CDKL5 protein. 
 
 
 
Figure 38. Effects of 5-days treatment with TATκ-GFP-CDKL5115 on mature neurons. (A) 
Mean total dendritic length of Golgi-stained granule cells in wild-type male mice (+/Y) and CDKL5 
KO male mice (-/Y) treated with vehicle or TATκ-GFP-CDKL5 via intraventricular injections given 
once a day for 5 consecutive days. (B) Scheme of a hippocampal slice showing the different layers 
and the position of CA1 pyramidal cells and granule cells. The molecular layer (Mol) of the dentate 
gyrus (DG) contains the granule cell dendrites. Values represent mean  SE. * p < 0.05; ** p < 0.01 
as compared to +/Y; # p < 0.05 as compared to the -/Y samples (Bonferroni’s test after ANOVA).  
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4.5.2 TATκ-CDKL5 restores neuronal survival 
It was observed that CDKL5 KO mice (−/Y) mice have fewer postmitotic neurons (DCX-
positive cells) than wild type (+/Y) mice in the hippocampal dentate gyrus [Fuchs et al. 2014]. 
Importantly, as shown in Fig. 39-A, the number of postmitotic neurons in TATκ-GFP-CDKL5115 
treated CDKL5 KO mice underwent an increase, becoming similar to that of wild type (+/Y) mice. 
In order to evaluate the effects of TATκ-GFP-CDKL5115 treatment on apoptotic cell death, 
we counted the number of apoptotic cells expressing cleaved caspase-3 in the hippocampal dentate 
gyrus. As previously discussed, neural precursors of CDKL5 −/Y mice exhibit an abnormally high 
proliferation rate. Quantification of cleaved caspase-3 cells showed that TATκ-GFP-CDKL5 
treatment completely normalized apoptotic cell death in CDKL5 KO mice (Fig. 39-B). This indicates 
that the increased death of postmitotic immature granule cells, a characteristic of CDKL5 KO mice, 
is rescued by TATκ-GFP-CDKL5 treatment. 
 
 
 
Figure 39. Effects of 5-days treatment with TATκ-GFP-CDKL5115 on survival. (A) 
Quantification of DCX positive cells in the dentate gyrus of WT male mice (+/Y), CDKL5 KO male 
mice (-/Y) with vehicle or TATκ-GFP-CDKL5. Treatment period consisted of one daily 
intraventricular injection given daily for 5 consecutive days. (B) Quantification of apoptotic cells 
(cleaved caspase-3 positive cells) mice treated as in A. Values represent mean  SE. * p < 0.05; ** p 
< 0.05 as compared to +/Y; # p < 0.05 as compared to the -/Y samples (Bonferroni’s test after 
ANOVA). 
 
Taken together, these data demonstrate that treatment with TATκ-GFP-CDKL5115 in CDKL5 
KO mice increased neurite length and survival of newborn cells in the hippocampus, indicating that 
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injected TATκ-GFP-CDKL5115 diffused from the lateral ventricle to the hippocampus and restored 
maturation and survival of postmitotic granule cells. 
 
4.6 Intracerebroventricular treatment with TATκ-CDKL5 restores connectivity 
4.6.1 TATκ-CDKL5 restores synaptic molecules expression 
A reduction in connectivity may be the counterpart of the dendritic hypotrophy that 
characterizes the newborn granule cells of CDKL5 KO mice. Synaptophysin (SYN; also known as 
p38) is a synaptic vesicle glycoprotein that is a specific marker of presynaptic terminals. We 
previously reported that in CDKL5 KO mice the optical density of SYN in the molecular layer of the 
hippocampus is significantly lower than in wild type mice [Fuchs et al. 2014], suggesting that 
CDKL5 KO mice have fewer synaptic contacts in the dentate gyrus. Furthermore, dendritic 
arborization is significantly reduced in cortical pyramidal neurons of CDKL5 KO mice compared to 
their wild type counterparts [Amendola et al. 2014]. At the same time, similar lower levels of SYN 
immunoreactivity in the layer III of the neocortex were observed. In CDKL5 KO (−/Y) mice treated 
with TATκ-GFP-CDKL5115 these defects were fully rescued (Fig. 40), suggesting that the positive 
impact of treatment with TATκ-GFP-CDKL5115 on dendritic structure was paralleled by restoration 
of the input to neurons. 
Fig. 40-A shows representative images demonstrating brain sections processed for SYN 
immunofluorescence from the molecular layer (Mol) of the dentate gryrus (DG) from a wild type 
(+/Y) mouse, a hemizygous CDKL5 KO (−/Y) mouse, and a hemizygous CDKL5 KO mouse treated 
with TATκ-GFP-CDKL5115 protein via intraventricular injections given once a day for 5 consecutive 
days (−/Y + TATκ-GFP-CDKL5). 
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Figure 40. Effects of 5-days treatment with TATκ-GFP-CDKL5115 on synaptophysin 
expression. (A) Representative images of brain sections processed for synaptophysin  
immunofluorescence from the molecular layer of the dentate gyrus (DG) from a WT male mouse 
(+/Y) and CDKL5 KO male mice (-/Y) treated with vehicle or TATκ-GFP-CDKL5. Scale bar = 80 
µm. Abbreviation: GR, granular layer; Mol, molecular layer. (B) Quantification of synaptophysin 
(SYN) optical density in the molecular layer of the hippocampus (left panel) and layer III of the 
cortex (right panel) in mice treated as in A. Data are given as fold difference vs. the corresponding 
zone of the molecular layer or cortex of wild type mice. Values represent mean  SD. ** p < 0.01; 
*** p < 0.001 as compared to +/Y; # p < 0.05 as compared to the -/Y samples (Bonferroni’s test 
after ANOVA). 
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4.6.2 TATκ-CDKL5 restores spine density and maturation 
In Golgi-stained sections, spines of granule cells were counted and spine density was 
measured on dendritic segments in the inner and outer half of the molecular layer. Untreated CDKL5 
KO adult mice showed a lower spine density compared to wild type mice, while treatment with 
TATκ-GFP-CDKL5115 protein fully restored density, erasing the difference between knockout and 
wild type conditions. Representative images are shown in Fig. 41 and the relative quantification can 
be observed in the histogram on the right. 
 
 
 
Figure 41. Effects of 5-days treatment with TATκ-GFP-CDKL5115 on spine number. (A) 
Images of Golgi-stained dendritic branches of granule cells of wild-type male mice (+/Y) and 
CDKL5 KO male mice (-/Y) treated with vehicle or TATκ-GFP-CDKL5 via intraventricular 
injections given once a day for 5 consecutive days. Scale bar = 5 µm. (B) Quantification of number 
of dendritic spines. Values represent mean  SE. ** p < 0.05 as compared to +/Y; # p < 0.05 as 
compared to the -/Y samples (Bonferroni’s test after ANOVA). 
 
To further investigate the effects of treatment with TATκ-GFP-CDKL5 protein on dendritic 
spines, we examined spine morphology of Golgi-stained granule neurons. Dendritic spines are 
heterogeneous in size and shape, and can be classified as: filopodia, thin-shaped, stubby-shaped for 
immature spines, while mushroom and cup shapes indicate mature spines (see Fig. 42-A). 
As shown in Fig. 42-C, the percentage of mature spines is lower in CDKL5 KO mice 
compared to wild type littermates, while the percentage increases to reach that of the wild type 
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condition in knockout mice treated with TATκ-GFP-CDKL5115. Conversely, the percentage of 
immature spines is higher in knockout mice and diminishes, reaching a similar percentage to the wild 
type condition after treatment with TATκ-GFP-CDKL5115. Images of Golgi-stained dendritic spines 
from granule cells of wild type male (+/Y) mice and CDKL5 KO (-/Y) mice are shown in Fig. 42-B. 
 
 
 
Figure 42. Effects of 5-days treatment with TATκ-GFP-CDKL5115 on spine morphology. 
(A) Schematic depiction of dendritic spines classified by shape as thin, stubby, mushroom- and cup-
shaped. Red asterisks indicate immature spines (filopodia + thin + stubby), blue asterisks over the 
mature spines (mushroom + cup). (Image taken from [Hering and Sheng 2001]) (B) Images of 
Golgi-stained dendritic spines of granule cells of wild-type male mice (+/Y) and CDKL5 KO male 
mice (-/Y) treated with vehicle or TATκ-GFP-CDKL5 via intraventricular injections given once a 
day for 5 consecutive days. Scale bar = 5 µm. Mature and immature spine are marked with blue and 
red asterisks respectively. (C) Percentage of immature and mature spines in mice as in A. *** p < 
0.001 as compared to +/Y; # p < 0.01 as compared to the -/Y samples (Bonferroni’s test after 
ANOVA). 
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Taken together, these data demonstrate that treatment with TATκ-GFP-CDKL5115 completely 
recovers connectivity in CDKL5 −/Y mice, by restoring synaptophysin expression and by correcting 
dendritic spine number and maturation. 
 
4.7 Intracerebroventricular treatment with TATκ-CDKL5 improves cognitive 
performance 
Following histological studies on the hippocampal region we investigated the effect of TATκ-
GFP-CDKL5115 on hippocampus-dependent behavior after a short course of treatment (5 days). Mice 
that had been injected for 5 days were subjected to a preliminary behavioral test, namely the passive 
avoidance task. This test is a fear-aggravated test used to evaluate learning and memory in rodent 
models of CNS disorders and requires the subjects to behave contrarily to their innate tendency to 
prefer dark areas and avoid bright areas (Fig. 43). Memory for the passive avoidance task is 
disrupted by hippocampal lesions [Deacon et al. 2002], demonstrating the involvement of this brain 
region in the tasks required for this behavioral test. 
After the mice spend an initial day exploring the chambers into which they are placed, they 
receive a foot shock. Mice with normal learning and memory will avoid entering the chamber where 
they were previously exposed to the shock. We previously reported that CDKL5 KO mice do not 
avoid the shock chamber on the second day, indicating a disruption of memory function [Fuchs et al. 
2014]. Unfortunately, we observed that after undergoing 5 days of treatment with TATκ-GFP-
CDKL5115 the hippocampal cognitive functions of knockout mice were not restored, as they showed 
a significantly shorter latency compared to their wild type counterparts (Fig. 43-C). 
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Figure 43. Effects of 5-days treatment with TATκ-GFP-CDKL5115 on hippocampus-
dependent behavior. (A) Scheme of a passive avoidance apparatus. (B-C) Passive avoidance test in 
WT male mice (+/Y) and CDKL5 KO male mice (-/Y) treated with vehicle or TATκ-GFP-CDKL5. 
Graphs show the latency time for entering the dark compartment on the first day (B) and on the 
second day (C). Values represent mean ± SE. *** p < 0.001 as compared to the untreated wild-type 
condition as tested with Fisher LSD after ANOVA. 
 
For this reason we prolonged the treatment with TATκ-GFP-CDKL5115 to 12 days (see 
treatment schedule shown in Fig. 44). The treatment period consisted of a single daily injection for 5 
consecutive days, followed by a two-day rest period and then 5 additional days of a single injection 
for a total of 10 injections. Moreover, after ascertaining that treatment did not cause evident side 
effects in terms of body weight and inflammatory response (see Fig. 45), we also started treating a 
group of mice with a higher dose of TATκ-GFP-CDKL5, by injecting the 107 kDa isoform of 
CDKL5. Experimental groups were subject to various behavioral tests starting from the least 
stressful ones, and the results, which are promising, are presented below. 
 
 
 
Figure 44. Prolonged ICV treatment schedule. Male CDKL5 WT (CDKL5
+/Y
) received 
treatment with TATκ-GFP (n=6) while CDKL5 KO (CDKL5-/Y) were treated with TATκ-GFP (n=6), 
TATκ-GFP-CDKL5115 (n=10) or TATκ-GFP-CDKL5107 (n=6) as indicated above.  Treatment period 
consisted of a single daily injection for 5 consecutive days, followed by a two day rest period and 
then 5 additional days of a single injection. There was a total of 10 injections which were done in a 
12 day period. 
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Figure 45. Monitoring of body weight and inflammatory response in mice treated with one 
daily intraventricular injection of protein for a total of 10 injections. (A) Body weight of CDKL5 
KO (-/Y) and wild-type (+/Y) mice treated with TATκ-GFP or CDKL5 KO (-/Y) mice treated with 
TATκ-GFP-CDKL5115 or TATκ-GFP-CDKL5107. Mice were allowed to recover for 7 days after 
cannula implantation and sacrificed 10 days after the last injection. (B) Immunohistochemical 
analysis of AIF-1 in brain slides of wild-type (+/Y) and CDKL5 KO (-/Y) mice treated with TATκ-
GFP-CDKL5115 or vehicle. Allograft inflammatory factor 1 (AIF-1) is an inflammation-responsive 
scaffold protein that is mainly expressed in immunocytes. It was reported to be associated with the 
activation of microglia/macrophages post central nervous system injury [Zhao, Yan, and Chen 
2013]. Note that no significant differences were observed in body weight nor in AIF-1 inflammatory 
activation, indicating no evident side effects in 12-days treated mice. 
 
4.7.1 TATκ-CDKL5 improves learning and memory ability 
As already stated, CDKL5 KO mice exhibit learning and memory deficits when compared to 
wild type mice. To examine memory and learning ability, both CDKL5 KO and wild type mice were 
administered 10 daily intraventricular injections of TATκ-GFP-CDKL5115, TATκ-GFP-CDKL5107 or 
TATκ-GFP. After a two-day rest period following the conclusion of the injections, all experimental 
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groups were tested with the Morris Water Maze (MWM). MWM measures the ability to find and 
recall the position of a platform submerged in water. Mice were trained for 5 consecutive days in the 
MWM task to locate the hidden escape platform in a circular pool. The latency to find the hidden 
platform during the trials was used as a measure of learning. After the training period, on the sixth 
day animals were subjected to a probe trial without a platform in order to test memory. 
The results of the MWM test are shown in Fig. 46. The graph shows quantification of the 
learning phase as determined via the MWM test in wild type (+/Y) mice treated with TATκ-GFP 
control protein and CDKL5 KO (−/Y) mice treated with TATκ-GFP, TATκ-GFP-CDKL5115, or 
TATκ-GFP-CDKL5107. Following treatment with the control protein (TATκ-GFP), no changes were 
shown in the learning curve compared to the previously reported trend of untreated wild type and 
CDKL5 KO mice [Fuchs et al. 2014]. TATκ-GFP treated wild type mice learned to find the platform 
by the third day, but no significant learning was detected in TATκ-GFP treated CDKL5 KO mice, 
indicating a learning deficit. Importantly, TATκ-GFP-CDKL5115 treated CDKL5 KO mice began to 
recover their learning ability on day 4 with continued improvement on day 5, while TATκ-GFP-
CDKL5107 treated CDKL5 KO mice began to recover their learning ability on day 3 and reached a 
performance similar to that of WT on days 4 and 5 (Fig. 46-A). 
Concerning the probe test, histograms in Fig. 46 B-D show the memory performance of 
experimental groups. TATκ-GFP treated CDKL5 KO (-/Y) mice found the platform with a longer 
latency (B), entered the quadrant with a reduced frequency (C), and spent a reduced amount of time 
in the quadrant of the platform (D) in comparison with TATκ-GFP treated WT (+/Y) mice. TATκ-
GFP-CDKL5115 treated CDKL5 -/Y mice showed a positive trend that was not statistically 
significant while TATκ-GFP-CDKL5107 treated CDKL5 -/Y mice showed statistically significant 
improvement in all parameters (Fig. 46 B-D). 
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Figure 46. Effect of treatment on hippocampus-dependent behavior assessed with the 
Morris water maze (MWM). (A) Spatial learning of WT male mice (+/Y) and CDKL5 KO male mice 
(-/Y) treated with TATκ-GFP (n = 6) or CDKL5 KO male mice (-/Y) treated with TATκ-GFP-
CDKL5115 (n = 10) or TATκ-GFP-CDKL5107 (n = 6) for 10 days. After treatment period and a two 
day rest period, mice received MWM testing. (B-D) Probe test showing that CDKL5 KO male mice (-
/Y) found the platform with a longer latency (B), entered the quadrant with a reduced frequency (C) 
and spent a reduced amount of time in the quadrant of the platform (D) in comparison with WT 
(+/Y) mice. TATκ-GFP-CDKL5115 treated CDKL5 -/Y mice showed a positive trend that was not 
statistically significant while TATκ-GFP-CDKL5107 treated CDKL5 -/Y mice showed statistically 
significant improvement in all parameters (B-D). Values represent mean  SE. * p < 0.05, ** p < 
0.01, *** p < 0.001 as compared to the wild type condition; # p < 0.05 as compared to the TATκ-
GFP treated CDKL5 KO condition (Fisher LSD test after ANOVA). 
100 
 
Memory and learning abilities were further examined in response to TATκ-GFP-CDKL5 
protein treatment using the Y-maze spontaneous alternation test. This hippocampus-dependent 
spatial reference memory task is used for measuring the willingness of mice to explore new 
environments. TATκ-GFP treated CDKL5 KO (-/Y) mice showed impairment in memory function in 
this task, as shown by a reduced percentage of correct alternations in comparison with TATκ-GFP 
treated wild type (+/Y) mice. CDKL5 KO mice treated with TATκ-GFP-CDKL5115 showed a slight, 
although not significant, improvement while CDKL5 KO mice treated with TATκ-GFP-CDKL5107 
showed a performance that was similar to that of wild types treated with TATκ-GFP (see Fig. 47). 
 
 
 
Figure 47. Effect of treatment on hippocampus-dependent spatial reference memory 
assessed with the Y-maze Spontaneous Alternation test.  WT male mice (+/Y) and CDKL5 KO male 
mice (-/Y) treated with TATκ-GFP (n = 6) or CDKL5 KO male mice (-/Y) treated with TATκ-GFP-
CDKL5115 (n = 10) or TATκ-GFP-CDKL5107 (n = 6) for 10 days were tested. One alternation is 
defined as consecutive entries in three different arms. The percentage of spontaneous alternations is 
defined as: (total alternations/total arm entries-2) x 100. TATκ-GFP treated CDKL5 KO (-/Y) mice 
were impaired in this task, as shown by a reduced percentage of right alternations in comparison 
with TATκ-GFP treated wild type (+/Y) mice. CDKL5 KO mice treated with TATκ-GFP-CDKL5115 
showed slight improvement while CDKL5 KO treated with TATκ-GFP-CDKL5107 showed 
performance similar to WT treated with TATκ-GFP. * p < 0.05, ** p < 0.01 as compared to the wild 
type condition; # p < 0.05 as compared to the TATκ-GFP treated CDKL5 KO -/Y condition (Fisher 
LSD test after ANOVA). 
 
Finally, the passive avoidance task, which was unsatisfactory after a short period of treatment 
(5 days), was repeated after a more prolonged treatment phase. Accordingly, after 10 days of 
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treatment, 2 days of rest and 6 days of MWM test, mice from the various groups received passive 
avoidance testing (Fig. 48). This test was performed after all the other behavioral tests, because it is 
rather stressful for animals in that it uses an electrical shock as an aversive stimulus. Fig. 48 
demonstrates the results from the passive avoidance test. Fig. 48-A indicates that on the first day the 
latency time to enter the dark chamber was similar for all groups. On day two, namely the testing 
period (Fig. 48-B), animals were placed in the light chamber once again. Memory of the adverse 
event received on the first day in the dark chamber was measured by latency time to enter that 
chamber. TATκ-GFP treated CDKL5 KO (−/Y) mice were severely impaired in performing this task, 
as demonstrated by a reduced latency to enter the dark compartment in comparison with TATκ-GFP 
treated wild type (+/Y) mice. It is important to note that TATκ-GFP-CDKL5 treated knockout mice, 
however, showed a similar latency time to that of wild type mice. This effect was observed with both 
of the TATκ-GFP-CDKL5 isoforms, and it was statistically significant in comparison to TATκ-GFP 
treated CDKL5 KO mice. 
 
 
 
Figure 48. Effect of treatment on hippocampus-dependent memory assessed with the 
passive avoidance (PA) test. (A-B) WT male mice (+/Y) and CDKL5 KO male mice (-/Y) treated 
with TATκ-GFP (n = 6) or CDKL5 KO male mice (-/Y) treated with TATκ-GFP-CDKL5115 (n = 10) 
or TATκ-GFP-CDKL5107 (n = 6) for 10 days were tested. The latency time to enter the dark chamber 
on the first day (A) and on the second day (testing period, B). TATκ-GFP treated CDKL5 KO (-/Y) 
mice were severely impaired in this task, while TATκ-GFP-CDKL5115 and TATκ-CDKL5107 treated 
CDKL5 KO mice showed similar latency time as compared to wild type mice (B). These differences 
were statistically significant in comparison to TATκ-GFP treated CDKL5 KO mice. ** p < 0.01 as 
compared to the wild type condition; # p < 0.05 as compared to the TATκ-GFP treated CDKL5 KO 
(-/Y) condition (Fisher LSD test after ANOVA). 
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Taken together, these data demonstrate that TATκ-CDKL5 treatment partially (at a lower 
dosage with 115 kDa CDKL5 isoform) or completely (at a higher dosage with 107 kDa CDKL5 
isoform) restores hippocampus-dependent learning and memory ability in CDKL5 KO mice. 
 
4.7.2 TATκ-CDKL5 improves motor behavior 
In order to examine the effect of TATκ-GFP-CDKL5 protein on motor behavior, mice were 
tested for limb clasping. To better evaluate the effect of treatment on clasping behavior and to 
eliminate intra-strain variability, each animal was tested both before and after the 10 days of 
treatment. Animals were suspended in the air by the tail for 2 minutes and the total time of clasping 
was measured from a video recording. Results from this test are shown in the histogram in Fig. 49 
and representative screenshots taken from videos show clasping behavior of experimental groups in 
the panels below. While wild type mice never exhibited hind-limb clasping, TATκ-GFP treated 
CDKL5 KO mice spent more than 30 % of the time in the clasping position. Similar data was 
observed in untreated CDKL5 KO mice, indicating that surgery and intraventricular injections, 
which may be stressful, do not alter clasping behavior (data not shown). Importantly, CDKL5 KO 
mice treated with TATκ-GFP-CDKL5115 or TATκ-GFP-CDKL5107 show a significant decrease in 
clasping time.  
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 Figure 49. Effect of treatment on motor behavior assessed with the hind-limb clasping test. 
All animals were suspended for 2 minutes and total time of hind-limb clasping was measured. The 
histogram reports time of hind-limb clasping as a percentage of the total time suspended. Treatment 
with TATκ-GFP-CDKL5115 and TATκ-GFP-CDKL5107 led to a statistically significant reduction in 
clasping time as compared to TATκ-GFP treated CDKL5 KO (-/Y). Below the histogram 
representative images of clasping behavior are shown. Values represent mean  SE. *** p < 0.001 
as compared to the wild type condition; ## p < 0.01 as compared to the TATκ-GFP treated CDKL5 
KO -/Y condition (Fisher LSD test after ANOVA). 
 
Taken together, these data demonstrate that treatment with TATκ-CDKL5 improved motor 
control in CDKL5 KO mice. 
 
4.8 TATκ-CDKL5 effects on neuronal maturation and survival are long lasting 
A protein replacement therapy needs to be continued during the whole life span of the patient. 
With the idea of possibly reducing the frequency of injections in view of a future treatment protocol 
in humans, we evaluated the persistence of positive effects after treatment cessation. 
Hence, twelve days after the completion of the treatment period, immediately after the 
behavioral tests, animals were sacrificed and histological analyses were performed. Granule cell 
dendritic morphology was analyzed through immunohistochemistry for DCX. Quantification of total 
dendritic length of newborn neurons in the dentate gyrus demonstrated that CDKL5 KO mice treated 
with TATκ-GFP-CDKL5107 maintained longer dendrites compared to TATκ-GFP treated CDKL5 
KO mice (Fig. 50). This finding indicates that treatment with TATκ-GFP-CDKL5107 leads to a 
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morphological change that is durable for at least 12 days from treatment cessation. The treatment 
dose, however, seems to be important; in fact, treatment with a lower dose of TATκ-GFP-CDKL5 
(isoform 115) did not have the same lasting effect on dendritic maturation (Fig. 50-A). 
 
 
 
Figure 50. Long-term effect of treatment on dendritic arborization of newborn neurons. 
(A) Quantification of total dendritic length in the dentate gyrus of WT (+/Y) and CDKL5 KO (-/Y) 
treated with TATκ-GFP and CDKL5 KO (-/Y) treated with TATκ-GFP-CDKL5115 or TATκ-GFP-
CDKL5107. (B) Examples of the reconstructed dendritic tree of newborn granule cells of WT (+/Y) 
treated with TATκ-GFP, KO (-/Y) treated with TATκ-GFP and KO (-/Y) treated with TATκ-GFP-
CDKL5107 respectively. Data indicate that treatment with TATκ-GFP-CDKL5107 leads to a 
morphological change that is durable for at least 12 days from time when dosing was discontinued. 
Values represent mean  SE. ** p < 0.01 as compared to the wild type condition; # p < 0.01 as 
compared to the TATκ-GFP treated CDKL5 KO (-/Y) condition (Bonferroni test after ANOVA). 
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Furthermore, quantification of the number of DCX-positive cells in the dentate gyrus (Fig. 
51-A), together with the quantification of the total number of cleaved Caspase 3-positive cells in the 
same region (Fig. 51-B), revealed that treatment with either TATκ-GFP-CDKL5115 or TATκ-GFP-
CDKL5107 can induce long-lasting survival of postmitotic granule neurons. 
 
 
 
Figure 51. Long-term effect of treatment on neuronal survival. (A) Quantification of the 
number of DCX-positive cells in the hippocampus (dentate gyrus) of WT male mice (+/Y), CDKL5 
KO male mice (-/Y), and CDKL5 KO male mice treated with TATκ-GFP-CDKL5115 or TATκ-GFP-
CDKL5107. Treatment period consisted of once daily intraventricular injection for 5 days followed by 
two day rest period then an additional 5 injections. Animals were sacrificed 12 days after the last 
injection. (B) Quantification of the total number of cleaved Caspase 3-positive cells in the 
hippocampus (dentate gyrus) of the same mice as in A. Mean ± SE * p < 0.05, ** p < 0.01 as 
compared to +/Y; # p < 0.05; ## p < 0.001 as compared to the -/Y samples (Bonferroni’s test after 
ANOVA). 
 
These data indicate that the positive effects of treatment with TATκ-GFP-CDKL5, in 
particular at a high dosage (107 isoform), persist for two weeks after treatment cessation. 
 
4.9 Systemically injected TATκ-CDKL5 reaches the mouse brain 
The route of administration of a drug can be a key problem for CNS drug delivery due to the 
presence of the blood brain barrier, a highly selective permeability barrier that separates the 
circulating blood from the brain extracellular fluid in the central nervous system. At the base of 
protein therapy is the design of a non-invasive strategy that allows administration of a therapeutic 
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protein to CNS. The possibility of the TATκ-CDKL5 systemic administration is, therefore, an 
essential step for the development of a protein therapy that is suitable for clinical treatment of 
patients with CDKL5 disorder. 
For this reason we assessed whether TATκ-GFP-CDKL5 protein crossed the blood brain 
barrier. We first evaluated whether TATκ-GFP-CDKL5 protein crossed the blood brain barrier in 
newborn mice, since they still have an “immature” and “leakier” blood brain barrier. Seven-day old 
mouse pups were subcutaneous injected with a single dose of culture medium of 293T cells 
transfected with TATκ-GFP-CDKL5115, TATκ-GFP or medium from untrasfected cells (vehicle); the 
dose corresponded to about 200 ng of the fusion protein. Localization of TATκ-GFP-CDKL5 and 
TATκ-GFP in the brain was evaluated by immunohistochemistry using an anti-GFP antibody and a 
TSA amplification kit. Images were taken at the level of the sensory-motor cortex and the 
cerebellum. Cells were counterstained using 4',6-diamidino-2-phenylindole (DAPI). Representative 
images demonstrating presence of the TATκ-GFP-CDKL5 protein in the sensory-motor cortex of 
mice are shown in Fig. 52. Given that the TATκ-GFP-CDKL5 protein was subcutaneous 
administered, this data demonstrates that TATκ-GFP-CDKL5 protein is effectively transported 
across an “immature” blood brain barrier and enters into brain cells. 
 
 
 
Figure 52. Localization of TATκ-GFP-CDKL5 into the brain after 4 hours from a single 
subcutaneous injection in 7-days old mouse pups. Immunohistochemistry was performed using an 
anti-GFP antibody and a TSA amplification kit. Images were taken at the level of sensory-motor 
cortex. 
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On the basis of these promising results, we evaluated whether TATκ-GFP-CDKL5 protein 
crosses the blood brain barrier in adult mice that have a completely formed, highly selective 
permeability barrier. The treatment schedule was planned as one daily tail vein intravenous injection 
of TATκ-GFP-CDKL5115 for 5 consecutive days (Fig. 53; the dose corresponded to about 200 ng of 
the fusion protein). Mice were sacrificed 1 hour after the last treatment and localization of TATκ-
GFP-CDKL5 and TATκ-GFP in the brain was evaluated by immunohistochemistry using an anti-
GFP antibody. We found presence of the TATκ-GFP-CDKL5 protein in the hippocampal dentate 
gyrus of adult mice (Fig. 54), demonstrating that TATκ-GFP-CDKL5 protein is effectively 
transported across a “mature” blood brain barrier. 
 
 
 
Figure 53. Intravenous treatment schedule. Mature mice (3-4 months of age) received a 
single intravenous injection on 5 consecutive days and were sacrificed 1 hour after the last injection. 
CDKL5 wild type mice (+/Y) received either vehicle or TATκ-GFP (n = 3). CDKL5 KO mice (-/Y) 
received either vehicle or TATκ-GFP-CDKL5 (n = 3). 
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Figure 54. Localization of TATκ-GFP-CDKL5 into the brain after 1 hours from 
intravenous injection in 3 months old mice. Immunohistochemistry was performed using an anti-
GFP antibody and a TSA amplification kit. Images were taken at the level of hippocampus (dentate 
gyrus). H = hilus; GR = granular layer. 
 
4.10 Systemic treatment with TATκ-CDKL5 restores neuronal maturation and 
survival 
In order to evaluate the effects of systemic treatment with TATκ-GFP-CDKL5, adult CDKL5 
KO mice were treated with TATκ-GFP-CDKL5 as previously described (Fig. 53, treatment 
schedule), while wild type counterparts received TATκ-GFP control protein. Control groups treated 
with vehicle were used for both of the genotypes as a baseline measure. 
We first quantified the number of cleaved caspase-3 positive apoptotic cells and DCX-
positive newborn neurons in the dentate gyrus of treated animals. Importantly, histograms in Fig. 55 
demonstrate that a systemic treatment of 5 days was able to restore neuronal survival in the 
hippocampal dentate gyrus of CDKL5 KO mice treated with TATκ-GFP-CDKL5. 
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Figure 55. Effect of 5-days intravenous treatment with TATκ-GFP-CDKL5 on neuronal 
survival. (A) Quantification of apoptotic cells (caspase-3 positive) in WT male mice (+/Y), CDKL5 
KO male mice (-/Y), WT male mice treated with TATκ-GFP and CDKL5 KO male mice treated with 
TATκ-GFP-CDKL5. Values represent mean  SD. ** p < 0.01 as compared to +/Y; # p < 0.01 as 
compared to the CDKL5 KO -/Y samples (Bonferroni’s test after ANOVA). (B) Quantification of 
DCX positive cells in the hippocampus (dentate gyrus) of WT male mice (+/Y), CDKL5 KO male 
mice (-/Y), WT male mice treated with TATκ-GFP and CDKL5 KO male mice treated with TATκ-
GFP-CDKL5. Values represent mean  SD. ** p < 0.01 as compared to +/Y; # p < 0.01 as 
compared to the CDKL5 KO -/Y samples  (Bonferroni’s test after ANOVA). 
 
We then evaluated the morphology of DCX-positive newborn hippocampal neurons and 
noticed a small but significant increase in neuronal maturation of TATκ-GFP-CDKL5 treated 
CDKL5 KO mice in terms of total dendritic length and number of ramifications (Fig. 56). 
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Figure 56. Effect of 5-days intravenous treatment with TATκ-GFP-CDKL5 on neuronal 
maturation. (A-B) Partial (but significant) recovery of dendritic tree length (A)  and segment 
number (B) of newborn granule cells in CDKL5 KO (-/Y) mice following once daily intravenous 
injection for 5 consecutive days with TATκ-GFP-CDKL5. WT male mice (+/Y) were treated with 
TATκ-GFP. Values represent mean  SE. ** p < 0.01; *** p < 0.001 as compared to the wild type 
+/Y samples; # p < 0.05 as compared to the CDKL5 KO -/Y samples (Duncan’s test after ANOVA). 
 
Taken together these data indicate that a short systemic treatment with TATκ-GFP-CDKL5115 
has positive effects on hippocampal neuronal maturation and survival. It is reasonable to hypothesize 
that a prolonged systemic treatment with TATκ-GFP-CDKL5115 may also recover the behavioral 
defects that were restored after ICV treatment in CDKL5 KO mice.  
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5 DISCUSSION 
 
No therapies are presently available for the improvement of the neurological phenotypes 
associated with CDKL5 disorder. Since mutations in the CDKL5 gene lead to a lack of functional 
CDKL5, delivery of a functional CDKL5 protein to the brain represents the best therapeutic 
approach. Our study provides novel evidence that an innovative approach, named protein substitution 
therapy, aimed at compensating for the lack of CDKL5 function by targeting a functional 
recombinant CDKL5 protein into the brain, is feasible. To deliver an active CDKL5 into the nervous 
system and within brain cells, we constructed the TATκ-CDKL5 fusion protein using the modified 
HIV protein transduction domain TAT as a delivering moiety. We demonstrated that TATκ-CDKL5 
fusion proteins can be delivered into cells and retain CDKL5 activity after internalization. When 
injected in vivo, TATκ-CDKL5 fusion protein was able to cross the blood brain barrier and diffuse 
into the brain. Finally, we treated CDKL5 KO mice with TATκ-CDKL5 protein and showed that 
neurobiological and neurobehavioral defects underwent an improvement, in several cases bringing 
brain development and behavior up to wild-type levels. 
It is worth noting that all the presented results were obtained in adult mice, indicating that 
neurodevelopmental defects in the CDKL5 KO condition may be corrected even after the early 
stages of brain development. Such promising results strengthen the idea that a protein substitution 
therapy with TATκ-CDKL5 fusion protein may be successfully developed for CDKL5 patients. 
 
5.1 Optimization of TATκ-CDKL5 fusion protein production 
In the present study we succeeded in producing and purifying a functional TAT-CDKL5 
fusion protein. We found that TAT-CDKL5 cannot be produced through E. coli expression system, 
as it is probably massively degraded. Indeed, various authors in the past years reported the difficulty 
in obtaining a constitutively active full-length CDKL5 through this system (e.g. [Katayama, 
Sueyoshi, and Kameshita 2015]). Conversely, we found that purification of TAT-CDKL5 in 
mammalian expression systems is feasible, but it is inefficient due to protein instability and poor 
solubility. In order to optimize production yields, we modified the TAT construct for secretion in the 
culture medium of transfected HEK 293T cells and we found that the new TATκ-CDKL5 secretable 
protein was more stable in this production system, giving higher amounts of full-length protein. 
Furthermore, we found that with a secretable TATκ-CDKL5, but not with the unmodified TAT-
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CDKL5 (data not shown), it is possible to select 293T stable clones expressing the fusion protein. A 
protein production through stable clone allows a more reproducible protein purification and it lowers 
costs. In the future, our results may help pharmaceutical companies to set up an efficient large-scale 
production system that might lead to the development of a TATκ-CDKL5 protein therapy for 
CDKL5 patients. 
 
5.2 Which TATκ-CDKL5 isoforms for protein substitution therapy? 
The first described CDKL5 protein isoform that was shown to be relevant in the brain was the 
115 kDa transcript [Fichou et al. 2011]. Nevertheless, another isoform identified by Williamson and 
colleagues, the 107 kDa isoform with an alternative C-terminus, was reported to be highly expressed 
in human and mouse brains, resulting, on average, to be 37-fold more highly-expressed than 
CDKL5115 [Williamson et al. 2012]. In the current study we exploited both the CDKL5 isoforms, 
creating various TATκ-CDKL5 constructs which differ in their purification tags. We found that 
TATκ-CDKL5107 fusion proteins are produced with higher yields compared to TATκ-CDKL5115 
constructs, consistently with the previous observation that CDKL5107 is more stable [Williamson et 
al. 2012]. Thanks to the modified TATκ sequence, all the TATκ-CDKL5 constructs were able to 
cross cell membranes indicating that, during the secretion process driven by the Ig κ-chain leader 
sequence at the N-terminus, the TAT was not inactivated. Conversely, unmodified TAT fusion 
proteins, when secreted by producer cells, are usually unable to enter the target cells, probably due to 
the furin-mediated cleavage within the TAT peptide [Flinterman et al. 2009]. The successful uptake 
of the secreted TATκ-CDKL5 proteins was demonstrated by several target cells, including cell lines 
(HEK 293T, SH-SY5Y) and primary cultures (NPCs). In order to investigate TATκ-CDKL5 fusion 
protein activity, we treated a neuroblastoma cell line (SH-SY5Y) with conditioned media containing 
secreted TATκ-CDKL5, which was previously reported to arrest the cell cycle and start 
differentiation under CDKL5 overexpression stimulus [Valli et al. 2012]. As expected, increasing 
levels of CDKL5 in neuroblastoma cells, brought about by treatment with TATκ-CDKL5, caused a 
reduced proliferation and improved differentiation. We observed a comparable anti-proliferative 
effect of CDKL5115 and CDKL5107 fusion proteins on neuroblastoma cells, indicating a similar 
cellular activity of the two CDKL5 isoforms. 
As specified above, TATκ-CDKL5 protein production in mammalian cells is limited. For this 
reason we first carried out in vivo treatment through intracerebroventricular (ICV) infusions in order 
to lower the total amount of protein required and reduce the physiological washout of administered 
protein. Since we did not have information on the quantity of CDKL5 protein needed to restore brain 
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levels in the knockout mice, we established the dosage of TATκ-CDKL5 protein to inject by taking 
into account the maximum achievable concentration of protein and the maximum bolus volume. 
Starting with the ICV infusion of TATκ-CDKL5115 protein, we observed an important amelioration 
in the neurological defects of CDKL5 KO mice, but not a full restoration. Thus we decided to treat 
animals with a higher dose of protein - maintaining the same concentration factor and the bolus 
volume - taking advantage of the more stable 107 kDa isoform. Importantly, with a higher dose of 
recombinant CDKL5 protein we observed a greater improvement in brain development and in the 
behavioral defects that characterize CDKL5 KO mice. These data suggest a dose-dependent effect of 
the CDKL5 protein therapy. An accurate investigation into dosage and effects, comparing the two 
CDKL5 isoforms, needs to be carried out in future studies.  
 
5.3 Pharmacological aspects of a protein therapy with TATκ-CDKL5 
5.3.1 Toxicology 
The longer treatment period consisted in 10 injections administered in 12 days. We did not 
observe evident side effects of treatment in terms of body weight variations or inflammatory local 
response. No toxic effects or immunogenicity problems regarding the TAT-PTD have been reported 
so far. Our results confirmed previous studies, showing that it is possible to deliver TAT-PTD in vivo 
without eliciting an immune reaction. To evaluate the toxicity of CDKL5 overdosing, we tested a 
group of wild-type mice that had been ICV-treated with TATκ-CDKL5115. No behavioral changes or 
adverse effects were found in these animals, indicating that there are no toxic effects of CDKL5 
overdosing in the brain. This could be explained by the fact that CDKL5 is an endogenous protein 
that undergoes a physiological turnover, thus limiting its local concentration and avoiding 
overdosing problems. Notably, our results suggest that the therapeutic dose of TATκ-CDKL5 fusion 
protein has a wide safety window.  
 
5.3.2 Therapeutic systems 
We evaluated the stability of TATκ-CDKL5 at different temperatures: storage temperature (-
80°C) and physiological temperature (37°C). We found that TATκ-CDKL5 fusion protein is stable 
and does not degrade or lose activity when it is preserved for a long time at low temperatures. 
Furthermore, we found that at 37°C a substantial amount of TATκ-CDKL5 protein is stable after 3 
days and is still detectable after 7 days. Such information enables the use of reservoir-based 
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therapeutic systems in future preclinical studies and drug development. This finding may also 
represent useful information in view of clinical trials that require patient compliance, which is surely 
higher with a therapeutic system than with lifelong daily injections. Furthermore, therapeutic systems 
allow for a controlled release, which enables a constant release of protein and, importantly, can be 
adapted to the patient. 
 
These experiments represent important translational research aimed at developing a safe and 
targeted treatment for CDKL5 disease. Our testing in animals provides the very first essential 
pharmacological information in terms of safety, dosage, and measures of efficacy that may guide the 
design of future human trials. 
 
5.4 Protein therapy with TATκ-CDKL5 restores neuronal survival and 
dendritic development in CDKL5 KO mice 
We have recently found that CDKL5 KO mice exhibit severe defects in the hippocampal 
region in terms of survival of immature granule cells and maturation of postmitotic neurons [Fuchs et 
al. 2014]. CDKL5 seems to modulate the intricate balance between precursor proliferation/survival 
and differentiation during the process of postnatal neurogenesis, thus playing a central role in brain 
development. As a consequence, inefficient expression of CDKL5 protein in the knockout condition 
is responsible for the neurological phenotype characterized, above all, by cognitive impairment.  
We exploited the new therapeutic tool of protein replacement therapy in order to compensate 
for the lack of CDKL5 protein in CDKL5 KO mice, with the intent of rescuing the levels of this 
kinase in the brain that are necessary for proper neuronal development. Accordingly, we found that a 
protein therapy with TATκ-CDKL5 restored the survival and maturation of neuronal cells of CDKL5 
KO mice. In particular, the survival of immature granule neurons of the hippocampal dentate gyrus 
was fully rescued and granule cell number was restored. In the CDKL5 KO mouse the dendritic 
arbor of granule cells exhibits a reduced length and number of branches, indicating a severe dendritic 
hypotrophy. We found that it is possible to restore the dendritic architecture of hippocampal granule 
neurons of adult CDKL5 KO mice by compensating for CDKL5 hypo-functionality with TATκ-
CDKL5. Taken together our results indicate that TATκ-CDKL5 replacement therapy restores two 
major developmental defects that characterize the brain of CDKL5 KO mice. 
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5.5 Protein therapy with TATκ-CDKL5 rescues connectivity in CDKL5 KO 
mice 
It was recently reported that in neurons CDKL5 mainly localizes to dendritic spines and is 
necessary for their correct genesis and maintenance, and for synapse formation [Ricciardi et al. 
2012]. Consistently with this observation, CDKL5 KO mice exhibit abnormally long and thin 
dendritic spines, with a sparse distribution, indicating an immature phenotype [Della Sala et al. 2015; 
Fuchs et al. 2014]. In parallel, an overall reduction of the inputs to the hippocampal molecular layer 
has been observed in young CDKL5 KO mice, as indicated by a reduced synaptophysin expression 
[Fuchs et al. 2014]. 
Importantly, protein therapy with TATκ-CDKL5 fully restores spine morphology and 
distribution in adult CDKL5 KO mice. Furthermore, we found a defective expression of 
synaptophysin in layer III of the neocortex and in the molecular layer of the hippocampus of 
untreated adult CDKL5 KO mice compared to their wild-type counterparts. The restoration of spine 
development induced by TATκ-CDKL5 was accompanied by an increase in synaptophysin 
immunoreactivity throughout the molecular layer and in cortical layer III, suggesting restoration of 
the input to neurons localized in these areas. 
 
5.6 Protein therapy with TATκ-CDKL5 restores memory performance in 
CDKL5 KO mice 
We previously reported that CDKL5 KO mice show a poorer performance in hippocampus 
dependent memory and learning tasks compared to wild-type mice [Fuchs et al. 2014]. This is 
consistent with the reduced number, impaired dendritic and synaptic development of the granule 
cells and dendritic hypotrophy of hippocampal pyramidal neurons. In the current study we found that 
when CDKL5 protein brain levels were restored through daily administrations of TATκ-CDKL5 
fusion protein, the cognitive performance of CDKL5 KO mice in hippocampus-dependent behavioral 
tasks was significantly improved. This indicates that the full recovery of hippocampal neurogenesis 
and synaptic development in treated mice were functionally effective. 
In particular, while TATκ-GFP-CDKL5115 fusion protein partially rescued the performance of 
knockout mice, treatment with the recombinant protein in the CDKL5107 isoform led knockout mice 
to levels that were similar to those of wild-type mice. Whether these results are due to the fact that 
the 107 kDa is the brain-specific CDKL5 isoform or simply indicate a dose-dependent effect still 
116 
 
remains to be clarified.  
 
5.7 Protein therapy with TATκ-CDKL5 restores stereotypic motor performance 
in CDKL5 KO mice 
It has been previously described that, when suspended by their tails, CDKL5 KO mice tend to 
retract their limbs toward their trunks in a dystonic fashion rather than extending them as observed in 
wild-type mice [Amendola et al. 2014]. Clasping behavior resembles the hand-wringing stereotype, a 
prominent motor phenotype in CDKL5 patients, and may be considered a motor function test. The 
clasping phenotype is observed in mice with lesions in the cerebellum, basal ganglia and neocortex 
[Lalonde and Strazielle 2011]. The underlying mechanism appears to include cerebello-cortico-
reticular and cortico-striato-pallido-reticular pathways, possibly triggered by changes in 
noradrenaline and serotonin transmission [Lalonde and Strazielle 2011]. Furthermore, it has been 
reported that mice lacking the postsynaptic scaffold PSD-95, a protein strongly linked to CDKL5 
function [Della Sala et al. 2015; Ricciardi et al. 2012; Zhu et al. 2013], develop dyskinesia 
phenotypes including limb clasping [Zhang et al. 2014]. Treatment with TATκ-CDKL5 fusion 
protein led to a strong reduction of the clasping trend in knockout mice. This finding suggests that 
TATκ-CDKL5 protein injected in the third cerebral ventricle diffused in a significant amount to the 
brain regions involved in the clasping phenotypes, and that increasing local levels of CDKL5 
improved neurotransmission in such areas.  
 
5.8 Current perspectives of protein replacement therapies with PTDs 
Protein therapy exhibits several advantages over small molecule drugs and is increasingly 
being developed for the treatment of disorders ranging from single enzyme deficiencies to cancer. 
Intracellular delivery is crucial for many therapeutic molecules; however, the ability to get large 
molecules across the plasma membrane poses great challenges. Protein Transduction Domains 
(PTDs), a group of small peptides capable of promoting transport of molecular cargo across the 
plasma membrane, have become important tools in promoting the cellular uptake of exogenously 
delivered proteins. Although the molecular mechanisms of uptake are not firmly established, PTDs 
have been shown to promote uptake of various molecules, including large proteins over 100 kDa 
(e.g. TAT-β-galactosidase, 120 kDa. [Schwarze et al. 1999]). PTDs have been widely used to 
facilitate the entry of proteins, small molecules, DNA and RNA into cells (reviewed in  [Copolovici 
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et al. 2014]). The first PTD was discovered in the late 1980s when a group studying the human 
immunodeficiency virus (HIV) described the PTD of the trans-activator of transcription protein, 
TAT [Green, Ishino, and Loewenstein 1989]. An 11-amino acid transduction domain (residues 47–
57 of HIV-1 TAT) was developed by Dowdy and co-workers in 1999 [Schwarze et al. 1999] and the 
following year the minimal PTD of TAT was identified as a 9-amino acid protein sequence [Wender 
et al. 2000]. TAT protein transduction domain nowadays represents the most characterized and the 
most widely used PTD. 
Protein replacement therapy is commercially available for various lysosomal storage diseases 
and represents a potentially exciting avenue for other inherited enzyme deficiency disorders that 
currently lack available treatments. Protein replacement therapies have the benefit of well-
understood safety profiles when compared with gene therapies, and also generally show increased 
specificity compared with small molecule mimetics [Zhang, Yang, and Gray 2009]. Protein 
replacement therapies are currently in development for various inherited disorders, including 
mitochondrial disorders [Rapoport et al. 2011], X-linked myotubular myopathy [Lawlor et al. 2013], 
Fabry disease [Higuchi et al. 2010] and phenylketonuria [Eavri and Lorberboum-Galski 2007]. 
Furthermore, protein transduction is also used in non-inherited conditions, such as 
ischemia/reperfusion-induced damage after myocardial infarction, and for other purposes, such as 
facilitation of intranasal delivery of insulin or facilitation of anticancer therapy (reviewed in [Dinca, 
Chien, and Chin 2016]). 
Importantly, several compounds involving PTDs have been tested in humans with no serious 
adverse effects [Verdurmen and Brock 2011]. These studies demonstrate that it is possible to safely 
administer PTD constructs in vivo as long as careful consideration is given to potential novel effects 
of conjugating a PTD to a previously untested cargo [Dinca, Chien, and Chin 2016]. 
To the best of our knowledge, no PTD-tagged proteins have yet entered human clinical trials. 
However, it is worth considering that numerous PTDs have entered clinical trials and that the 
extensive use of PTD-protein therapy in experimental disease models has demonstrated the 
feasibility and efficacy of using PTD-tagged proteins as therapeutic agents. These considerations 
strongly suggest the potential impact on developing novel PTD-protein therapies for human disease. 
 
5.9 Protein therapy with TATκ-CDKL5 as an ideal tool to treat CDKL5 patients 
To date no cure is available for CDKL5 disorder and the standard of care for patients only 
targets specific symptoms. For instance there have been outlined treatment regimens for epilepsy, 
which, unfortunately, often appears to be refractory [Fehr et al. 2013]. In addition, symptomatic 
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treatments have shown different effects on different patients, probably due to the variety of 
mutations in the CDKL5 gene, thus hindering the possibility to establish clear guidelines for 
clinicians. 
Very recently, some pharmacological treatments that are able to rescue various aspects of 
brain development have been discovered. These therapies are targeted to molecules in the CDKL5 
KO mouse that have been found to manifest an altered expression or activity at particular stages of 
life [Della Sala et al. 2015; Fuchs et al. 2015]. Nevertheless, the treatments may not have an effect in 
all phases of development, and may not act on all the central and peripheral symptoms typical of the 
knockout condition, because molecule expression and the activation of signaling pathways varies 
depending on age and localization. This point represents a major issue, since the hyper-
activation/inhibition of a signaling cascade may cause significant adverse effects. Furthermore, it 
remains to be assessed whether the targeted pathways that are exploited in order to treat the CDKL5 
mouse model are also altered in CDKL5 patients. 
The only common feature that is certainly shared by all CDKL5 patients is the lack of a 
functional CDKL5 protein, and this deficiency is the uphill cause of all the molecular alterations 
which could result. Therefore, compensation of CDKL5 protein levels with gene or protein therapy 
should theoretically restore all the reversible alterations of CDKL5 patients. In particular, protein 
substitution therapy has the great advantages of a relatively rapid translation to humans and the 
possibility to control the dosage for a patient-based treatment. It is particularly important to fit a 
protein therapy to the single patient because different mutations in the large CDKL5 gene cause a 
certain variability in the expression of CDKL5 fragments, which, in some cases may be partially 
active. In such cases, for instance, the dose of recombinant CDKL5 administered should be lowered. 
 
To conclude, this study states the practicability of a protein substitution therapy for CDKL5 
disorder, showing that the major defects observed in the CDKL5 KO mouse model can be rescued by 
restoring CDKL5 brain levels through TATκ-CDKL5 fusion protein administration. Hopefully our 
findings may pave the way for studies in humans. 
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